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ABSTRACT 
Mitochondria are known as the powerhouse of the cell due to their central role in 
energy generation and as the site of key metabolic pathways. Over the past 15 years, 
it has become unequivocally clear that most pro-apoptotic stimuli require a 
mitochondria-dependent step, involving the permeabilisation of the mitochondrial 
outer membrane to apoptogenic factors, such as cytochrome c and Smac/DIABLO. 
The release of these factors into the cytosol is tightly regulated by proteins of the 
Bcl-2 family and results in the activation of the caspase cascade, leading to cell 
death. This event is considered as a point of no return in the apoptotic pathway and is 
often inhibited in cancer.  
Cardiolipin (CL) is a mitochondria-specific phospholipid that contains four acyl-
chains. CL has been implicated in many of the mitochondria-dependent steps that 
lead to the release of apoptogenic factors including interaction with the Bcl-2 family 
protein tBid, Bax-dependant mitochondrial outer membrane permeabilization and 
cytochrome c release. Despite this growing body of evidence, the mechanism by 
which CL and its fatty acyl chain composition regulate mitochondrial apoptotic 
pathways remains unresolved, mostly due to the lack of cellular model. Tafazzin is a 
mitochondrial enzyme, which is mutated in Barth syndrome (BTHS) and is involved 
in the maturation process of CL. In BTHS, loss of tafazzin activity results in a 
decrease in mature CL, making it a good model to investigate the role of CL in 
apoptosis.  
Using BTHS patients-derived lymphoblastoid cells and HeLa cells in which tafazzin 
was stably knocked-down using RNA interference, this study provides the first 
evidence that mature CL are required for an efficient extrinsic apoptotic pathway in 
type II cells. Further investigation of the impaired apoptotic pathway revealed that 
the major block is in the activation of caspase-8. In this work, mature CL was 
identified as a crucial component of a mitochondrial platform required for caspase-8 
translocation, oligomerization and activation following Fas signalling in type II cells. 
These results support a model in which once the first cleavage of procaspase-8 
occurs at the DISC, the p43/p10 heteromer product translocates and inserts into the 
mitochondrial membrane in a CL-dependant manner. In the mitochondria, caspase-8 
further oligomerizes and auto-cleaves to adopt its fully active form p18/p10. 
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Additionally, it is shown here that mature CL is required for the physiological 
association of full-length Bid, the major caspase-8 cleavage substrate, with 
mitochondria. Thus, Bid is directly available for active caspase-8 on the 
mitochondrial surface where it cleaves into tBid, which in turn inserts into the 
mitochondrial outer membrane and induces cytochrome c release. Therefore, by 
tethering full-length Bid on mitochondria and by providing an activation site for 
caspase-8 following Fas signalling, CL brings together both the enzyme and its 
substrate and provides a platform from which the mitochondrial phase of apoptosis is 
launched. 
In summary, the data presented in this thesis provide the first evidence that mature 
CL participates in a new mitochondrial associated platform, called the “mitosome”, 
required for the activation of caspase-8 in type II cells. 
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1 Introduction 
1.1 Apoptosis: historical overview and definition 
The first recognition of physiological cell death mechanisms appeared in the mid- 
nineteenth century with the observation by Carl Vogt in 1842, that cells die during 
the development of the nervous system [1]. Developmental biologists then realized 
that cell death was essential for successful embryogenesis and metamorphosis, both 
in insects and mammals. In 1965, Lockshin and Williams established a new concept, 
programmed cell death, which was used to describe the controlled and sophisticated 
mechanism of cell-destruction occurring during insect development [2]. The term 
“apoptosis” was introduced in 1972 by Kerr and colleagues [3], who recognized that 
the morphological features of liver and lymphocyte cells dying, due to toxin or 
hormones, resembled that described for the developmental cell death by the 
embryologist Glucksmann earlier [4]. Apoptosis was named after an ancient Greek 
word, referring to the process of leaves falling from trees, to describe the novel cell 
death phenotype, morphologically distinct from classical necrosis. Apoptosis is now 
considered to be a genetically controlled process of cell death, essential for the 
development and life of multicellular organisms.  
1.2 Morphological classification of cell death  
A cell is considered dead when it has lost the integrity of the plasma membrane. 
Three distinct cell death morphologies have been defined in mammals: apoptosis, 
necrosis and autophagy. Apoptotic cells are characterized by stereotypical 
morphological changes [5]. The cell rounds up and shrinks and its chromatin 
condenses (piknosis) and fragments (karyorrhexis). The plasma membrane becomes 
blebbed and the cell is fragmented into membrane-enclosed structures, called 
apoptotic bodies, which contain cytosolic, nuclear and organelle material. In vivo, 
apoptotic bodies are recognized and engulfed by macrophages or other specialized 
phagocytes and thus removed from the tissue to avoid an inflammatory reaction. It is 
of note that in tissue culture, apoptotic cells progress into secondary necrosis 
resulting in the loss of membrane integrity. Those phenotypic features are the 
consequences of biochemical events, in particular the activation of endonucleases, 
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responsible for internucleosomal cleavage of the DNA (DNA ladder), and the 
activation of a family of cysteine-dependant aspartate-specific proteases, called 
caspases, that mediate the degradation of specific cellular proteins. Caspase 
activation constitutes one of the molecular features of the apoptotic pathway and is 
therefore frequently used as a marker of apoptosis. Another biochemical hallmark of 
apoptosis is the externalization of phosphatidyl-serine (PS) to the outer leaflet of the 
plasma membrane where it forms a recognition signal for phagocytes. Apoptosis is 
an energy-dependant process requiring ATP for optimal caspase activation.  
Necrosis is characterized morphologically by an overall swelling of the cytoplasm 
(oncosis) and organelles and a rapid loss of the plasma membrane. In vivo, leaking of 
cellular contents after membrane rupture initiates an inflammation reaction in the 
affected-tissue. In contrast to apoptosis, necrosis has long been considered a non-
programmed, passive, form of cell death initiated by cellular “accidents” such as 
toxic insults or physical damage. However, over the past few years, accumulating 
evidence in favour of a physiological role of necrosis suggests that its activation and 
process may also be tightly regulated [6]. Necrosis was described during bones 
development and it also participates in intestinal epithelial cell homeostasis [7, 8]. 
Moreover, the fact that inhibition of apoptosis can induce necrotic cell death [9] has 
indicated that necrosis, may in some circumstance, constitute a default and 
programmed-cell death mechanism which substitutes for failed apoptosis [6, 10].  
Autophagy is morphologically defined by the formation of double membrane 
vesicles or autophagosomes that encapsulated cytosolic contents and organelles such 
as mitochondria [11]. Fusion of the autophagosome with the lysosome results in the 
degradation of its contents by lysosomal enzymes. These vesicles are distinguishable 
by electron microscopy from the endosomes, lysosomes or apoptotic blebs [11]. 
Autophagy was first characterized as a survival strategy employed by yeasts to 
survive nutrient deprivation, by providing amino acids and other essential 
components to the cells [12]. It is an evolutionary conserved mechanism that plays a 
role in the turnover and elimination of long-lived proteins and organelles [13]. 
Recent data indicate that autophagy is essential in the early development of 
Drosophila, Caenorhabditis elegans (C.elegans) and mice [14-16] but its precise role 
in this process remains to be defined. Silencing autophagic genes in mice and C. 
elegans increased cell death, supporting the idea that autophagy has a survival role 
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during early development. On the other hands, autophagic vesicles have also been 
observed in dying cells where the apoptotic pathway was inhibited [17, 18]. As 
described above for necrosis, autophagy may be another alternative pathway of cell 
death which could be unravelled when apoptosis is inhibited. Whether or not 
autophagy represents a proper mechanism of cell suicide, independent of caspases, or 
only a survival strategy is still a matter of debate.  
Although these three types of cell death are morphologically very distinct, a growing 
body of evidence indicate that they are tightly interconnected and the existence of 
common molecular regulating pathways was suggested.  
1.3 Significance of apoptosis 
Apoptosis is an evolutionary conserved and regulated mechanism of programmed 
cell death that plays a crucial role in the development and homeostasis of 
multicellular organisms by eliminating superfluous, aged, damaged and infected 
cells. During development, many cells are produced in excess and are eliminated by 
apoptosis to contribute to the morphogenesis of the different tissues and organs [19]. 
Cell death in the interdigital mesenchymal tissue for example, results in the 
formation of individualized digits in animals. Other examples include the ablation of 
tadpole tails during amphibian metamorphosis, massive neuronal cell death in the 
development of the brain, deletion of uterus and Wolffian duct during the formation 
of the male and female reproductive organs etc. Once, development is complete, the 
viability of multicellular organisms is constantly controlled by a balance between cell 
proliferation and cell death. In human body, one hundred thousands cells are 
removed every second by apoptosis and the same number is regenerated by mitosis 
[20]. In the immune system, apoptosis has an essential role not only in the 
development and maintenance of the immune repertoire, but also in the regulation of 
the immune response [21]. During their development, lymphocytes undergo stringent 
selection that results in the elimination of non functional and auto-reactive 
lymphocytes.  In response to pathogens, the immune system rapidly activates and 
amplifies the number of antigen-specific lymphocytes via rapid cell division and 
inhibition of apoptosis. After pathogen clearance, the immune system restores its 
cellular homeostasis by selectively eliminating these activated lymphocytes. This 
phase requires the activation of the death receptor Fas (also known as CD95 or APO-
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1) located at the plasma membrane and the resetting of the balance between pro- and 
anti-apoptotic molecules, resulting in the apoptosis of activated lymphocytes. In 
addition to controlling cell number, apoptosis can act to preserve tissue integrity. 
Aged or damaged cells with severe DNA damage that cannot be repaired undergo 
programmed cell death to avoid the replication of these mutations. Metazoans also 
use apoptosis as a mechanism of defence against viral infection. Early elimination of 
infected cells limits virus replication and spread to neighbouring cells. However, 
viruses have developed strategies to inhibit apoptosis of the host cell by expressing 
inhibitors of key components of the apoptotic program.  
1.4 Dysregulation of apoptosis and pathology 
Since apoptosis is an essential mechanism required for the development and survival 
of metazoans, its dysregulation is involved in a plethora of human diseases [22].  
Evidence indicate that insufficient apoptosis can be manifested as cancer, 
autoimmune lymphoproliferative syndrome (ALPS) and some metabolic disorders 
while accelerated cell death is evident in acute and chronic degenerative diseases, 
stroke, ischemic heart disease, acquired immunodeficiency, and infertility. However, 
the role of apoptosis in disease pathology is not always straightforward. For example, 
viral infections and autoimmune disorders have been correlated with either an excess 
or a lack in apoptotic cell death and cancer cells have the ability to evade the immune 
response by inducing apoptosis of immune cells.  
It is now established that apoptosis plays a role in all facets of cancer development 
including tumour initiation, progression and during metastasis. The importance of 
apoptosis in cancer development emerged in the early 80s, when Tsujimoto and 
colleagues cloned and identified the bcl-2 oncogene at the chromosome translocation 
t(14:18) in leukemic and follicular lymphoma cells [23, 24]. This translocation 
juxtaposes the bcl-2 gene with the immunoglobulin heavy chain locus and results in 
the overexpression of bcl-2. In contrast to oncogenes identified at the time due to 
their ability to transform and immortalize cells, bcl-2 appeared to localize to 
mitochondria and promote cell survival by inhibiting apoptosis [25-27]. 
p53 was the first tumour suppressor gene linked to apoptosis [28]. p53 mutations 
occur in the majority of human cancers and have been associated with advanced 
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tumour stage and with poor patient survival [29]. p53 was first established as a 
checkpoint protein involved in cell cycle arrest and maintaining genomic integrity 
after DNA damage [30]. The first evidence for a role of p53 in cell survival emerged 
in 1991 when Moshe Oren and colleagues demonstrated that reintroduction of wild 
type p53 into a murine myeloid leukaemic cell line could induce apoptosis [28]. 
Although the initial studies of bcl-2 and p53 established the importance of apoptosis 
in carcinogenesis, it is now clear that mutations in many apoptosis-regulators can 
lead to cancer. Therefore, in the past few years the identification of novel targets that 
reactivate apoptosis in cancer cells has been one of the major goals of cancer 
research. New promising targets and advance anti-cancer therapy based on the 
modulation of apoptosis were identified and will be discussed in section 1.7.  
1.5 Apoptotic signalling pathway 
1.5.1 Activation of apoptosis 
Apoptosis can be triggered by a wide variety of physiological, pathogenic or 
cytotoxic stimuli. In mammal cells, induction of apoptosis occurs via two distinct 
pathways: extrinsic and intrinsic (Figure 1-1). The extrinsic pathway integrates 
extracellular signals through the binding of external ligands to death receptors 
located at the plasma membrane (e.g Tumour Necrosis Factor (TNF) receptor family, 
Fas and TNFR1). The intrinsic pathway is activated under conditions of intracellular 
stress (such as DNA damage, deprivation of survival signals and oxidative stress) 
and involves organelles to propagate death signals. Over a number of years, 
mitochondria have been identified as central executors of intrinsic apoptosis 
following a wide variety of death signals [31, 32]. Both extrinsic and intrinsic 
pathways lead to the activation of the cysteine-dependant aspartate-specific 
proteases, called caspases, which are responsible for the morphological features of 
apoptosis (section 1.5.6). 
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Figure 1-1: Extrinsic and intrinsic pathway of apoptosis. 
The extrinsic apoptosis engage the cell surface death receptors such as TNFR1, Fas 
receptor or TRAIL. Engagement of these receptors by their specific ligand induces their 
trimerisation and leads to the assemblage of the DISC at the plasma membrane. In this 
complex, procaspase-8 is activated and in turn cleaves and activates the effector caspase-3 
that degrades essential cellular proteins and confers the apoptotic morphological features. 
The intrinsic pathway involves mitochondria and is activated following a wide variety of 
intracellular stress such as DNA damage, oncogene activation, ER stress, growth factor 
deprivation, oxidative stress and others. Transduction of these signals requires the 
permeabization of the mitochondrial outer membrane by proteins of the Bcl-2 family and 
results in the release of mitochondrial apoptogenic factors to the cytosol. Once released in 
the cytosol, these apoptogenics factors including cytocrome c, Smac/DIABLO, AIF, EndoG 
and Omi/Htra2 activate different cellular programs committing the cells to death. In type II 
cells, the BH3-only protein Bid relays the signals from the death receptors to the 
mitochondria and therefore links the extrinsic and intrinsic pathway. 
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1.5.2 Death receptors extrinsic pathway 
1.5.2.1 The death receptors family 
The death receptors (DR) belong to the TNF receptor superfamily and are involved 
in the transduction of either apoptotic or survival signals. DR are transmembrane 
proteins composed of cysteine-rich extracellular domains and a characteristic 
cytoplasmic region composed of around 80 residues called death domains (DD) 
essential for transmitting the death signal. To date, eight members have been 
described: TNF receptor 1 (also known as DR1), Fas receptor (also known as DR2, 
CD95 and APO-1), DR3 (APO-3), TNF-Related Apoptosis-Inducing Ligand receptor 
1 (also known as TRAILR1 and DR4), TRAILR2 (also known as DR5 and 
KILLER), DR6, ectodysplasin A receptor (EDAR) and nerve growth factor receptor 
(NGFR) [33]. Two types of DR can be identified depending on their signalling 
complex. Fas receptor, TRAILR1 or TRAILR2 activation leads to the formation of 
the Death Inducing Signalling Complexe (DISC) and results in the induction of 
apoptosis [34, 35]. The others, TNFR1, DR3, DR6 and EDAR recruit different set of 
molecules and transduce, in addition to apoptosis, other cellular responses including 
proliferation, differentiation and survival [36]. The binding of TNF to the TNFR1 
can trigger the formation of the DISC but also the assembly of two other signalling 
platforms that ultimately result in the activation of two major transcription factors, 
the nuclear factor κB (NF- κB) and c-Jun. These transcription factors are responsible 
for the expression of genes involved in diverse biological processes such as, cell 
growth and death, development, oncogenesis and immune responses [37]. To date, 
out of the DR family, the Fas receptor signalling pathway is the most well-
characterized [35].  
1.5.2.2 Fas receptor signalling pathway 
The Fas receptor is a widely expressed glycosylated transmembrane protein essential 
for the regulation of apoptosis in a large variety of tissues. As already mentioned, the 
Fas receptor signalling pathway participates in downregulation of the immune 
response by eliminating activated T and B lymphocytes after clearance of the 
pathogen, but it also plays a important role in the control of cellular homeostasis in 
other organs, such as liver [38].  Under physiological conditions, Fas-mediated 
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apoptosis is activated by the binding of the natural ligand, Fas Ligand (FasL) to its 
receptor Fas. FasL exists in two forms, a transmembrane form expressed on the 
surface of cells and a trimeric soluble form generated by the cleavage of the 
membrane-bound form by metalloproteases. Fas activation can also be artificially 
induced by the addition of anti-Fas antibodies (Ab) [39]. Ligation of FasL or anti-Fas 
Ab changes the conformation of the receptor and results in clustering of the receptor 
[40]. This oligomerization, likely a trimerization, is required for the recruitment of 
the DISC at the plasma membrane and for the engagement of the cell death 
machinery [41].  
1.5.2.3 The Death Inducing Signalling Complex  
The DISC was first described in 1995 by Krammer and Peter as a complex of 
proteins that were recruited to the activated Fas-receptor [41]. These proteins have 
been identified since and have been shown to associate within the complex via 
homotypic contacts involving the presence of specific domains (Figure 1-2). The 
DISC consists of oligomerized Fas receptor, the Fas-Associated Death Domain 
protein (FADD), the procaspase-8 (or procaspase-10) and the cellular FLICE-
inhibitory protein (FLIP) [34]. After engagement of the Fas-receptor, FADD 
associates via its C-terminal death domain (DD) with the DD of the Fas-receptor. 
FADD contains another protein-protein interaction domain at its N-terminus: the 
Death Effector Domain (DED). FADD acts as an adaptor molecule within the 
complex and recruits the N-terminal DED domain of the procaspase-8, procaspase-
10 and FLIP.  Association of procaspase-8 to the DISC results in its activation. The 
mechanism whereby procaspase-8 is activated is still controversial and will be 
discussed in more details in the section 1.5.6.5. Then recruitment and activation of 
procaspase-8 leads to the cleavage and activation of the downstream effector 
caspases, such as caspase-3, and to the degradation of cellular proteins responsible 
for the apoptotic morphological features.  
Procaspase-10 also contains a tandem of DED domains and can thus be recruited by 
FADD, however its role in apoptosis is not yet clear [42, 43]. Like its close 
homologue caspase-8, caspase-10 may serve as an initiator caspase in DR-mediated 
apoptosis and may drive forward the signal to the executioner caspases [44, 45]. No 
homologue of caspase-10 was found in mouse. In human, family-inherited inactive 
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mutant of caspase-10 was reported to be associated with autoimmune 
lymphoproliferative syndrome (ALPS) and cancer [46, 47]. 
 
 
 
Figure 1-2: The Death Inducing Signalling Complex. 
After ligation by their cognate ligands, death receptors oligomerize at the plasma membrane 
and recruit FADD through their cytosolic DD. FADD binds procaspase-8 (or procaspase-10) 
via its DED to form the death-inducing signalling complex (DISC). Clustering of procaspase-
8 to the receptor results in its activation into the heterodimeric active caspase-8 form. FLIP 
competes with procaspase-8 for its recruitment to the receptor. 
 
FLIP was originally identified as a viral death inhibitor v-FLIP expressed by the γ-
herpes viruses to escape its elimination by infected cells [48]. v-FLIP consists of two 
tandem DEDs and therefore acts as a competitive inhibitor of caspase-8 for its 
association with FADD. To date, two cellular homologues have also been 
characterized in human, c-FLIPs (short form) and c-FLIPL (long form). c-FLIPs, like 
v-FLIP, functions as a dominant-negative inhibitor of caspase-8. However, c-FLIPL 
is a more complex protein that resembles the overall structure of caspase-8 but 
contains a mutated protease-like domain. This inactive homologue was reported to 
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inhibit Fas-mediated apoptosis by competing with caspase-8 for its recruitment to the 
DISC, but also to activate apoptosis by activating procaspase-8. The physiological 
relevance of c-FLIP and the mechanism whereby c-FLIP regulates Fas-mediated 
apoptosis at the DISC are still unclear and require more investigations.  
Evidence for the physiological importance of the Fas-receptor pathway come from 
mouse strains and from human patients presenting a defect in genes encoding 
components of the DISC. Inactive mutations of the Fas locus in lymphoproliferation 
mice (lpr) or Fas knockout mice are associated with an excessive accumulation of 
CD4-/CD8- T cells (premature thymocytes), splenomegaly, massive enlargement of 
the lymph nodes, and a low level of platelets and red blood cells due to autoimmune 
reactions [49, 50]. In humans, a similar phenotype with dysfunctional Fas has been 
reported. Mutations in Fas receptor in children have been associated with 
autoimmune lymphoproliferative syndrome (ALPS) [51]. Therefore, Fas-mediated 
apoptosis is a fundamental process in the regulation of the immune system. The 
biological importance of the Fas pathway has also been highlighted by the similar 
phenotype of the FADD and caspase-8 knockout mice. Disruption of the FADD or 
caspase-8 genes in mice was lethal in utero, and was thought to be due to 
abnormalities in heart development and abdominal hemorrhage [52, 53]. FADD and 
caspase-8 deficient mouse embryonic fibroblasts (MEFs) are resistant to Fas- and 
TNFα−mediated apoptosis but are still sensitive to death induced by intrinsic stimuli 
such as DNA damage. Familial mutations of caspase-8 have also been associated 
with immunodeficiency in humans due to defects in T and B cells development [54]. 
In this context, caspase-8 deficiency is compatible with normal embryonic 
development but it leads to post-natal defects in the activation of naïve-lymphocytes. 
More recently, conditional deletion of caspase-8 in mice has revealed non-apoptotic 
functions of caspase-8 [55]. Caspase-8 was shown to be essential for the function of 
hematopoietic progenitors in bone marrow and for the differentiation of 
macrophages. The similarity in the phenotype of FADD and caspase-8 knockouts 
indicates that these two proteins are essential components of the Fas-mediated 
apoptosis machinery and also emphasizes the physiological importance of the 
extrinsic pathway in the regulation of the immune system. In addition, these data 
strongly indicate that FADD and caspase-8 play an essential role in cardiac and 
lymphohematopoietic development.  
François Gonzalvez, 2007                                                                                                      26 
1.5.2.4 Type I and type II extrinsic pathways 
Depending on the cell type, two distinct Fas-signalling pathways can be activated 
after binding of either anti-Fas antibody or FasL [56, 57]. In type I cells, engagement 
of the Fas-receptor is followed by rapid DISC formation resulting in strong 
association and activation of procaspase-8 at the DISC. This directly activates 
caspase-3, which executes apoptosis. In these cells, caspase activation does not 
require a mitochondrial amplification step (cannot be blocked by Bcl-2 or Bcl-XL) 
though it does trigger mitochondrial alterations (such as cytochrome c release and 
mitochondrial depolarization). In type II cells, DISC formation and thus procaspase-
8 association are low and activation of caspase-3 requires a mitochondrial-dependant 
step. In these cells, apoptosis is inhibited by Bcl-2 or Bcl-XL. The physiological 
relevance of these two apoptotic pathways has recently emerged in vivo using 
transgenic animals. Hepatocytes from mice expressing a human Bcl-2 transgene were 
completely protected from Fas-induced apoptosis whereas Bcl-2 transgenic T cells 
and thymocytes were still sensitive [58, 59]. Similar results were found in Bax/Bak 
double knockout mice and in Bid-deficient mice [60-62]. Moreover, overexpression 
of Bcl-XL in mice protected B cells against Fas-induced apoptosis [63]. All together, 
these data indicate that thymocytes and T cells are type I cells and hepatocytes and B 
cells behave like type II cells. These two pathways are equally represented in tumour 
cell lines [64]. Type I and type II tumour cells were shown to express different set of 
genes: mesenchymal-like genes in type I and epithelial-like genes in type II cells. 
However, the significance of these two pathways in normal cell lines and in 
carcinogenesis is still unclear.  
1.5.3 Mitochondrial intrinsic pathway 
Mitochondria are intracellular double-membraned organelles that possess two well-
defined compartments, an intermembrane space surrounded by the outer membrane 
and a matrix surrounded by the inner membrane. The inner membrane is folded into 
numerous cristae and under physiological conditions it is almost impermeable to 
ions, a property required for the energy-production process, oxidative 
phosphorylation. It has long been known that mitochondria are the ATP generating 
powerhouses of the cell and the site of other key metabolic pathways. However, in 
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the early 1990s it became clear that in addition to these critical life supporting roles, 
mitochondria play a central part in the execution of apoptotic cell death [27, 65-68].  
1.5.3.1 Mitochondria: powerhouses of the cell 
About 2 billion years ago, a symbiosis occurred between a primitive anaerobic 
eukaryote (proto eukaryotes) and an aerobic eubacteria. This alliance allowed each 
partner to exploit the energy opportunities of the rising atmospheric oxygen and gave 
birth to the ancestor of eukaryotic cells, the protoeukaryotes. The endosymbiotic 
eubacteria were to become mitochondria [69]. Mitochondria utilize oxygen to 
oxidize metabolic substrates and to generate energy in the form of ATP. This 
process, called oxidative phosphorylation (OXPHOS), forms the basis of cellular 
respiration. OXPHOS was first described in 1961 by Peter Mitchell as the 
chemiosmotic theory which earned him the Nobel Prize in chemistry in 1978. 
Mitchell suggested that the transfer of electrons through the different respiratory 
complexes generates an electrochemical gradient of protons, which constitute the 
driving force for ATP synthesis [70]. This hypothesis is now generally accepted as 
the fundamental principle of OXPHOS (Figure 1-3). 
 
Figure 1-3: Mitochondrial oxidative phosphorylation 
I, II, III, IV refer to the respiratory chain complexes. V denotes the ATP synthase. Q, 
coenzyme Q; cytc, cytochrome c; OM, outer mitochondrial membrane; IM, inner 
mitochondrial membrane; e-, electrons. The black arrows represent the transfer of electrons 
through the electron transport chain. The red arrows show the flux of protons across the 
mitochondrial inner membrane.  
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During OXPHOS, electrons are transferred from NADH or FADH2 to the terminal 
acceptor, oxygen, via a series of oxidoreductive reactions through four respiratory 
chain complexes: NADH dehydrogenase (complex I), succinate dehydrogenase 
(complex II), cytochrome c reductase (complex III), and cytochrome c oxidase 
(complex IV) (Figure 1-3). Complex I and II transfer electrons from NADH and 
FADH2 [products of the tricarboxylic acid cycle (TCA)], to ubiquinone, which is 
reduced to ubiquinol. The electrons are then transferred from ubiquinol to 
cytochrome c via complex III. Finally, complex IV transfers the electrons from 
reduced cytochrome c to oxygen, which is then reduced to water. These complexes 
are located within the mitochondrial inner membrane. During the electron transport, 
complex I, III and IV translocate protons into the mitochondrial intermembrane 
space establishing a proton gradient across the inner mitochondrial membrane. This 
generates both a pH gradient and an electric potential across the mitochondrial inner 
membrane, called the mitochondrial membrane potential (Δψm). The electrochemical 
gradient of protons is used by the ATP synthase complex (complex V) as the driving 
force to phosphorylate ADP. In total, oxidation of one NADH transfers two electrons 
to oxygen and leads to the expulsion of 10 protons into the mitochondrial 
intermembrane space, which generates between 2 and 3 ATP molecules. Under 
aerobic conditions, OXPHOS functions in combination with glycolysis and the TCA 
cycle, to generate approximately 36 molecules of ATP per molecule of glucose 
oxidized.  
In addition to supplying energy to the cells, mitochondria carry out several essential 
metabolic reactions, including beta-oxidation of fatty acids and anabolic reactions 
such as amino acid, pyrimidine, heme, nucleotide and phospholipid synthesis. 
Moreover, mitochondria also participate in the calcium signalling and are the 
primary site of production of oxygen radicals.  
1.5.4 Mitochondria: central executioner of apoptosis 
1.5.4.1 Historic overview 
A role for mitochondria in apoptosis was first suggested in the early 90’s with the 
discoveries that the apoptotic-inhibitor Bcl-2 protein resides at the mitochondria and, 
that the presence of mitochondrial fractions is required for an efficient in-vitro 
apoptosis in Xenopus laevis oocyte extracts [27, 65]. This connection became more 
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evident when in 1995 Guido Kroemer demonstrated that cells undergoing apoptosis 
exhibited an early dissipation of their mitochondrial potential associated with 
production of reactive oxygen species [66, 67]. This evidence was quickly followed 
by the demonstration by Doug Green that cytosolic extracts from apoptotic cells 
were able to induce DNA fragmentation in a caspase-dependant and Bcl-2 inhibited 
manner [71]. Using a cell-free system, Xiadong Wang identified cytochrome c as the 
key factor required for apoptosis and proposed for the first time that mitochondria 
amplify apoptosis by releasing cytochrome c to the cytosol [68]. One year later, Don 
Newmeyer provided evidence that cytocrome c release from the mitochondria is 
controlled by Bcl-2 [72]. All these pioneering discoveries launched the fascinating 
mitochondria-mediated apoptotic research.  
1.5.4.2 Mitochondrial outer membrane permeabilization  
The mitochondrial intrinsic pathway is initiated following a wide variety of apoptotic 
stimuli including DNA damage, oncogene activation (such as Myc), endoplasmic 
reticulum (ER) stress, cytoskeletal damage, survival factor deprivation, DR 
engagement and others [31, 32]. Transduction of the apoptotic cascades requires the 
mitochondrial outer membrane permeabization (MOMP) [73]. MOMP is an early 
pivotal event that leads to the release of proteins normally localized in the 
mitochondrial intermembrane space. Known as apoptogenic factors, these proteins 
include cytochrome c [68], Smac/DIABLO [74], HtrA2/Omi [75], AIF [76] and 
Endonuclease G [77] of which cytochrome c has been the most intensively studied. 
Once released to the cytosol, these apoptogenics factors activate different cellular 
programs committing the cells to death [78]. Therefore, MOMP is often considered 
as the point of no return in the mitochondrial apoptotic pathway [79]. The release of 
cytochrome c, Smac-DIABLO and HtrA2/Omi to the cytosol drives the activation of 
caspases [80, 81]. Some evidence suggests that this event is a rapid and synchronized 
process achieved by all the mitochondria of a given cell within five minutes [81]. In 
these permeabilized mitochondria, the electron transport chain remains functional 
and maintains the Δψm until the activation of caspases [81, 82]. Apart from 
performing their pro-apoptotic function in the cytosol and nucleus, there are 
indications that once activated, caspases target the mitochondria and induce the 
degradation of respiratory complexes leading to the disruption of the electron transfer 
chain, loss of Δψm and the production of reactive oxygen species [83, 84]. At the 
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same time, caspase activation may also result in the release of the two other 
apoptogenic factors, AIF and Endonuclease G [80]. It is possible that the 
feedforward effect of caspases on the mitochondria is part of the induction of 
secondary necrosis described above.  
Beside MOMP, the release of cytochrome c from mitochondria appears to be more 
complex than simply diffusing out through the porated mitochondrial outer 
membrane and is thought to involve changes in mitochondrial configuration. Most of 
the cytochrome c is entrapped within the mitochondrial cristae and therefore, 
remodelling of these cristae is required to allow a complete release of cytochrome c 
[85]. This remodelling is critically controlled by two mitochondrial proteins, the 
rhomboid intra-membrane protease PARL and the dynamin-related protein OPA1 
[86, 87]. A decrease in Δψm has also been shown to induce matrix remodelling and to 
increase the pool of cytochrome c available for release [88]. Furthermore, 
mitochondrial fission can occur at the same time as MOMP and the proteins 
regulating fusion or fission have been shown to regulate MOMP [89]. The process of 
MOMP, and cytochrome c release in particular, has been intensively investigated in 
the past ten years. However, the exact mechanism remains unclear.  
1.5.4.3 Bcl-2 family proteins 
Bcl-2 family of proteins functions as a “life/death” switch that regulates MOMP and 
thus controls fate of cells. The Bcl-2 family of proteins are evolutionary conserved 
and are divided into three subfamilies according to their function and their homology 
shared within four Bcl-2-homology domains (designated BH1-4) (Figure 1-4). The 
anti-apoptotic members (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1 in humans) contain all 
four BH domains and they all repress the release of apoptogenic factors from 
mitochondria. The pro-apoptotic members  promote MOMP and are subdivided into 
two groups, the multi-domains proteins (Bax, Bak and Bok) containing the 3 
domains BH1-3 and the BH3 only proteins including eight members, Bid, Bad, Bim, 
Bik, Puma, Noxa, Bmf and Hrk [90]. 
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Figure 1-4: The Bcl-2 family of proteins (adapted from Cory et al, 2003). 
Bcl-2 family is divided into anti-apoptotic members that promote cell survival and pro-
apoptotic members. BH1 to BH4 (Bcl-2 homology domains 1-4) are regions which share 
relatively high similarity with Bcl-2. Many family members contain a carboxy-terminal 
hydrophobic transmembrane domain (TM) involved in the targeting of the proteins to 
intracellular membranes.  
 
Structural studies of the Bcl-2 family members have provided many important 
insights into their mechanism of action during apoptosis. They all present a similar 
three dimensional structure consisting of 6 or 7 amphipathic alpha-helices folded into 
a globular domain [91]. The pro-survival members (Bcl-2 and Bcl-XL) present a 
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hydrophobic groove on their surface responsible for the binding of the BH3 domain 
of the pro-apoptotic members [92, 93]. This interaction neutralizes the pro-apoptotic 
members. The ability of the Bcl-2 proteins to hetero-dimerize among themselves 
provides the basis for the “life/death” rheostat [94]. The multi-domain pro-apoptotic 
proteins (Bax and Bak) are constitutively expressed, but in healthy cells they are kept 
inactive to avoid their lethal effect. The BH3 only proteins act as sentinels, upstream 
from the multi-domain members and they become activated in response to different 
cellular stresses specific for each member (e.g, DR engagement for Bid, ER stress for 
Bik, cytokine deprivation for Bim and Bad, DNA damage for Puma and Noxa etc.). 
Once activated, the BH3 only proteins further activate the multi-domain pro-
apoptotic proteins required for MOMP. The mechanism of this activation is still 
debated. To date, two models have been proposed, the direct and the indirect 
activation model [95, 96]. It was proposed that depending on their affinity for the 
Bcl-2 family members, the BH3 only proteins are divided into two groups [95]. Bid 
and Bim interact with and directly activate the multi BH domain pro-apoptotic 
proteins, Bax and Bak, whereas Bad and Bik function as “sensitizers” by binding the 
hydrophobic pocket of the anti-apoptotic members and freeing the pro-apoptotic 
multi BH domain proteins. On the other hand, the indirect activation model suggests 
that the BH3-only proteins only antagonize the anti-apoptotic proteins and prevent 
their neutralization of Bax and Bak (without the need for direct activation) [96]. In 
any events, it is clear that appropriate balance between pro- and anti-apoptotic 
proteins is required for tissue homeostasis. Deregulations of this balance have been 
implicated in several pathologies including cancer, autoimmune disease, 
degenerative disorders and others.  
1.5.4.4 Mechanism of mitochondrial outer membrane 
permeabilization 
MOMP is entirely controlled by the Bcl-2 family proteins. The multi-domain 
proteins Bax and Bak play a central role in the execution of this process. Although, 
mice lacking Bax or Bak developed normally, Bax/Bak double knock-out mice died 
peri-natally or present severe developmental defects [61]. Moreover, cells deficient 
in both Bax and Bak, but not cells lacking only one of these proteins were 
completely resistant to various apoptotic stimuli that induce MOMP [62]. This 
suggests that in vivo, Bax and Bak play redundant roles in regulating apoptosis. Over 
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the past ten years, the mechanism by which Bax or Bak regulate MOMP has been 
extensively studied and the following model has evolved: since structures of the Bcl-
2 proteins show striking similarity to the pore-forming domain of colicins and 
diphtheria toxins it was suggested that these proteins may have the ability to form 
pores in the mitochondrial outer membranes [93]. In live cells, Bax and Bak are 
present as inactive monomers. Bax is a cytosolic protein whereas Bak resides at the 
surface of mitochondria and ER [97, 98]. In response to death signals, Bax and Bak 
are activated by the BH3-only proteins and undergo conformational changes that 
induce the exposure of their N-terminal domains. This results in the stable insertion 
and subsequent oligomerization of Bax and Bak in the mitochondrial outer 
membrane [99, 100]. These oligomers are thought to permeabilize the mitochondrial 
outer membrane resulting in the release of cytochrome c from the mitochondria [99, 
100]. In vitro experiments using artificial reconstituted membranes suggested that 
activated Bax induces MOMP by forming a proteo-lipidic pore with the 
mitochondrial phospholipid, cardiolipin (CL) [101]. The importance of cardiolipin in 
this process is also controversial and will be discussed in section 1.6.  
It is worth noting that another Bax and Bak independent mechanism has also been 
suggested to induce MOMP. This involves the opening of a high conductance pore, 
the permeability transition pore (PTP) located at the contact sites between the 
mitochondrial outer and inner membranes [102]. The topology of such a pore 
remains unclear but it assumes to be composed of several proteins including VDAC 
(Voltage Dependant Anion Channel), ANT (Nucleotide Adenylic Translocator) and 
cyclophilin D [103]. Opening of this pore results in the influx of ions and small 
molecules into the matrix leading to osmotic swelling of the matrix and the rupture 
of the mitochondrial outer membrane. However a growing body of evidence, using 
genetic models, suggests that the PTP is not involved in MOMP occurring during 
apoptosis but rather participates in necrotic cell death following calcium overload 
and ROS production [104, 105].  
1.5.4.5 Execution of mitochondrial apoptotic signals 
1.5.4.5.1 Cytochrome c release 
The release of cytochrome c from mitochondria was initially shown to induce the 
activation of caspase-3 [68]. Once released, cytosolic cytochrome c binds to Apaf-1, 
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a protein characterized by the presence of a caspase-recruitment domain CARD and 
a nucleotide binding domain [106]. Binding of dATP or ATP to the nucleotide 
binding domain of Apaf-1 results in the oligomerization of cytochrome c/Apaf-1 into 
a 1.4 MDa multimeric complex called the apoptosome [107]. Apaf-1 then recruits, 
via its CARD domain, the initiator pro-caspase-9, resulting in the clustering and 
activation of the enzyme [108]. Therefore, the apoptosome functions as an activating 
platform for pro-caspase-9. Activated caspase-9 is then able to cleave and activate 
caspase-3 and caspase-7, which, in turn, cleave their substrates, leading to the 
morphological features of apoptosis [109]. Determination of the structure of the 
apoptosome by cryo-electron microscopy revealed a wheel-shaped complex with 
seven-fold symmetry [110]. Results from knockout mice model have underscored the 
importance of the apoptosome pathway in apoptosis. Since cytochrome c is an 
essential protein for cellular respiration it has been difficult to evaluate the 
importance of this protein in developmental apoptosis [111]. This issue was resolved 
by generating a knockin mouse expressing a mutant of cytochrome c (KA mutant), 
which is still able to transfer electron but fails to activate Apaf-1 [112]. This mutant 
presented a similar phenotype to that seen in Apaf-1 and caspase-9 knockout mice 
[113-115]. These mutants displayed embryonic or peri-natal lethality due to severe 
defects in the central nervous system. MEFs generated from these mutants were 
equivalently resistant to apoptotic stimulations and failed to activate the caspase 
cascade.  
1.5.4.5.2 Smac/DIABLO and Omi/HtrA2 release 
In some cases, cytochrome c release is not sufficient to initiate the caspase cascade. 
To avoid spontaneous caspases activation, which would have a catastrophic 
damaging effect, cells have evolved another check-point to control the activity of 
caspases. In the cells, activated-caspases are kept inactive by the Inhibitor of 
Apoptosis Proteins (IAPs). IAPs bind to mature caspases (caspases-3, 7, 9) via their 
BIR (Baculovirus IAP Repeat) domains and inhibit caspase activity [116]. Murine 
Smac and its human ortholog DIABLO are mitochondrial proteins of 25 KDa that are 
released from the mitochondria simultaneously with cytochrome c during apoptosis 
[74, 117]. Once in the cytosol, Smac/DIABLO lowers the threshold for caspase 
activation by neutralizing the inhibitory effect of the IAPs. In fact, Smac/DIABLO 
binds the BIR domains via its N-terminal region and thus competes with caspases for 
the interaction with the IAPs [118]. However, Smac-knockout mice were viable and 
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cells generated from these animals responded normally to wide variety of apoptotic-
stimuli [119].  
Omi/HtrA2 is a mitochondrial serine-protease of 49 KDa that lowers the threshold 
for caspase activation in a similar fashion to Smac/DIABLO [75]. The physiological 
relevance of this redundancy is still unclear.  
1.5.4.5.3 AIF and EndoG release 
Apoptosis-inducing factor (AIF) is a 57 KDa flavoprotein located in the 
mitochondrial intermembrane space that shares homology with bacterial 
oxidoreductases [76]. After release from the mitochondria, AIF translocates to the 
nucleus where it induces chromatin condensation and DNA degradation in a caspase-
independent manner [76]. Disruption of AIF in mice was embryonically lethal [120]. 
However, in contrast with the cytochrome c knockin, Apaf-1 and caspase-9 knockout 
mice, which were lethal due to defects in brain development, AIF knockout mice 
died during early embryogenesis [113-115, 120]. Moreover, embryonic stem cells 
lacking AIF remained sensitive to a wide variety of apoptotic stimuli, ruling out a 
general requirement for AIF in cell death [120].  Therefore, the lethality of AIF 
knockout mice is more likely to be caused by general developmental defects 
unrelated to apoptosis but due to the requirement of AIF for mitochondrial function, 
such as the formation of complex I in the respiratory chain [121]. 
Endonuclease G (EndoG) is a 30 KDa protein that resides in the mitochondrial inter 
membrane space where it is thought to be involved in the replication of 
mitochondrial DNA [122]. By analogy with AIF, EndoG translocates from the 
mitochondria to the nucleus during apoptosis and directly induces DNA degradation 
in a caspase-independent manner [77].  However, EndoG knockout mice were viable 
and indicated that EndoG is not required for apoptosis [123]. 
The identification of AIF and EndoG first suggested that mitochondria may execute 
apoptosis in a caspase-independent manner. However, as mentioned previously the 
involvement of these two proteins in apoptosis is still uncertain. AIF and EndoG are 
released from the mitochondria during apoptosis, but this is likely to occur long after 
a cell has commited to die, after caspases activation [80].  
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1.5.5 Bid and the type II death receptor signalling pathway 
As mentioned in section 1.5.2.4, DR-mediated apoptosis must be amplified by the 
mitochondrial pathway in type II cells. In this case, the connection between the 
extrinsic and intrinsic pathways is established by the BH3 interacting domain death 
agonist protein (Bid). Bid is a 22 KDa protein, which was identified as a BH3 only 
pro-apoptotic member of the Bcl-2 family [124]. In healthy cells, Bid predominantly 
resides in the cytosol. Following Fas-receptor activation, Bid is cleaved in its N-
terminal region by activated caspase-8. The p15 truncated-Bid (tBid) rapidly 
translocates from the cytosol to the mitochondria and triggers cytochrome c release 
[125, 126]. tBid interacts with mitochondria at the contact sites between the inner 
and outer membranes via a specific binding to cardiolipin (CL) [127, 128]. The 
model of CL as a mitochondrial “docking” site for tBid will be discussed in section 
1.6.6.3. Targeting of tBid to mitochondrial CL is independent of its BH3-domain and 
leads to mitochondrial dysfunction [129, 130]. Moreover, the interaction of tBid with 
CL results in changes in mitochondrial configuration characterized by the opening of 
the cristae to the intermembrane space [85, 131, 132]. These BH3-independent 
events may represent a prerequisite step to predispose mitochondria to MOMP. The 
cytochrome c-releasing activity of tBid-requires the presence of either Bax or Bak 
[62]. Through its BH3 domain tBid activates the oligomerization of the multi-domain 
proteins Bax and Bak and results in the permeabilization of the mitochondrial outer 
membrane to cytochrome c and other apoptogenic factors [99, 100]. 
The importance of this link between the extrinsic and the intrinsic pathways was 
demonstrated in vivo using Bid knockout mice [60]. These mice survived the 
injection of anti-Fas antibody whereas wild-type mice died from hepatic failure due 
to apoptosis. Hepatocytes lacking Bid were resistant to Fas-induced apoptosis and 
failed to release cytochrome c and to activate caspases (type II cells). However, 
thymocytes and MEFs from these mice were still sensitive to Fas-mediated apoptosis 
(type I cells). 
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1.5.6 Caspase family 
1.5.6.1 Definition and classification 
Caspases belong to a conserved family of proteases that use a cysteine residue as a 
catalytic nucleophile to cleave their substrates specifically after aspartic acid 
residues. In metazoans, caspases play an essential role in apoptosis and 
inflammation. The first member of the family, caspase-1, was discovered in humans 
in 1992 as an important regulator of inflammation and originally called interleukin-
1β converting enzyme (ICE) [133, 134]. The role of caspases in apoptosis emerged 
several months later from genetic analysis in the nematode C. elegans. The team of 
Robert Horvitz generated C. elegans mutants in order to identify genes involved in 
developmental cell death. In 1993, they cloned the first cell death gene ced3 and 
showed that it encodes a cysteine protease (CED3) related to the mammalian ICE 
[135]. Since then, a number of caspases have been cloned from mammals and other 
species. Twelve caspases have now been identified in human, ten in mouse, four in 
chicken, four in zebrafish, seven in Drosophila melanogaster and four in C. elegans 
[136]. Based on their function, structure and substrate specificity, human caspases 
are classified into three groups (Figure 1-5).  
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 Figure 1-5: Domain organization of human caspases. 
Caspases have been grouped according to their function and sequence homology. The 
positions of aspartic acids (D) required for the maturation cleavage sites are shown in red. 
CARD, Caspase Recruitment Domain; DED, Death Effector Domain; Large and Small, the 
mature subunits of the fully active enzyme.  
 
Group I or inflammatory caspases (caspase 1, 4, 5, 12) are characterized by the 
presence of a Caspase Recruitment Domain (CARD) at the N-terminus and they 
preferentially cleave their substrate after sequence XEHD where X is a hydrophobic 
residue [137]. Recently, caspase-12 has been shown to negatively regulate the 
inflammatory response by inhibiting the activity of caspase-1 [138, 139]. However, 
caspase-12 does not recognize the peptide XEHD and may specifically cleave itself 
at the ATAD site [140].  Group II, or effector caspases, (caspase 3, 6 and 7) 
recognize the tetrapeptide DEXD and are responsible for the cleavage of cellular 
components during apoptosis. Group III, or initiator caspases (caspases 2, 8, 9, 10) 
are characterized by the presence of protein-interacting domains in their N-terminus 
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(either CARD or DED) and they cleave specifically the sequence (I/L) EXD present 
in effector caspases and other substrates.  
1.5.6.2 Caspase organization 
In healthy cells, caspases are present in the cytosol as inactive precursors (also 
known as zymogen or pro-caspases). These precursors must undergo a maturation 
process in order to be activated. The structure of pro-caspases is highly conserved 
(Figure 1-5). Pro-caspases are composed of a pro-domain at the N-terminus and two 
C-terminal active subunits, one large (17-20 kDa) and one small (10-12 kDa). These 
different domains are separated by a linker peptide containing caspase cleavage sites 
that participate in the maturation process of the zymogen. Initiator caspases contain 
long pro-domains (>90 amino acids) with CARD or DED motifs (Figure 1-5). These 
motifs participate in interactions with other proteins and are essential for the 
transmission of the apoptotic signal. Conversely, effector caspases possess short pro-
domains limited to 20-30 amino acids. During apoptosis, caspases undergo a 
hierarchical cascade of activation from the initiator to the effector caspases. Active 
caspases have a highly conserved, dimeric structure resulting from the association of 
two identical catalytic subunits. Each catalytic subunit contains one active site and is 
composed of one large and one small active domains. Upon maturation, pro-caspases 
are proteolytically processed at the cleavage site located between the large and the 
small subunits. In the past few years, the mechanism of caspase activation has been 
extensively investigated and debated. Considering that active caspases contain large 
and small domains derived from the zymogen, it has been assumed that all caspases 
are activated by proteolytic cleavage of their inter-subunit linker [141]. However, it 
is now well established that initiator and effector caspases are activated via two 
distinct processes.  
1.5.6.3 Activation of the initiator caspases  
Initiator caspases are the first to be activated during apoptosis, and they initiate the 
cascade of caspases that culminate in the degradation of essential cellular proteins by 
activating the executioner caspases. At first, initiator caspases were thought to be 
activated by induced proximity where the assembly of multiprotein complexes 
(PIDDosome for caspase-2, DISC for caspase-8, apoptosome for caspase-9) brings 
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together multiple identical pro-caspases leading to their autoprocessing. This model 
is supported by several observations, which demonstrated the cleavage of the active 
subunits during the formation of fully active initiator caspases [142]. Recently 
however, a growing body of evidence has led to the re-evaluation of this activation 
process, and a refined version of the proximity-induced model has been proposed 
[143-145]. Initiator caspase zymogens exist in the cytosol as latent monomers. After 
induction of apoptosis, the recruitment of these monomers to the activating 
complexes (such as DISC or apoptosome) effectively increases their local 
concentration allowing monomers to adopt a dimeric active conformation [143-145]. 
In this model, known as the proximity-induced dimerization, the dimerization 
provides essential active site rearrangements and thus is considered as a prerequisite 
for the activation of the initiator caspases. Proteolysis of the inter-subunit linkers is 
also required for the activation of the enzyme but it occurs after dimerization of the 
zymogen [143]. Whereas dimerization is sufficient to trigger self-processing of the 
initiator caspases, their auto-cleavage alters their substrate specificity and favours 
processing of the effector caspases [143, 146]. In other words, in the proximity-
induced dimerization model, processing of an initiator caspase is not sufficient to 
induce its activation unless it is already in a dimeric configuration but it is required to 
drive forward the cascade of caspases. More recent works have re-investigated the 
activation process of initiator caspases [147, 148]. Contrary to the proximity-induced 
dimerization, these studies suggested that processing of caspase-8 is sufficient to 
drive activation of this caspase and that a dimerization platform is not a prerequisite 
for this process. The significance of the dimerization and cleavage of the initiator 
caspases is still debatable and need to be further clarified. 
1.5.6.4 Activation of the effector caspases 
In contrast to the initiator caspases that are monomeric as zymogens, the effector 
caspases are held in the cytosol as inactive dimers. Following apoptotic stimulation, 
effector pro-caspases are converted into catalytically active enzymes by cleavage in 
the linker region between their large and small active subunit. In most instances, this 
activating event is catalysed by active initiator caspases. The precise mechanism 
whereby effector caspases are activated after cleavage is still unclear. Analysis of the 
crystal structure of caspase-7 demonstrated that upon cleavage, the region of the 
active site of the enzyme undergoes conformational changes that render it accessible 
François Gonzalvez, 2007                                                                                                      41 
to its substrates [149]. The active site is composed of four surface loops, L1 to L4, all 
from the same monomer and is stabilized by the L2’ loop from the adjacent 
monomer. The catalytic cysteine is in the L2 loop. After cleavage, L2’ is flipped by 
180 degrees to unravel the catalytic site of L2. The high degree of similarity between 
the effector caspases strongly suggests that this mechanism of activation is conserved 
for caspase-3 and caspase-6.  
Caspase-3 is the major effector caspase, which cleaves a plethora of cellular 
substrates during apoptosis [150]. Caspase-7 is highly similar to caspase-3 and it 
demonstrates similar substrate specificity [151]. Mice deficient in either caspase-3 or 
caspase-7 were viable on this genetic background whereas those that lacked both 
caspases had defects in heart development and died immediately after birth [152]. 
MEFs lacking both enzymes are resistant to intrinsic and extrinsic apoptotic stimuli, 
suggesting that caspase-3 and caspase-7 carry-out redundant, but essential functions 
during the execution of cell death. In stark contrast, caspase-6 presents a different 
substrate specificity and does not seem to be required for apoptosis [153]. 
1.5.6.5 Regulation of caspase-8 activity 
Caspase-8 was identified in 1996 as a component of the DISC. It is homologous to 
FADD and the ICE family and was originally named FLICE (FADD-Homologous 
ICE/CED3-like Protease) and MACH [154, 155]. In cells, procaspase-8 is expressed 
as two functional isoforms, caspase-8/a and 8/b (55 and 53 kDa, respectively) 
encoded by the same gene. Both zymogen are recruited to the DISC after Fas-
activation [156]. Pro-caspase-8 is composed of a large prodomain containing a 
tandem of two DED domains and two active subunits, one large of 18 kDa and one 
small of 10 kDa (Figure 1-5).  
Caspase-8 is the first caspase to be activated after DR stimulation. As mentioned 
above, caspase-8 activation is thought to follow the proximity induced-dimerization 
model. After Fas receptor engagement, cytosolic monomers of pro-caspase-8 are 
recruited via their DED to the DISC located at the plasma membrane. This clustering 
results in the dimerization of the zymogens which then acquire a limited capacity of 
enzymatic activity [144, 146]. In this context, dimerization favours an enzymatically 
competent conformation and promotes autoprocessing of the dimer [143]. In vitro, 
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dimerized procaspase-8 is capable of undergoing self cleavage between the p10 and 
p18 domains (intramolecular processing), as well as cleaving the neighbouring 
monomer (proteolysis in trans). However, judging from the crystal structure, it 
appears that the two catalytic subunits of the dimeric zymogen form a globular 
structure where the catalytic cysteines diametrically oppose each other making it 
difficult for one active site to cleave the other subunits [157]. Therefore, it is more 
likely that caspase-8 autoprocesses by intramolecular cleavage. In this scenario, 
formation of the dimeric zymogen is a prerequisite event for the autoprocessing of 
caspase-8 [146]. Upon dimerization, procaspase-8 is cleaved firstly between its two 
active subunits and secondly in the region linking the prodomain and the large active 
subunit to finally form the dimeric active enzyme. These two sequential cleavage 
events are required for the full activity of caspase-8. The inability of fully active 
caspase-8 to cleave procaspase-8 in vitro and the fact that only autoprocessed form of 
caspase-8 is capable of cleaving caspase-3 efficiently suggest that dimerized pro-
caspase-8 and fully processed caspase-8 have different substrate specificity [146]. 
Moreover, the processed form of caspase-8 shows higher activity compared to the 
zymogen (called zymogenicity) [151]. Therefore, dimerization of caspase-8 
zymogens represents the first activating event that confers sufficient activity for 
autoprocessing and for further activation. 
Procaspase-8 is predominantly localized in the cytosol but was also recently shown 
to loosely associate with the mitochondrial outer membrane [158, 159]. After Fas-
activation, mitochondria-associated procaspase-8 is cleaved to form an active dimer 
that moves to the cytosol and specifically targets its substrates, such as Bid and 
plectin [158, 159]. Since the signal is initiated at the cell surface, it is conceivable 
that a small amount of caspase-8, which is activated at the DISC, moves to the 
mitochondria and cleaves mitochondria-associated procaspase-8. In type II cells, the 
activation of caspase-8 is delayed and requires a mitochondrial step regulated by Bcl-
2 and Bcl-xL [56]. Interestingly, it was found that Bcl-xL can block the activity of 
caspase-8 at the mitochondrial membrane by indirectly sequestering the enzyme at 
the mitochondrial outer membrane [159]. These data suggest that in type II cells, 
caspase-8 might be activated at the mitochondrial membrane. Details of the 
mechanisms of activation of caspase-8 at the mitochondrial membranes of type II 
cells await further investigation.  
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In addition to its crucial role in DR-mediated apoptosis, it appears recently that 
caspase-8 also participates in growth and development mechanisms, not only of 
lymphocytes, but of several other tissues. The inactive homologue of caspase-8, c-
FLIPL, plays an important role in this process. In fact, c-FLIPL is able to dimerize 
and activate caspase-8, which in turn cleaves c-FLIPL and results in the recruitment 
of adaptor proteins that promote the activation of NF-κB and lead to cell 
proliferation [160]. 
1.6 Cardiolipin in apoptosis 
Cardiolipin (CL) is a mitochondria-specific phospholipid which is known to be 
intimately linked with the mitochondrial bioenergetic machinery. Accumulating 
evidence now suggests that this unique lipid also takes active roles in several of the 
mitochondria-dependant steps of apoptosis [161]. 
1.6.1  Cardiolipin synthesis 
The name “cardiolipin” alludes to the fact that it was first isolated from beef heart in 
1942. CL or diphosphatidylglycerol can be distinguished from other 
glycerophospholipids by its dimeric structure containing four acyl chains per 
molecule and potentially having two negative charges (Figure 1-6).  
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Figure 1-6: Molecular structure of cardiolipin. 
Cardiolipin is a dimer of phosphatidyl glycerol (PG, in red) and phosphatidic acid (PA, in 
black). It contains four acyl chains, two phosphate groups and three glycerols. Under 
physiological pH, one of the phosphates is deprotonated, making CL a negatively charged 
phospholipid. 
 
 CL is exclusively localized to the membranes of bacteria and mitochondria 
providing more evidence for the endosymbiotic origin of the mitochondria. The 
biosynthetic pathway of CL has been well described in mammals [162, 163]. CL is 
synthesized de novo in a four step pathway catalyzed by four mitochondrial enzymes, 
yielding a CL archetype. The first three steps correspond to the phosphatidyl-
glycerol pathway and pass through the generation of the common intermediates, 
phosphatidic acid (PA) and phosphatidyl-CMP. In the first step, CDP-diacylglycerol 
synthetase catalyses the activation of PA into CDP-diacylglycerol (CDP-DG). In a 
second reaction phosphatidyl-glycerol phosphate synthetase (PGS1) adds one 
molecule of glycerol-3-phosphate to the CDP-DG yielding a molecule of 
phosphatidyl-glycerol-3-phosphate (PGP). PGP is then rapidly dephosphorylated to 
form phosphatidyl-glycerol (PG) by PGP phosphatase. The final step is unique to CL 
synthesis and is catalyzed by CL synthase. During this reaction, PG condenses with a 
molecule of CDP-DG resulting in the generation of diphosphatidylglycerol or CL. 
The human CL synthase gene has recently been identified by its ability to restore the 
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CL profile of a CL synthase deficient yeast mutant [164, 165]. Each molecule of CL 
contains four acyl chains. Considering the variety of fatty acids, the number of 
potential combinations of the acyl chains is high, and indeed, the pattern of CL 
molecular species varies between organisms and even between tissues. Eukaryotic 
CL has a characteristic acyl chain pattern that is essentially restricted to C18 chains 
[166]. In human heart the predominant C18 fatty acid is linoleic acid (C18:2) so heart 
CL contains mostly C18:2 acyl chains. However human lymphoblasts CL contain 
predominantly oleyl chains (C18:1) [167]. The significance of this specificity is still 
not understood. Interestingly, the enzymes involved in the pathway of CL synthesis 
exhibit no selectivity for a specific acyl chain length [168]. Therefore, once 
synthesized in mitochondria, a maturation step replacing the original acyl chains with 
specific C18 unsaturated ones is required (Figure 1-7). 
 
 
Figure 1-7: Remodelling cycle of cardiolipin. 
The degree of unsaturation of CL acyl chains is constantly maintained by the cycle of two 
reactions. First, phospholipase A2 hydrolyses one acyl chain of CL and generates a 
monolyso-CL (MLCL). Second, tafazzin catalyses the transfer of unsaturated acyl-chain from 
phosphatidyl-choline (PC) to MLCL. This results in the formation of mature CL with 
unsaturated acyl chains and lysophosphatidyl-choline (LPC).  
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The generation of mature CL requires a cycle of two reactions: the hydrolysis of one 
original acyl chain to generate a monolyso-CL (MLCL), now containing only three 
acyl groups, followed by the reacylation of MLCL with the specific acyl chain. 
Phospholipase A2 catalyzes the first step of acyl chain removal [169]. Reacylation of 
MLCL has been reported in rat and pig liver [170, 171]. This activity has recently 
been shown to be catalyzed by tafazzin, a mitochondrial enzyme whose mutations 
cause the Barth syndrome [172]. Tafazzin is a transacylase that catalyses the transfer 
of unsaturated acyl chains from phosphatidyl-choline (PC) to MLCL. 
1.6.2 Barth syndrome 
Barth syndrome (BTHS, MIM#302060) is the first human disease discovered in 
which the primary cause is due to an alteration of CL metabolism [173, 174]. BTHS 
is clinically characterized by the triad cardioskeletal myopathy, neutropenia, and 
growth retardation. It has a high rate of mortality during infancy and early childhood 
due to cardiac arrest or overwhelming bacterial infections. 3-methylglutaconic 
aciduria is an important biochemical marker for the syndrome and is now recognized 
as a fourth major criterion for the diagnosis. Almost all children with BTHS have 
clinically significant heart failure and muscular hypotonia leading to general 
weakness and to delayed motor development. Cardioskeletal myopathy is due to 
mitochondrial dysfunction. Tissue biopsies from BTHS patients contained 
mitochondria with abnormal structure and diminished OXPHOS [173]. Neutropenia 
corresponds to a deficiency in circulating neutrophils. In BTHS, neutropenia is not 
due to an increase in apoptosis but rather from a maturation arrest at the 
premyelocyte stage of neutrophil development [173]. 
This genetic disorder is due to mutations in the tafazzin gene (TAZ) located in the 
Xq28.12 region in the human genome [175]. The tafazzin gene contains 11 exons and 
possesses two putative alternative translational initiation sites. The function of the 
second initiation site has not yet been defined. In humans, four different transcripts 
are produced due to alternative splicing of exons 5 to 7 which encode four protein 
variants ranging from 28.5 to 33.5 kDa [176, 177]. In tafazzin-deficient yeast, only 
the human variant lacking exon 5 was able to restore cardiolipin synthesis and to 
complement the retarded growth [178]. However, since exon 5 is only present in 
primate species, the function of the full length protein must be investigated in cells 
that normally include this exon. Moreover, identification of an exon 5 mutation in 
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BTHS patients strongly indicates that exon 5 is required for the activity of tafazzin in 
human [177]. Further investigation is required to understand the activities of the 
different tafazzin variants. To date, over 90 different pathogenic mutations have been 
reported and mapped in all 11 exons [177]. These include frameshift, non-sense, 
splice-site, and missense mutations and they result in either a complete loss of 
protein expression or in the expression of non-functional truncated tafazzin.  
The first evidence that CL has a role in BTHS emerged in 2000 with the observations 
made by Barth and his colleagues that the total amount of CL as well as the rate of 
linoleyl chains incorporation into CL decreased in BTHS fibroblasts without detected 
changes in overall phospholipid synthesis [179]. Therefore, it was postulated that 
tafazzin is involved in the remodelling process of CL. Analyses of the CL profile 
from different tissues obtained from BTHS patients have revealed that the decrease 
in CL levels is associated with an increase in MLCL, further supporting this 
hypothesis [180, 181]. Recently, the enzymatic function of the full length isoform of 
Drosophila melanogaster tafazzin has been characterized. It is now described as a 
phospholipid transacylase that catalyzes the transfer of linoleyl chain from PC to 
MLCL [172].  
1.6.3 Cardiolipin localization in mitochondria 
CL is specific to mitochondrial membranes but its precise localization within the 
different compartments of the organelle is still a subject of controversy. For many 
years, it was assumed that CL is exclusively associated with the mitochondrial inner 
membrane. CL appears to be more abundant in the inner leaflet than in the outer 
leaflet of the inner membrane, where they represent 18% and 6% of the total 
phospholipid composition, respectively [182]. More recently traces of CL have also 
been found in the mitochondrial outer membrane (~4%) and in the contact sites 
between the mitochondrial outer and inner membranes [183-185]. Through contact 
sites, CL may reach the mitochondrial outer membrane and the cytosolic face of the 
mitochondria. This notion is supported by the fact that the two major phospholipids 
present in contact sites, phosphatidyl-ethanolamine (PE) and CL (~25 % each) have 
the ability to adopt non bilayer hexagonal HII phase [186] (Figure 1-8). Such 
structures are known to contribute to the fusion of two membranes [187]. 
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Figure 1-8: Cardiolipin at the mitochondrial contact sites. 
The non-bilayer hexagonal structure of lipids was characterised in vitro and proposed to 
contribute to the structure of contact sites between the inner and outer membranes of 
mitochondria. Negatively charged phospholipids (such as CL) are more likely to adopt this 
structure which may fuse the mitochondrial membranes at the contact sites and redistribute 
cardiolipin on the cytosolic face of the mitochondria. CLs are highlighted in blue.  
 
1.6.4 The role of cardiolipin in bioenergetics 
The exclusive presence of CL in bioenergetic membranes suggests that it interacts 
with the electron transport chain complexes involved in OXPHOS. Indeed, CL is 
required for optimal activity of complex I (NADH dehydrogenase), complex II 
(Succinate dehydrogenase), complex IV (cytochrome c oxidase) and complex V 
(ATP synthase), four large complexes integrated in the inner mitochondrial 
membrane [188, 189]. Furthermore, complexes III, IV and V were shown to contain 
CL in their quaternary structure [188, 190, 191] and CL was observed within the 3D 
crystal structure of Escherichia coli succinate dehydrogenase, an orthologue of the 
mitochondrial respiratory complex II [192]. CL is also required by mitochondrial 
substrate carriers, including the ANT, acylcarnitine translocase and phosphate carrier 
[193-196]. It was therefore reasonable to predict that a deficiency in CL would result 
in alterations in cell respiration. The Chinese hamster ovary (CHO) cell line 
containing a temperature-sensitive (ts) mutant of PG synthase (CHO-PGS-S) has 
provided the first indication of the potential involvement of CL in cellular 
bioenergetics [197]. At the non-permissive temperature (40ºC) these cells exhibit a 
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decrease in oxygen consumption and ATP production, accompanied by a 
compensatory increase in glycolysis [198]. However, since these cells have reduced 
levels of both PG and CL at 40ºC, it is not possible to attribute these bioenergetic 
defects to CL alone. Other studies using the CL synthase deficient yeast mutant 
crd1Δ have provided more direct evidence for the requirement of CL for 
mitochondrial bioenergetics. Somewhat surprisingly, the crd1Δ mutant was able to 
grow, though not as efficiently as wild type yeast, on non-fermentable carbon 
sources, indicating that CL is not essential for OXPHOS in yeast [199]. However, 
several bioenergetic defects associated with a reduction of ANT activity, decreased 
mitochondrial membrane potential, and an overall decrease in OXPHOS, were 
observed in the crd1Δ mutant when grown under stress conditions [200-202]. Thus, 
CL appears to be required for sustaining mitochondrial inner membrane integrity, 
rendering it more resistant to unfavourable conditions such as high respiration rate, 
high temperature and hypotonic shock. 
In mitochondria, only 15% of cytochrome c is free in the inter-membrane space [85, 
203] while most of it is attached to the mitochondrial inner membrane via specific 
interactions with CL [204, 205]. Two types of interactions, hydrophobic and 
electrostatic, have been linked to two distinct CL binding sites on cytochrome c. 
Initially, these interactions were thought to play a role in the electron-shuttle activity 
of cytochrome c by keeping the molecule in the proximity of the respiratory chain 
[204]. More recently, CL-cytochrome c interactions were suggested to participate in 
the regulation of apoptosis. 
1.6.5 Cardiolipin maintains the structure of the mitochondrial 
inner membrane  
At 40ºC, the mitochondria of CHO-PGS-S cells appear swollen and have 
disorganized cristae [198, 206]. However, as mentioned above, these alterations 
cannot be solely attributed to CL, since these cells lack both CL and PG. A more 
recent study of HeLa cells in which the expression of CL synthase was decreased by 
RNA interference (RNAi) indicated that CL is directly required for maintenance of 
mitochondrial structure [165]. This report, however, contrasts with the phenotype of 
the crd1Δ yeast mutants, which lack CL but maintain normal mitochondrial 
morphology [207]. The differences between CL synthase-deficient mammalian cells 
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and yeast may be due to the ability of PG to supplant the membrane-preserving 
function of CL in yeast.  
1.6.6 Cardiolipin in relation to apoptosis 
1.6.6.1 Cardiolipin levels and oxidative stress 
 Loss of CL is associated with diverse pathophysiological conditions such as ageing 
and ischemia/reperfusion processes [208, 209]. For example, the loss of CL during 
ischemia/reperfusion injury is followed by a decrease in OXPHOS which may 
contribute to myocyte death in the peri-infarct regions of the ischemic myocardium. 
The decline in mitochondrial respiratory functions causes the accumulation of 
reactive oxygen species (ROS). Under normal physiological conditions 
mitochondrial CL may protect cells from oxidative stress in part through the 
deacylation-reacylation cycle discussed above. However, CL is also a vulnerable 
target of ROS due to its unsaturated acyl chains and its close proximity to ROS 
generation sites. ROS cause the peroxidation of CL and a parallel decrease in the 
activities of complexes I and IV [210, 211]. Currently this seems to be very much a 
“chicken and egg” issue, and it is unclear whether ROS trigger the loss of CL or 
whether loss of CL triggers ROS generation. It is clear, however, that during many 
cell death processes ROS and loss of CL are closely linked in a cycle of CL 
peroxidation. Peroxidation of CL also occurs following a variety of apoptotic stimuli 
such as by nitric oxide, Fas receptor stimulation, NGF deprivation, staurosporine and 
actinomycin D treatments [212-214]. Interestingly, apoptosis via a pathway 
involving a decrease in CL synthesis was seen in neonatal rat cardiac myocytes and 
in breast cancer cells treated with saturated fatty acids, particularly palmitate [215, 
216]. 
1.6.6.2 Cardiolipin - cytochrome c interactions regulate 
cytochrome c release  
As mentioned above, the majority of cytochrome c is bound to the outer leaflet of the 
mitochondrial inner membrane. Cytochrome c has a net charge of +8 at physiological 
pH allowing it to bind membranes primarily through electrostatic interactions with 
the head groups of anionic phospholipids such CL [204, 205]. Cytochrome c has a 
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hydrophobic cavity which may account for hydrophobic interactions with the fatty 
acyl chains of CL [217]. Two CL binding sites on cytochrome c have been proposed; 
the A site which facilitates electrostatic interactions with the negative charges of CL 
and the C site which is involved in hydrophobic interactions with the fatty acyl 
chains of CL [204]. These sites are responsible for two different conformations of 
cytochrome c in the intermembrane space: a loosely bound conformation involving 
site A and a tightly bound conformation at site C that partially embeds the protein in 
the membrane [218]. Loosely bound cytochrome c participates in the transfer of 
electrons from complex III to complex IV, as well as in ROS scavenging [219, 220]. 
Tightly bound cytochrome c was proposed to possess peroxidase activity that utilizes 
hydrogen peroxide generated in the mitochondria to peroxidate CL [214].   
For both types of CL binding it was proposed that cytochrome c release from 
mitochondria would first require the dissociation of its interactions with CL (Figure 
1-9) [221, 222]. This is consistent with recent findings showing that in CL-deficient 
cells, a greater fraction of cytochrome c is free or loosely bound [165]. The fact that 
in vitro, cytochrome c has a lower affinity for peroxidized CL than CL, suggests that 
CL peroxidation may enable cytochrome c detachment from the inner membrane 
(Figure 1.9). Complete release of cytochrome c into the inter membrane space 
requires dissociation of both the hydrophobic and the electrostatic interactions 
between cytochrome c and CL [223]. The final release of cytochrome c from 
mitochondria requires additional steps in the process, consisting of the 
permeabilization of the outer membrane. Cristae remodelling was also shown to be 
required for cytochrome c re-distribution within the mitochondrial inter membrane 
space before its release [85] but whether the dissociation of CL-cytochrome c 
interactions is related to this process awaits further study. Still, the studies described 
above strongly indicate that CL and cytochrome c are physically associated and for 
some functions at least they are also interdependent. 
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Figure 1-9: Dissociation of cardiolipin-cytochrome c interaction during apoptosis. 
Cytochrome c (red) is attached to cardiolipin on the outer surface of the mitochondrial inner 
membrane and therefore, permeabilization of the mitochondrial outer membrane is not 
sufficient for cytochrome c release. The dissociation of cytochrome c from cardiolipin is a 
prerequired step for outer membrane permeabilization and is triggered by cardiolipin 
peroxidation. Recently it was shown that cardiolipin peroxidation is catalyzed by the bound 
cytochrome c itself. 
 
1.6.6.3 Cardiolipin: docking site for tBid 
The first apoptosis-promoting role of CL emerged from biochemical studies of tBid 
interactions with mitochondrial lipids using liposomes and the CHO-PGS-S cell line 
[127]. Wang and co-workers showed that the pro-apoptotic protein tBid interacts 
exclusively with liposomes that contain at least physiological levels of CL and 
demonstrated that tBid co-localization with CHO-PGS-S mitochondria is CL-
dependent. The CL-binding domain of tBid was mapped to helices 4-6 of the Bid 
protein [127]. Interestingly, helix 6 was later shown to be a part of a hairpin structure 
which is important for the lipid binding properties of tBid [224]. Subsequently, 
electron tomogram studies showed that tBid interacts with mitochondria specifically 
at the inner and outer membrane contact sites, which are rich in CL [128]. As 
discussed above, CL-rich membranes may adopt a non-bilayer hexagonal HII 
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configuration at the contact sites (Figure 1-8), enabling the access of CL to the 
cytosolic surface of mitochondria [185]. The model of CL as a mitochondrial 
“docking” site for tBid is supported by several studies (Figure 1-10). For example, in 
vitro assays using artificial membranes or isolated mitochondria showed that 
recombinant tBid can bind CL and MLCL [131, 132, 225-227]. Adding tBid to 
isolated mitochondria immediately inhibits ADP-stimulated respiration and oxidative 
phosphorylation, as a result of ANT inactivation [129, 130]. The function of tBid 
may be either BH3-domain-dependent or independent. The former induces 
oligomerization of the multi-BH domain pro-apoptotic Bcl-2 proteins Bax and Bak 
on the mitochondrial outer membrane, while a BH3-independent interaction of tBid 
with CL [227] could be responsible for cristae remodelling, [131] and for inhibition 
of OXPHOS [130]. Cristae remodelling and perturbations of mitochondrial 
bioenergetics take place simultaneously and are both independent of Bak. It is 
possible therefore that tBid acts by two sequential mechanisms: the first is BH3 
domain independent, which involves CL, leading to structural and functional 
impairment, and the second is BH3 domain dependent, employing interactions with 
other pro-apoptotic Bcl-2 proteins, namely Bak and Bax, leading to mitochondrial 
outer membrane permeabilization. Thus, the interaction of tBid with CL may prime 
mitochondria for the action of Bax and Bak.  
 
Figure 1-10: Cardiolipin serves as a docking platform for the Bcl-2 proteins tBid. 
After cleavage, tBid translocates to the mitochondria via a specificic interaction with CL (in 
blue) exposed to the surface of the mitochondrial contact sites. This leads to an unravelling 
of the pool of cytochrome c trapped in the mitochondrial cristae. 
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1.6.6.4 Cardiolipin redistribution 
Another feature of CL observed under apoptotic conditions is its redistribution within 
and between membranes. The exposure of CL on the outer leaflet of the 
mitochondrial inner membrane was observed after death receptor stimulation before 
mitochondria depolarization and PS exposure on the plasma membrane, and at the 
same time as ROS generation [228]. Peroxidation of CL may account for this 
redistribution by altering their molecular organization and favouring formation of a 
non-bilayer hexagonal structure [229]. This could increase exposure of CL on the 
contact sites of mitochondrial membranes and provide access for tBid. It is also 
suggested that Bid, which exhibits lipid transfer activity in vitro, relocates CL and 
MLCL to the plasma membrane of cells undergoing apoptosis [230, 231]. The 
mechanism and the significance of this relocation are still unclear. In addition, tBid 
may reorganize CL into micro-domains as was demonstrated in artificial lipid 
monolayers containing physiological amount of CL [130]. Considering the possible 
role of CL in maintaining mitochondrial structure, changes in CL organization may 
result in structural changes of the mitochondrial inner membrane which in turn may 
affect the activity of membrane-embedded proteins such as ANT. Therefore, it is 
conceivable that tBid affects the structure and function of mitochondria by binding to 
and redistributing mitochondrial CL within the mitochondrial inner membrane and/or 
within other cellular compartments.  
1.6.6.5 Cardiolipin and MOMP 
CL has also been proposed to be required for the action of other pro-apoptotic Bcl 2 
proteins [101]. To study individual functions of Bcl-2-family proteins Newmeyer and 
co-workers took an in vitro approach using liposomes and outer mitochondrial 
membrane vesicles. Their work has provided evidence that permeabilization of 
liposomes to dextran required both the presence of activated Bax and physiological 
levels of CL. Therefore, it was suggested that Bax may permeabilize the 
mitochondrial outer membrane by altering the local organization of CL without 
overall damage to the membrane itself (Figure 1-11). In contrast to this report, other 
studies using either the CL synthase deficient yeast crd1Δ or mitochondria from CL 
synthase knocked-down cells have shown that Bax does not require CL for the 
induction of cytochrome c release [129, 165, 232]. However, as discussed above, it is 
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possible that in yeast, PG, which accumulates in the absence of CL synthase, 
compensates for the loss of CL. It still awaits clarification whether CL or its PG 
precursor are needed, for Bax to release cytochrome c [233]. This is particularly 
interesting since hydrophobic and electrostatic interactions make a different 
contribution to the binding of cytochrome c to CL or PG [234].  
 
Figure 1-11: Cardiolipin and permeabilization of the mitochondrial outer membrane. 
Cardiolipin participates with tBid and Bax in the perforation of the mitochondrial outer 
membrane. The mechanism is still elusive. 
 
1.6.6.6 Cardiolipin-cytochrome c peroxidase activity 
CL peroxidation appears to be an early event preceding the release of cytochrome c 
and caspase activation. The mechanism of CL peroxidation and its involvement in 
apoptosis has gained more attention recently [214, 235]. Kagan and colleagues 
showed that cytochrome c can interact with CL that contains two or more unsaturated 
acyl groups (C18:2 mostly) to form a hydrogen peroxide peroxidase capable of 
oxidizing CL to peroxi-CL (Figure 1-9). Using cytochrome c-/- mouse embryonic 
cells they provided the first evidence that cytochrome c is required for the 
peroxidation of CL. The CL-cytochrome c complex acts as a potent CL-specific 
oxygenase required for the release of pro-apoptotic factors such as cytochrome c and 
Smac/DIABLO. It is noteworthy that oxidized CL does not merely allow cytochrome 
c to detach from the mitochondrial inner membrane but rather has an active role in 
inducing apoptosis: when added to isolated mitochondria oxidized CL alone induces 
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cytochrome c and Smac/DIABLO release [214]. Importantly, the peroxidase activity 
of the CL-cytochrome c complex depends on unsaturated acyl chains on CL. Indeed, 
incubation of HL60 cells with the poly-unsaturated fatty acid docosahexaenoic acid 
(C22:6), enriches CL with C22:6 acyl chains, sensitizing the cells to staurosporine-
induced apoptosis [214]. This promoted the notion that enriching CL with saturated 
acyl chains may protect from apoptosis. But although in vitro, saturated CL cannot 
stimulate CL-cytochrome c peroxidase activity [214], CL synthase in a cellular 
context does not incorporate saturated PG to form fully saturated CL [216]. 
Nevertheless, the results, together with the suggestion that oxidized CL may have a 
promoting effect on the pro-apoptotic activity of Bcl 2 proteins, point to the 
importance of CL acyl chain composition and suggest that manipulation of CL 
oxidation may present a good target for sensitising cells to apoptosis. This also raises 
the question whether Bcl-2 proteins can regulate CL-cytochrome c peroxidase 
activity. 
1.7 Apoptosis: a target in cancer therapy 
Evading apoptosis is one of the six cardinal hallmarks of cancer [236]. Cancer cells 
have developed several strategies to evade programmed cell death by either 
negatively regulating death activators (e.g caspases) or overactivating apoptosis 
inhibitors (e.g Bcl-2). Over the past 15 years, advances in the knowledge of the 
molecular mechanisms of apoptosis provided numerous suitable targets for drug 
development and thus opened new therapeutic venues for the treatment of cancer. 
Reactivation of this endogenous pathway in tumour cells is the goal of many new 
anti-cancer strategies.  
1.7.1 Targeting the TRAIL pathway  
As mentioned in section 1.5.2.1, the TNF-Related Apoptosis-Inducing Ligand 
receptors (TRAILR) belong to the TNFα family of receptors. To date, two types 
have been identified, TRAILR1 (DR4) and TRAILR2 (DR5). In analogy with Fas-
receptor, activation of the TRAIL receptors induces the formation of the DISC, 
which ultimately leads to cell death. However, whereas Fas agonists have revealed 
severe toxicity in normal tissues [237], TRAIL seems to be a more promising 
candidate for cancer therapy, because it specifically kills tumour cells. Two strategies 
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have been developed by pharmaceutical companies to activate this endogenous 
pathway. They include the administration of either recombinant proteins, consisting 
of active fragment of the ligands, or agonistic antibodies that bind to TRAIL receptor 
and induce apoptosis [238]. In most cases, resistance of tumours to chemotherapy is 
due to defects in the intrinsic apoptotic pathway, as a result of mutations in the 
tumour suppressor p53 pathway, or due to the overexpression of the anti-apoptotic 
Bcl-2 proteins. However, TRAIL mediated apoptosis is independent of p53 and can 
bypass the “Bcl-2 checkpoint” by directly activating the caspases cascade 
independently of the mitochondrial pathway. To date, three TRAIL-targeting drugs 
are in clinical trial, with the most advanced candidate being in phase II (TRAIL R2 
antibody; Human Genome Sciences, Inc.). However, the endogenous inhibitor of 
caspase-8, FLIPs, is overexpressed in a wide variety of tumours and may represent a 
barrier to the success of TRAIL-mediated therapy [48]. Inhibitors of FLIPs have 
been clinically tested and shown to restore the sensitivity of tumours to TRAIL 
antibodies [239]. Combination of these two targeted therapies may provide 
promising perspective for future anti-cancer therapies.  
1.7.2 Targeting the IAPs 
Another strategy evolved by cancer cells to evade apoptosis is to inhibit the active 
caspases by overexpressing IAPs. Therefore, inhibiting IAPs in cancer cells have 
emerged as an attractive strategy for cancer therapy. IAPs sequester active caspases 
(caspases-3, 7, 9) via the presence of BIR domains (section 1.5.4.5.2). Two 
approaches to inhibit IAPs have been developed. The first one takes advantage of the 
properties of the endogenous IAPs inhibitors (Smac/DIABLO and Omi/HtrA2) and it 
implys small compounds that mimic these inhibitors [240]. All the compounds 
developed so far have not shown conclusive anti-cancer activity and thus remained in 
pre-clinical stages. An alternative strategy involves the screening of chemical 
libraries for compounds which displace caspases from IAPs [241]. Several 
compounds, which were identified by using pro-caspase-3 and XIAP have 
demonstrated promising single-agent activity in mice tumour xenografts without 
toxicity to normal tissues [241].  
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1.7.3 Targeting the Bcl-2 family proteins 
Since altered expression and function of the Bcl-2 family proteins have been reported 
in cancer, these proteins and their regulators have also emerged as attractive targets 
for cancer therapy. Overexpression of anti-apoptotic Bcl-2 proteins is frequent in 
cancer and is associated with chemo-resistance. Two strategies have been developed 
to target these proteins. The first approach consists of sensitising cancer cells to 
chemotherapeutic treatment by reducing the expression of Bcl-2 proteins. 
Modulators of steroid/retinoid family of nuclear receptors, such as tamoxifen, have 
been shown to suppress transcription of Bcl-2 and may be promising 
chemosensitizers. DNA based drugs using antisense oligodeoxynucleotides targeting 
Bcl-2 mRNAs have also shown encouraging clinical results. To date Bcl-2 antisense 
is the only apoptosis-based therapy for cancer which is in phase III (Genasense; 
Genta, Inc) [242]. The second strategy is based on blocking the hydrophobic groove 
of the anti-apoptotic Bcl-2 proteins that bind and neutralize the BH3-domain of the 
pro-apoptotic members. Several natural products that mimic the BH3 peptidyl 
structure have been identified. Gossypol (Ascenta Pharmaceutical, Inc., NCI) derived 
from cotton seed have shown efficacy against cancer and is now in phase II clinical 
trial. Other companies have designed synthetic chemical antagonists that bind the 
BH3-pocket of Bcl-2. Several synthetic BH3 mimetics are now in late preclinical and 
early clinical development. The pan-Bcl-2 family inhibitor, GX15-07, developed by 
Gemin X Biotechnologies (Canada) has just advanced to a phase I clinical trial. 
Recently, using a structural based screening, Abbott Laboratories have identified a 
very promising BH3 mimetic, ABT-737 [243]. ABT-737 potently inhibits Bcl-2, 
Bcl-XL and Bcl-w and causes regression of established tumours in mice. This drug is 
now at early stages of clinical trials.  
1.8 Aims  
As mentioned in section 1.6, CL was found to be involved in many of the 
mitochondria-dependent steps that lead to the release of apoptogenic factors from 
mitochondria. Despite this growing body of evidence implicating CL in apoptosis, 
the mechanism by which CL and its fatty acyl chain composition regulate 
mitochondrial apoptosis remains unresolved. This thesis is focused on the role of CL 
and its fatty acyl chains in regulating apoptosis. 
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2 Materials and experimental procedures 
2.1 Materials 
2.1.1 General reagents 
Unless listed, all reagents were purchased from Sigma. Materials for tissue culture 
were obtained from Becton Dickinson.  
Amersham: ECL western-blotting detection kit 
Anachem: Pure nitrocellulose transfer membrane 0.22μm 
Biorad: agarose gel casters, agarose gel tanks, Mini-Protean III Ready Gel System 
for SDS-PAGE and Western-Blotting 
Dharmacon: non targeting siRNA pool 
Fisher Scientific: glycerol, glycin, KCl, KH2PO4, MgCl2, NaCl, Na2CO3, SDS, 
sucrose 
Finnzymes: DyNamo SYBR Green 2-step qPCR Kit 
Invitrogen: Lipofectamine 2000 transfection reagent, Novex mini-cell gel tank, 
NuPage 4-12% Bis-Tris gels, DH5α competent cells, DMEM, RPMI, Hepes, L-
glutamine, trypsin 
Melford: Tris-Base Ultrapure 
Qiagen: plasmid purification kits (mini and maxi), gel extraction kit, PCR 
Purification kit, RNA extraction kit 
Roche Applied Science: Rapid DNA ligation kit, RNA PCR kit, restriction enzymes 
Stratagen: QuikChange Site-Directed Mutagenesis Kit 
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Severn Biotech Ltd: 30% Acrylamide (19:1 bis-acrylamide)  
2.1.2 Primers sequences 
Name Experiement Sequence 5’-3' 
cTAZHIII 5’ 
Cloning TAZ delta 
exon 5 cDNA into 
pEGFPN1 vector 
CCCAAGCTTGGGTGGGGATGCCTCTGCAC 
cTAZSalI 3’ 
Cloning TAZ delta 
exon 5 cDNA into 
pEGFPN1 vector 
ACGCGTCGACGATCTCCCAGGCTGGAGGTGG 
pEGFPN1 
Forward 
Sequencing pEGFPN1 
vector CGGAACTCAGATCTCGAGCTC 
pEGFPN1 
Reverse 
Sequencing pEGFPN1 
vector TGAACTTGTGGCCGTTTTACGTCG 
TazzEx7mut3 
Forward 
Site-directed 
mutagenesis in 
pcDNA3TAZHisTag 
GCATATCTTCCCAGAAGGCAAGGTCAACATG 
AGTTCCGAATTCCTGCG 
TazzEx7mut3 
Reverse 
Site-directed 
mutagenesis in 
pcDNA3TAZHisTag 
CGCAGGAATTCGGAACTCATGTTGACCTTGC 
CTTCTGGGAAGATATGC 
TAZ 
Forward RT-PCR and qPCR CCCAGAAGGGAAAGTGAACA 
TAZ 
Reverse RT-PCR and qPCR GAGCTGCTCTGCCTGAGTCT 
GAPDH 
Forward RT-PCR and qPCR TCCACCACCCTGTTGCTG 
GAPDH 
Reverse RT-PCR and qPCR ACCACAGTCCATGCCATCAC 
Actin 
Forward RT-PCR and qPCR TCCATCATGAAGTGTGACGT 
Actin 
Reverse RT-PCR and qPCR TACTCCTGCTTGCTGATCCAC 
T7 Sequencing pcDNA3TAZHisTag 
TAATACGACTCACTATAGGG 
SP6 Sequencing pcDNA3TAZHisTag 
ATTTAGGTGACACTATAG 
pSR5’ Sequencing pSUPERRetroGFPNeo GGAAGCCTTGGCTTTTG 
pSR3’ Sequencing pSUPERRetroGFPNeo GATGACGTCAGCGTTCG 
Table 1 Primer sequences 
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2.1.3 Antiserum 
Target Supplier Description Dilution Incubation time 
Actin Sigma Mouse monoclonal 1:5000 1 hour 
Bax Upstate Rabbit polyclonal 1:1000 overnight 
Bak Upstate Rabbit polyclonal 1:1000 overnight 
Bcl-2 BD Pharmingen Mouse monoclonal 1:1000 overnight 
Bcl-XL 
Craig 
Thompson 
Lab 
Rabbit polyclonal 1:1000 overnight 
human Bid Cell Signaling Rabbit polyclonal 1:1000 overnight 
mouse Bid R&D Goat polyclonal 1:1000 overnight 
mouse Bid Santa Cruz Goat polyclonal 1:1000 overnight 
Caspase-3 Cell Signaling Rabbit monoclonal 1:1000 overnight 
Caspase-8 (anti-
DED) 
BD 
Pharmingen Mouse monoclonal 1:1000 overnight 
Caspase-8 (anti-
p18) Cell Signaling Mouse monoclonal 1:1000 overnight 
Cytochrome c 
Clone 6H2.B4 
BD 
Pharmingen 
Mouse monoclonal 
Immunofluorescence 1:300 2 hours  
Cytochrome c 
Clone 7H8.2C12 
BD 
Pharmingen 
Mouse monoclonal 
Western-blot 1:1000 overnight 
Cytochrome c 
oxidase subunit  
IV 
Molecular 
Probes Mouse monoclonal 1:1000 overnight 
Fas receptor 
Clone CH11 Upstate 
Mouse 
immunoaffinity IgM 
Apoptosis induction 
0.3 or 
0.5 
μg.ml-1 
depending 
on 
experiement 
GFP Sigma Mouse monoclonal 1:1000 2 hours  
NADH 
Dehydrogenase 
Molecular 
Probes Mouse monoclonal 1:1000 overnight 
Succinate 
Dehydrogenase 
subunit B 
Molecular 
Probes Mouse monoclonal 4μg.ml-1  overnight 
PARP BD Pharmingen Mouse monoclonal 1:1000   overnight 
Smac-Diablo 
Clone 56 
BD 
Pharmingen 
Mouse monoclonal 
Western-blot 1:1000 overnight 
Smac-Diablo 
Clone 7 
BD 
Pharmingen 
Mouse monoclonal 
Immunofluorescence 1:300 2 hours 
Tafazzin ABCAM Goat polyclonal 1:1000 overnight 
Table 2 Primary antibodies list 
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Description Supplier Catalogue Number Dilution 
Incubation 
time 
Anti-mouse IgG, 
HRP-linked 
antibody 
Cell 
Signaling 7076 1:5000 1 hour 
Anti-rabbit IgG, 
HRP-linked 
antibody 
Cell 
Signaling 7074 1:5000 1 hour 
Anti-goat IgG, 
HRP-linked 
antibody 
Chemicon 
International AP106P 1:5000 1 hour 
Table 3 Secondary antibodies list 
 
2.1.4 RNA interference oligonucleotides sequences 
Name Gene targeted Sequence sense 
siTaz Human 
Tafazzin 
GGGAAAGUGAACAUGAGUUTT 
shTaz Human 
Tafazzin 
GATCCCCAAGGGAAAGTGAACATGAGTT 
TTCAAGAGAAACTCATGTTCACTTTCCCTT
TTTTTA 
siBid Human Bid GAAGACAUCAUCCGGAAUATT 
siCaspase-8 Human 
Caspase-8 
AAGGGUGAUGCUCUAUCAGAUTT 
Table 4 RNA interference targeting sequences  
 
2.2 Experimental procedures 
2.2.1 Plasmid constructs 
 
2.2.1.1 Cloning tafazzin full-length and delta exon 5 cDNAs 
into pLpC retroviral vector 
Tafazzin full-length and delta exon 5 cDNAs were kindly provided by David Brooks 
of the University of Pennsylvania (USA). Both cDNAs were extracted from pCR2.1 
vector by double digestion with the restriction enzymes EcoRV and Hind III (Roche) 
and sub-cloned into the retroviral expression vector pLpC (provided by Scott Lowe). 
pLpC was first digested with XhoI (Roche), blunted using the Klenow fragment 
(Cambio) and then digested with HindIII. pLpC contains element derived from 
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Moloney murine leukaemia virus and Moloney murine sarcoma virus and was 
designed for retroviral gene delivery. It provides sequences essential for the 
production of retroviruses: two long terminal repeats (LTR) located at the 5’ and the 
3’ of the multiple cloning site and the packaging signal Ψ. However, it does not 
encode all the proteins required for the packaging of retroviral particles. 
2.2.1.2 Cloning tafazzin delta exon 5 cDNA into pEGFPN1 
vector 
Tafazzin delta exon 5 cDNA was generated by PCR using the cTAZHIII 5’and 
cTAZSalI 3’ primers (Table 1) containing HindIII and SalI restriction sites 
respectively, to allow cloning into the HindIII and SalI sites of the pEGFPN1 vector. 
Once the PCR product had been amplified, it was digested using the HindIII and SalI 
restriction enzymes to leave compatible ssDNA overhangs for ligation into the 
disgested vector. Positives clones were sequenced using pEGFPN1 forward and 
reverse primers (Table 1) to confirm the correct formation of the fusion protein.  
2.2.1.3 Cloning siRNA Taz duplex into pSUPERRetroGFPNeo  
To generate a short hairpin RNA (shRNA) encoding plasmid, a pair of 
complementary DNA oligonucleotides of 64 pb containing the siRNA Taz targeting 
sequence in both sense and anti-sense orientation (Table 4) were designed according 
to OligoEngine’s instructions. The pSUPERRetroGFPNeo vector (OligoEngine, 
USA) was sequentially digested by BglII and HindIII. Then, the oligonucleotides 
were annealed and ligated with the BglII and HindIII sites of the linearized vector. 
DH5α competent bacteria were transformed with the ligation product (see Bacterial 
Transformation below). Positives clones were sequenced using the pSR5’ and 
pSR3’primers (Table 1). The tafazzin targeting shRNA encoding vector was called 
shTaz.  
2.2.1.4 Site-directed mutagenesis in pcDNA3TAZHisTag 
The siRNA recognition sequence of pcDNA3TAZHisTag (provided by Frederick 
Vaz, Laboratory Genetic Metabolic Diseases of Amsterdam) has been mutated using 
a Mutagenic PCR kit from Strategene according to the manufacturer’s instructions. 
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The TazzEx7mut3 forward and reverse primers were used (Table 1). Briefly, the 
PCR program used was 95ºC for 30 secondes, 52ºC for 1 minute and 68ºC for 8 
minutes. The cycle was repeated 18 times. The silent mutations were generated at the 
third position of codons 182, 183 and 184 of tafazzin exon 7 in order to conserve the 
amino acids sequence while protecting the mutated-plasmid from siRNA-mediated 
degradation. After PCR, the parental plasmid was digested by DpnI for 2 hours at 
37ºC. DH5α competent cells were transformed with the digestion product (see 
Bacterial Transformation below) and DNA harvested. In order to confirm the 
presence of the mutations, constructs were sequenced using specific primers of the 
T7 and Sp6 promoters of pcDNA3 (Table 1). 
2.2.2 Bacterial transformation  
50 μl of DH5α competent cells were incubated on ice and 4 μl of plasmid DNA were 
added. Cells were left on ice for further 30 minutes and heat-shocked at 42ºC for 40 
seconds. 250 μl of LB medium was added and cells were incubated at 37ºC for 30 
minutes. Cells were then plated onto agar plates containing the relevant antibiotic 
and left to grow overnight at 37ºC. Colonies were picked from the plates and 
cultured overnight for DNA purification using Qiagen miniprep or maxiprep 
purification kits.  
2.2.3 Tissue culture  
2.2.3.1 Lymphoblastoid cell lines: DB037, DB015.2, DB105.2 
and DB105.3 
The lymphoblastoid cell lines were generated from the blood of 2 unrelated patients 
with Barth Syndrome (DB105.2 and DB105.3) and 2 unrelated control-disease 
individuals (DB037, DB015.2). These were a gift from Richard I. Kelley of the 
Kennedy Krieger Institute (Baltimore, USA) and were immortalised by Epstein-Barr 
virus transformation. Cells were routinely cultured in RPMI 1640 complete medium 
(Invitrogen, UK) supplemented with 10% foetal calf serum (FCS, Harlan SERA-Lab, 
UK), 2 mM L-glutamine (Invitrogen, UK), penicillin (50 IU/ml) and streptomycin 
(50 μg/ml) at 37ºC under 5% CO2 atmosphere. The serum was heat-inactivated at 
56ºC for 30 minutes prior to use. Lymphoblastoid cells were seeded at a density of 
3.105 cells/ml and cultures were split at confluence.  
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2.2.3.2 HeLa cells 
The cervical carcinoma HeLa cell lines were cultured in DMEM medium 
(Invitrogen, UK) supplemented with 10% FCS (Harlan SERA-Lab, UK) and 2 mM 
L-glutamine (Invitrogen, UK). For routine culturing, cells were washed in phosphate-
buffered saline (PBS, Beatson Institute Facilities), incubated with trypsin solution 
(0.25 g/100ml of PBS-EDTA, Invitrogen, UK) and then plated at a density that 
maintained exponential growth until needed.  
2.2.3.3 BD RetroPackTM PT67 cells 
The PT67 Cell Line (BD Biosciences Clontech, UK) is derived from a mouse 
fibroblast (NIH 3T3) cell line and is designed to package retrovirus with a dualtropic 
envelope that recognizes receptors on mouse, rat, human, hamster, mink, cat, dog, 
and monkey cells. These cells were infected with a retroviral vector containing the 
Gag-Pol and Env sequences but are unable to produce viruses because of the absence 
of packaging signal Ψ. Upon transfection with a retroviral vector which provides the 
Ψ signal, these helper-defective packaging cells are capable of providing in trans the 
necessary proteins gag-pol and env required for the packaging, processing, reverse 
transcription and integration of the retroviruses into host genome. The PT67 cells 
were maintained in DMEM medium (Invitrogen, UK) supplemented with 10% FCS 
(Harlan SERA-Lab, UK) and 2 mM L-glutamine (Invitrogen, UK) and grown at 
37ºC under 5% CO2 atmosphere. Once confluent, the cells were washed with PBS, 
incubated with trypsin solution and plated at a density that maintained exponential 
growth until needed. 
2.2.3.4 Freezing and thawing cells 
To create frozen cell stocks, harvested cells were re-suspended in 90% FCS 
supplemented with 10% Dimethylsulphoxide (DMSO), and transferred to a cryo 
freezing container (Nalgen, USA) and frozen overnight at -80ºC before being placed 
in the vapour phase of a liquid nitrogen cell tank. Cells were thawed rapidly at 37ºC 
and added to warmed medium. Cells were then centrifuged at 500 x g for 5 minutes 
and re-suspended in warmed medium to remove the DMSO. Cells were regularly 
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tested for microplasma contamination by luciferase assay at the Beatson Institute of 
Cancer Research. 
2.2.4 Transfection of cell lines 
2.2.4.1 HeLa cells 
HeLa Cells were transfected with Lipofectamine 2000 reagent (Invitrogen, UK) 
according to the manufacturer’s protocol. Briefly, cells were seeded into 6 wells-
plate (4.105 cells per wells) and grown overnight (until 80-90% confluency) in 
complete DMEM medium (C-DMEM) without antibiotics. The day of transfection, 
DNA and Lipofectamine 2000 were prepared separately in 250 μl of serum free-
DMEM and incubated for 5 minutes at room temperature. Diluted DNA was 
combined with the Lipofectamine 2000 and the mix was incubated for 20 minutes at 
room temperature. The transfection complexes were added dropwise to the cells and 
incubated for 4 hours at 37ºC before replacing the medium with fresh C-DMEM. 
Cells were then grown for 48 hours before being assayed.  
2.2.4.2 PT67 cells transfection and production of retroviruses 
Transfections of the dualtropic packaging cells with retroviral vectors were carried 
out using calcium phosphate co-precipitation method. PT67 cell lines were seeded 
into 10 cm plate and grown overnight to 80-90% confluency at the day of 
transfection. To prepare DNA for transfection, 15 μg was diluted into 500 μl of 2X 
HBS (50 mM HEPES, 250 mM NaCl, 1.5 mM NaHPO4; pH 7.12) and the mix was 
completed to 940 μl with water. 60 μl of 2 M CaCl2 was added dropwise and the mix 
was then inverted vigorously for 3 to 15 seconds. The complex DNA/CaPO4 was 
incubated 30 minutes at 37ºC and added dropwise to the cells. The cells were 
incubated overnight at 37ºC and the medium was replaced with a fresh C-DMEM. 
For the last 24 hours of virus production, packaging cells were grown at 32ºC since 
the virus half-life is much lower at 37ºC than at 32ºC. After 10 hours at 32ºC, the 
medium was replaced with 6 mL of RPMI medium supplemented with 20% FCS and 
2 mM L-glutamine. The retroviruse-containing media were collected 14 hours latter 
and passed through a 0.45 μm syringe-operated filter and freshly used to infect the 
targeted cell line.  
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2.2.5 Retroviruses infection of lymphoblastoid cell lines 
Lymphoblastoid cells (2.5 106) were resuspended in 5 mL of fresh retroviral 
supernatant and incubated at 32ºC under 5% CO2 atmosphere. To increase efficiency 
of the retroviral infection, 2.5 μg.ml-1 of polybrene was added to the retroviral 
supernatant. After 12 hours incubation, the viral supernatant was removed and the 
lymphoblastoid cells were resuspended in 6 mL of fresh RPMI 1640 complete 
medium. Cells were then grown at 37ºC. To control the retroviral infection, the cells 
were infected in parallel with a GFP-expressing retrovirus. The cells were then 
cultured for one week (until expression of the GFP was observed in the control) and 
the infected cells were selected in complete medium containing appropriate 
concentration of the selection antibiotic. 
2.2.5.1 DB037GFP and DB105.2GFP 
To establish lymphoblastoid DB037GFP and DB105.2GFP cell lines, DB037 and 
DB105.2 were infected with a retrovirus expressing pLpCGFP vector (gift from 
Kevin Ryan, Beatson Institute) and selected using 0.5 μg.ml-1 puromycin.  
2.2.5.2 DB105.2TAZΔ5 
To establish lymphoblastoid DB105.2TazΔ5 cell lines, DB105.2 cells were infected 
with a retrovirus expressing pLpCTAZΔ5 vector and selected using 0.5 μg.ml-1 
puromycin. 
2.2.6 Establishment of stable transfected HeLa cell lines 
Once transfected, cells were grown for 48 hours in a 6-wells plate. Then, cells were 
splited 1:15 into 150 mm plates in complete medium containing the appropriate 
concentration of selection antibiotic. This medium was changed every week and the 
cells were grown until the formation of visible colonies (2-4 weeks). The antibiotic 
resistant clones were picked by trypsinization in plastic rings and seeded into one 
well of a 48-well plate containing 200 μl of complete medium with the selection 
drug. 
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2.2.6.1 HeLa shControl and shTaz 
To establish shControl and shTaz HeLa cell lines, HeLa cells were transfected as 
described previously with the vectors pSUPERGFPNeoScramble (a gift from Kevin 
Ryan, Beatson Institute) or pSUPERGFPNeoTAZ, respectively. Stable clones were 
selected in 0.5 mg.ml-1 G418.  
2.2.6.2 HeLa Bcl-XL 
To generate HeLa Bcl-XL, HeLa cells were transfected with the pcDNA3Bcl-XL 
plasmid (a gift from Craig Thompson, University of Pennsylvania, USA). Stable 
clones were selected in 0.5 mg.ml-1 G418.  
2.2.7 Preparation of cell lysates for protein analysis 
Incubated cells (treated or untreated) were washed twice in cold PBS and lysed in 
RIPA buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 % Triton X100, 1% 
sodium deoxycholate, 0.1% SDS supplemented with protease inhibitors (SIGMA)]. 
Extracts were incubated for 20 minutes at 4ºC and then centrifuged at 12,000 x g for 
5 minutes at 4ºC to remove cell debris. Supernatants were transferred to fresh tubes 
and the protein concentration was assessed in 96-well plates using the BCA Protein 
Assay kit (Pierce) according to the manufacturer’s instructions. Dilution series of 
BSA from 0.08 to 2 mg/mL was used as standard. Ten μL of each protein extract 
(either undiluted and/or diluted 1:10) and each standard were added to 200 μL of the 
BCA assay reagent. The 96-well plate was incubated at 37oC for 30 minutes and light 
absorbance at 540 nm was analysed using a SpectraMax plus plate reader (Molecular 
Devices). A standard curve of absorbance versus protein concentration was then 
drawn and the protein concentration of each sample was determined accordingly. 
2.2.8 Protein sample preparation 
Lysates were diluted to a final protein concentration of 2 mg/mL using lysis buffer 
and 2X sample buffer (5% v/v β-mercaptoethanol, 62.5 mM Tris-HCl, 2% w/v 
sodium dodecyl sulphate, 25% v/v glycerol, 0.01% w/v bromophenol blue) and 
boiled for 10 minutes. SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel 
electrophoresis) was used to separate proteins and their size was determined by their 
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position on the gel with reference to molecular weight markers. The presence of a 
particular protein could then be determined by Western blot analysis (see 2.2.10). 
Loading was normally controlled by visualization of β-actin unless specified 
otherwise. 
2.2.9 SDS-PAGE 
Cell lysates or mitochondrial extracts were resolved on SDS-PAGE. Denaturing 
polyacrylamide gels of 10, 12 or 15 % acrylamide (National Diagnostics) were cast 
using a mini-Protean gel caster (BioRad). Gels were poured into the caster, overlaid 
with butan-2-old saturated water and allowed to set for 1 hour. Once set, water was 
removed and stacking gel (5% acrylamide, 125 mM Tris [pH 6.8], 1% SDS, 4 mM 
EDTA) was poured. Both reservoirs were then filled with 1x SDS-PAGE running 
buffer (250 mM Tris-Base, 192 mM glycine, 0.1% SDS). Protein samples 
(concentration dependent on protein to be visualised) were loaded and run through 
the stacking gel at 80 V before separating at 120 V.  
2.2.10 Western blotting 
After electrophoresis, proteins were transfered from the gel to a nitrocellulose 
membrane (0.22 μm, Anachem) using the wet transfer system (Biorad) in 1X SDS 
PAGE Blotting buffer (250 mM Tris-Base, 192 mM glycine, 0.01%SDS) in 20% 
methanol. The blotting device was placed in a tank filled with ice cold buffer and 
transfer was carried out at a current of 200 mA for 2 hours. The nitrocellulose 
membrane was blocked for non-specific interactions with 5% dried milk powder 
(Marvel) in PBS 0.05% Tween-20 at room temperature for 1 hour. The membrane 
was then incubated with the primary antibody (see Table 2 for dilution and 
incubation time). Following, further 3 washes for 10 minutes in PBS; 0.05 % Tween-
20, the appropriate peroxidase-conjugated secondary antibody was added to the 
membrane for 1 hour at room temperature (concentration specified in Table 3). 
Membranes were again washed three times for 10 minutes in PBS 0.05 % Tween-20 
and finally visualised by using enhanced chemiluminescent reagents (Amersham) 
and exposure to Fuji X-Ray film. To reprobe the membrane with another primary 
antibody, antibodies were stripped by incubating the membrane for 15-45 minutes 
(depending on the antibody) at room temperature in stripping buffer (200 mM 
François Gonzalvez, 2007                                                                                                      71 
glycine, 1% SDS, pH2.5). The membrane was then reblocked in 5% dried milk 
before being incubated with a new primary antibody. 
2.2.11 RNA interference 
Twelve hours before transfection, HeLa cells were plated in 12 wells plate at a 
density of 0.8 105 cells.ml-1. Cells were then transfected with 50 nM of siRNA using 
lipofectamine according to the manufacturer’s instructions. Efficiency of silencing 
was generally validated by western-blot 48 hours post-transfection. The siRNA 
targeted sequences of siBid, siCaspase8, siTaz were designed and generated by 
MWG (UK). These sequences are shown in Table 4.  
The targeting sequence of siTaz was used to generate a pair of complementary DNA 
oligonucleotides of 64 pb (Table 4). These oligonucleotides were annealed and 
cloned into the pSUPERRetroGFPNeo vector to generate a tafazzin-targeting shRNA 
vector (shTaz). HeLa cells were then stably transfected with shTaz as described 
previously. Clones were lysed and RNA and proteins were extracted. The efficiency 
of the gene silencing was finally analysed by quantitative PCR and western-blot. 
HeLa cells transfected with pSUPERGFPNeoScramble were used as controls 
(shControl).  
2.2.12 RNA extraction  
Total cellular RNA was extracted from 10 cm plates of cells at 80% confluency 
using RNA-Bee reagent (TEL-Test, NC, Texas), in accordance with the 
manufacturer’s instructions. Cells were lysed using 8 ml of RNA-Bee and incubate 
for 5 minutes to ensure complete dissociation of nucleoprotein complexes. 
Chloroform (0.8 ml) was then added and the homogenate was incubated for 5 
minutes at 4ºC and centrifuged at 12,000 x g for 15 minutes at 4˚C. After 
centrifugation, the homogenate was separated into two phases: the lower blue 
phenol-chloroform phase and the colourless upper aqueous phase. RNA remained 
exclusively in the aqueous phase whereas DNA and proteins were in the interphase 
and organic phase. The upper phase was carefully transferred to a fresh tube and an 
equal volume of isopropanol was added to precipitate the RNA. The supernatant was 
then removed and the remaining RNA pellet was washed in 1 ml of 75% ethanol. 
The samples were vortexed briefly and centrifuged at 7,500 x g for 5 minutes at 4˚C. 
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RNA pellets were dissolved in 30 μl of dietypyrocarbonate (DEPC)-treated dH2O. 
RNA concentration was determined by UV spectrophotometry. The purity of the 
RNA extraction was assesed using the ratio of absorbance at 260 nm and 280 nm. 
When the final preparation is free of DNA or proteins, this ratio should be in the 
range of 1.8-2.0. RNA samples were stored at -70˚C.  
2.2.13 Reverse Transcriptase - Polymerase Chain Reaction 
(RT-PCR) 
cDNAs were prepared by reverse transcription of RNA using the GeneAmp RNA 
PCR kit (Applied Biosystems, Roche) according to the manufacturer’s instructions. 
Briefly, 1 μg RNA was added to a master mix including 4 μl of 25 mM MgCl2, 2 μl 
of 10 x PCR Buffer II (500 mM KCl, 100 mM Tris-HCl, pH 8.3), 8 μl of 10 mM 
dNTPs, 20 U of RNase inhibitor, 50 U of MuLV Reverse Transcriptase, 1 μl of 50 
μM Random Hexamers. The reaction mix was incubated for 10 minutes at room 
temperature and reverse transcription was carried out at 42ºC for 15 minutes on 
Peltier Thermal Cycler (DNA Engine). The reaction was stopped by heating at 99ºC 
for 5 minutes and cDNAs were then stored at -20ºC. 
PCRs were carried out using the GeneAmp RNA PCR kit (Applied Biosystems, 
Roche) on a Peltier Thermal Cycler (DNA Engine). Ten μl of cDNAs was amplified 
in a final volume of 50 μl containing 1 nM of each primer, 1.25 U of AmpliTaq DNA 
polymerase, 4 μl of 10X PCR Buffer II and 2 μl of 25 mM MgCl2. The PCR 
reactions were carried out using the following program: Initial denaturation at 95˚C 
for 2 minutes, 25 cycles of denaturation-annealing-elongation (95˚C for 2 minutes, 
60˚C for 1 minute) and a final elongation at 72˚C for 7 minutes. Reaction products 
were resolved on 1% agarose gel containing 0.1 μg.ml-1 of ethidium bromide and 
cDNAs visualised using a UV transilluminator. 
2.2.14 Quantitative Real Time Polymerase Chain Reaction 
(qRT-PCR) 
cDNA synthesis and qRT-PCR were carried out using the DyNAmo SYBR Green 2-
step qRT-PCR Kit (Finnzymes). Total RNAs were first reverse transcribed into 
cDNAs using the MuLV Reverse Transcriptase. Briefly, 1 μg RNA was added to a 
master mix including 10 μl of RT buffer (including dNTPs mix and 10 mM MgCl2), 
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1 μl of Random Hexamers (300 ng/μl) and 2 μl M-MuLV RNase H+ reverse 
transcriptase. cDNA synthesis was performed using the following parameters: Primer 
Extension at 25˚C for 10 minutes, cDNA synthesis at 37˚C for 30 minutes, reaction 
termination at 85˚C for 5 minutes. 
qRT-PCR was carried out using 2 μl of cDNAs, 10 μl 2X qPCR master mix, 
(containing modified hot start Tbr DNA polymerase, SYBR Green I, optimized PCR 
buffer, 5 mM MgCl2 and dNTPs mix), and 0.5 μM of designed primers for gene of 
interest. For each condition, GAPDH and actin primers were used as reference to 
standardise data. The PCR reaction was performed in 96 wells optical plate on a 
gradient Thermal Cycler (Chromo 4, DNA Engine) and analysed using the MJ 
Opticon Moniter Analysis Software version 3.1. The qPCR reactions were carried 
out using the following program: Initial denaturation at 95˚C for 15 minutes, 44 
cycles of denaturation-annealing-elongation (94˚C for 10 seconds; 60˚C for 30 
seconds; 72˚C for 30 seconds) followed by a final elongation step at 72˚C for 10 
minutes. The fluorescent signal was analysed at each cycle of amplification. To 
check the specificity of the amplified products a melting curve from 70˚C to 95˚C 
was performed at the end of the final extension.  
2.2.15 Induction of cell death 
For cell death induction, cells were plated at the required density to be 80 % 
confluence on the day of the treatment. To induce apoptosis, cells were treated with 
the appropriate concentration of anti-Fas antibody (CH11 clone, Upstate, UK), 
mouse TNFα recombinant protein (Roche Applied Science, Germany) together with 
cycloheximide (Sigma) or with etoposide (Sigma) at 37oC for varying length of time 
as indicated for each experiments.  
2.2.16 Assessment of cell death 
2.2.16.1 Propidium Iodide staining 
Once treated with a cell death-inducing agent, HeLa cells were trypsinized and 
resuspended in their original medium containing the floating dead cells. After 
centrifugation, cells were resuspended in 500 μL PBS containing 1 μg.ml-1 
Propidium Iodide (Molecular Probes, Invitrogen, UK) and left at room temperature 
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for 10 minutes. Flow cytometric analyses were then performed using a FACScan 
(Becton Dickinson, San Jose, USA). The resulting fluorescence was captured via 
585/42 nm band pass filter (FL-2) and analysed using the Cell Quest software 
(Becton Dickinson, San Jose, USA). In each experiments, 104 cells were analysed.  
2.2.16.2 Annexin V/Propidium Iodide staining  
To analyse apoptosis induction in lymphoblastoid cells, cells were harvested as 
described previously. After centrifugation, 2 μl of Annexin V-FITC (BD 
Biosciences, UK) was added to cells’ pellet. Pellets were then resuspended in 500 μl 
of binding buffer [10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, and 2.5 mM 
CaCl2] containing 1 μg.ml-1 Propidium Iodide (PI). Cells were incubated in the dark 
for 15 minutes at room temperature. Flow cytometric analyses were performed using 
the FACScan. Florescence was captured using the 530/30 nm band pass filter (FL-1) 
for Annexin V-FITC and 670 nm band pass (FL-3) for PI.  
2.2.17 Mitochondrial membrane potential assay 
To monitor mitochondrial membrane potential, treated or untreated cells were 
harvested as described previously and incubated in 500 μL of standart growth 
medium containing 50 nM of the mitochondrial potential probe 
Tetramethylrhodamine ethyl ester perchlorate (TMRE) (Molecular probes, 
Invitrogen). The cell suspension was allowed to equilibrate for 20 minutes at 37oC in 
the dark. Flow cytometry was performed with the FACScan using the 585/42 nm 
band pass filter (FL-2) to assess the mitochondrial membrane potential. In each 
experiments, 104 cells were analysed.  
2.2.18 Monitoring of caspase activities  
Caspase-3 and caspase-8 activities were assessed using the caspase-3 and caspase-8 
detection kits respectively, according to the manufacturer’s instructions 
(Calbiochem, UK). Briefly, cells were harvested and resuspended in 300 μl of 
complete medium. To monitor caspase activities, 1 μl of cell permeable peptides, 
Red-DEVD-fmk (caspase-3) or Red-IETD-fmk (caspase-8), were added and the cells 
were incubated for 30 minutes at 37oC. Cells were washed in Wash Buffer 
(Calbiochem, UK) and resupend in 500 μl of Wash Buffer. Flow cytometric analyses 
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were performed using the FACScan. Fluorescence was captured using the 585/42 nm 
band pass filter (FL-2). 
2.2.19 Transmission electron microscopy 
Cells (20. 106) were harvested and resuspended in 1 mL of fixative solution [0.1 M 
Sodium cacodylate; 2% glutaraldehyde (EM grade), pH 7.4]. Cells were then 
centrifuged at 500 x g and 1 mL of fixative solution was added to cover the cell 
pellets. Samples were stored at 4°C and sent to the Electron Microscopy Unit of 
Cancer Research UK (London). The cell pellets were sectioned using a cryo-
ultramicrotome and analysed by transmission electron microscopy (TEM). Analysis 
was carried out by Ken Blight.  
2.2.20 Fluorescent microscopy 
2.2.20.1 Tafazzin localization 
HeLa cells were seeded in 6 wells plate and transfected using lipofectamine with 100 
ng of pEGFPTAZ or pEGFPN1 (control). Twenty four hours after transfection, cells 
were incubated at 37 oC for 20 minutes in the presence of 50 nM of TMRE. After two 
washes in warm PBS, the cells were resupended in warm complete medium and the 
fluorescence was captured under a Leica SP2 confocal microscope using TCS 
software.  
2.2.20.2 Immunocytochemistry 
HeLa cells were seeded on coverslips at 2.105 cells.ml-1 and treated with anti-Fas 
antibody to induce apoptosis. Twelve hours after treatment, cells were washed twice 
with PBS and fixed for 15 minutes at room temperature in 3.7% paraformaldehyde 
(PFA). After 3 washes in PBS, fixed cells were permeabilized for 5 minutes at room 
temperature using 0.2% Triton X-100 and non specific binding was blocked for 1 
hour in 10 % FCS. Samples were stained using anti-cytochrome c antibody (BD 
Pharmingen, 566432) or anti-Smac/DIABLO antibody (BD Pharmingen, 612244) for 
2 hours at room temperature and then washed 4 times for 4 minutes with PBS-0.025 
% Tween 80. Samples were then incubated with anti-mouse IgG coupled with 
cyanine 3 (Jackson Immuno Research) for 1 hour at room temperature and washed 
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for 4 times for 4 minutes with PBS-0.025 % Tween 80. The coverslip were finally 
drained, mounted in medium containing DAPI (Vectashield, Vector Laboratories, 
USA) and sealed with nail varnish. Samples were analysed under a Leica SP2 
confocal microscope using TCS software. 
2.2.21 Preparation of mitochondrial fractions from anti-Fas 
antibody treated HeLa cells 
HeLa cells were plated into 10 cm plate to reach 80 % confluency at the day of the 
treatment. After activation of Fas-induced apoptosis, cells were harvested and 
resuspended in their original medium containing the detached dead cells. All of the 
following steps were performed at 4 oC. Cells were harvested as described previously 
and washed twice in cold PBS. Cells were then washed in cold Mitochondrial 
Isolation Buffer (MIB) [200 mM Mannitol, 70 mM Sucrose, 1 mM EGTA, 10 mM 
HEPES, 0.05% BSA; adjusted at pH 7.4]. Pellets were then resuspended in 1 ml of 
MIB and incubated at 4oC for 5 minutes. Cells were homogenized by 60 passes in a 
tight-fitting Dounce hand homogenizer. Mitochondrial fractions were then prepared 
by differential centrifugation of cell homogenates. The homogenates were separated 
by centrifugation at 750 x g for 5 minutes, yielding a mitochondria-rich supernatant 
and a nuclear and cell debris containing pellet. The mitochondria were finally 
pelleted by centrifugation 10,000 x g for 10 minutes and resuspended in a minimal 
volume of MIB. Mitochondrial protein concentration was assessed using the BCA 
Protein Assay kit (Pierce).  
2.2.22 Isolation of mitochondria for in vitro assay 
For in vitro analysis, mitochondria were isolated from 108 HeLa cells or 3.108 
lymphoblastoid cells. Cells were washed twice in cold PBS and once in cold MIB. 
Pellets were resuspended in 10 ml MIB and the cells were lysed by 20 strokes in a 
¼’’ cylinder cell homogenizer (H&Y Enterprises, Redwood USA). Mitochondria 
were then isolated by differential centrifugation as described above.  
2.2.23 Oxygen consumption monitoring 
Isolated mitochondria (0.5 mg protein.ml-1 per assay) from lymphoblastoid cells were 
suspended in reaction buffer (125 mM KCl, 2.5 mM MgCl2, 5 mM HEPES, 1 mM 
KH2PO4, 0.2 mM EGTA and 0.5% BSA; pH 7.4). The mitochondrial respiration rate 
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(Vox) was monitored using a Clark-type electrode at 25°C (StrathKelvin). 
Mitochondrial electron transport chain was alimented with 10 mM succinate, an 
electron donor to complex II. To avoid the reflux of electrons from complex II to 
complex I, complex I was inhibited by the addition of 10 μM rotenone. The energy 
coupling of the succinate-oxydizing mitochondria was tested using 200 μM of ADP. 
  
2.2.24 In vitro cytochrome c release assay 
Isolated mitochondria were resuspended at 0.5 mg.ml-1 in the reaction buffer (125 
mM KCl, 1 mM KH2PO4, 2.5 mM MgCl2, 0.2 mM EGTA, 5 mM HEPES, 0.1% BSA 
; pH 7.4) containing protease inhibitor cocktail. Mitochondria were energized with 
10 mM succinate and the reflux of electrons to complex I was inhibited by the 
addition of 10 μM rotenone. After 5 minutes incubation at room temperature (time 
for the mitochondria to establish their orthodox configuration), mitochondria were 
treated with the appropriate concentration of recombinant peptides or proteins and 
incubated at 37°C for 15 minutes. Mitochondria were collected by centrifugation at 
10,000 g for 5 minutes. Supernatants and pellets were then analysed by SDS-PAGE 
and immunoblotting for the presence of cytochrome c or any indicated protein. 
2.2.25 In vitro Bak oligomerization assay 
To assess the oligomerization of Bak on mitochondrial membranes, mitochondria 
were isolated and treated with appropriate concentration of recombinant peptides or 
proteins as described for the cytochrome c release assay. After centrifugation, 
supernatants were collected and mitochondrial pellets were cross-linked with the 
homobifunctional cross-linker, Bis-MaleimidoHexane (BMH) (Pierce) which 
conjugates sulfhydryl groups (-SH). For the cross-linking reaction, mitochondria 
were resuspended in reaction buffer and incubated for 30 minutes at room 
temperature in the presence of dimethylsulfoxide (DMSO) (vehicle control) or in 10 
mM BMH. The mitochondria were then pelleted and resuspended in protein sample 
buffer containing DTT in order to quench the cross-linking reaction. Pellets were 
then analysed by SDS-PAGE on a 4-12% gradient gel (Nupage, Invitrogen) and 
immunoblotted for the presence of Bak.  
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2.2.26 Mitochondrial-caspase-8 oligomerization assay 
HeLa cells were plated in 10 cm plate to reach 80 % confluency on the day of 
treatment. After the activation of Fas-induced apoptosis for 12 hours, cells were 
harvested and resuspended in their original medium containing the detached dead 
cells. After two washes in PBS, cells were resuspended in cross-linking buffer (210 
mM Mannitol, 70 mM Sucrose, 1 mM EGTA, 5 mM HEPES; pH 7.4) and 
permeabilized by using 0.05 % digitonin (Calbiochem). Ten mM BMH (or DMSO 
for vehicle control) was added and the cells were incubated for 30 minutes at room 
temperature. The cells were then homogenized by 10 passes in a tight-fitting Dounce 
hand homogenizer and mitochondrial fractions were prepared by differential 
centrifugation as described above. To quench the cross-linking reaction, 
mitochondrial pellets were resuspended in protein sample buffer containing DTT and 
finally analysed by SDS-PAGE in a 4-12% gradient gel (Nupage, Invitrogen) and 
immunoblotted for caspase-8. 
2.2.27 Mitochondrial membranes insertion assay  
To analyse whether a protein was integrated into the mitochondrial membranes, 
isolated mitochondrial pellets were resuspended for 30 minutes at 4°C in an alkali 
buffer containing 0.1 M Na2CO3, (pH 11.5). At the end of the incubation, the 
mitochondrial membranes (Alkali-resistant fractions), containing the integrated 
proteins, were pelleted by ultracentrifugation at 100,000 x g for 30 minutes at 4°C. 
The supernatants (S100), alkali-sensitive fractions, containing the proteins which are 
loosely attached to the mitochondrial membranes were also collected. Alkali-
resistant and sensitive fractions were then analysed by western blot. The efficiency of 
the alkali-extraction was controlled using two mitochondrial proteins, the NADH-
deshydrogenase subunit-3 (a membrane integral protein) and the subunit-B of 
succinate deshydrogenase (loosely associated to the matrix side of the mitochondrial 
inner-membrane).  
2.2.28 CL and MLCL analysis 
Lymphoblastoid or HeLa cells (20.106) were harvested and washed twice in PBS. 
Cells pellets were placed in dry ice and sent to to the Laboratory of Genetic and 
Metabolic diseases at the University of Amsterdam. The extraction of lipids and CL 
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analysis were carried out by Riekelt Houtkooper. Cell pellets were sonicated for 20 
seconds and phospholipids were extracted from the equivalent of 1 mg of protein of 
the homogenates as follows. After addition of 3 ml of 1:1 chloroform-methanol (v/v) 
the internal standards (tetramyristoyl-cardiolipin and dimyristoyl-
phosphatidylglycerol) were added to the extraction. This mixture was shaken 
vigorously and placed on ice for 15 min, after which it was centrifuged at 1,000 x g 
for 10 min. The supernatant was transferred in a new tube, and the protein pellet was 
reextracted with 3 ml of 2:1 chloroform-methanol (v/v). The combined organic 
layers were evaporated under nitrogen at 45°C. The residue was dissolved in 150 µl 
of chloroform/methanol/water (50:45:5 v/v/v) containing 0.01% NH4OH, and 10 µl 
of this solution was injected into the HPLC MS system (Thermo Electron 
Corporation, Waltham, MA). The phospholipids were separated from interfering 
compounds by a linear gradient between solution B (chloroform-methanol, 97:3, v/v) 
and solution A (methanol-water, 85:15, v/v). Solution A and B contained 0.1 ml and 
0.01 ml of 25% (v/v) aqueous ammonia per liter of eluent, respectively. The gradient 
(0.3 ml/min) was as follows: 0–10 min: 20% A to 100% A; 10-12 min, 100% A; 12-
12.1 min: 100% A to 0% A; and 12.1–17 min, equilibration with 0% A. A splitter 
between the HPLC column and the mass spectrometer was used, and 75 μl/min 
eluent was introduced into the mass spectrometer. A TSQ Quantum AM (Thermo 
Electron Corporation) was used in the negative electrospray ionization mode. 
Nitrogen was used as nebulizing gas. The source collision-induced dissociation 
collision energy was set at 10 V. The spray voltage used was 3600 V, and the 
capillary temperature was 300°C. Mass spectra of CL and monolysocardiolipin 
MLCL molecular species were obtained by continuous scanning from m/z 400 to m/z 
1000 with a scan time of 2 s. The spectra of CL and MLCL species were acquired 
during their corresponding retention time in the HPLC elution profile. The CL 
internal standard was set at 100% in each spectrum. 
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3  Role of CL in apoptosis 
3.1 Introduction 
Over the past few years, CL has emerged as an important actor in many of the 
mitochondrial-dependant steps that lead to the release of apoptogenic factors [161]. 
Two initial studies implicated CL in the pro-apoptotic function of the Bcl-2 family 
proteins: first as “docking sites” for tBid on mitochondrial membranes [127, 128] 
and the second as a prerequisite for the activation of Bax and the permeabilization of 
the mitochondrial outer membrane [101]. CL was also described to have an anti-
apoptotic function, anchoring cytochrome c associated with the mitochondrial inner 
membrane thus preventing its release in the intermembrane space [223]. In that 
model, complete release of cytochrome c requires an additional step to dissociate its 
interactions with CL. The peroxidation of the unsaturated acyl chains of CL may 
control this dissociation [222]. In fact, this event is catalyzed by cytochrome c and is 
required for the release of cytochrome c itself, and of other apoptogenic factors 
[214].  
Despite this growing body of evidence implicating CL in apoptosis, the mechanism 
by which CL and its fatty acyl chain composition regulate mitochondrial pathways to 
apoptosis remains controversial. This discrepancy is mainly due to technical issues. 
As mentioned previously (section 1.6) most studies have been limited to in vitro use 
of artificial membrane systems or studies in yeast mutants. Recently, the human CL 
synthase gene was cloned and stably knocked down using shRNAs in the human 
epithelial carcinoma HeLa cell line [165]. Decreasing CL synthase expression in 
HeLa cells inhibited CL synthesis and manifested with a decrease in CL level and 
accumulation of its precursor PG. In this model, the acyl-chain composition of CL 
and MLCL was not modified indicating that CL synthesis does not affect its 
remodelling [165]. CL-deficiency leads to severe alterations in mitochondrial 
structure and to accelerated necrosis-like cell death likely due to an accumulation of 
free cytochrome c in the inter membrane space [165]. However, the residual levels of 
CL in cardiolipin-deficient cells were still able to sustain the activities of the 
respiratory chain complexes [165]. Therefore it is likely that reduction of the total 
pool of CL may render the cells more sensitive to bioenergetic insults and thus more 
sensitive to necrosis. To date, no mutation of CL-synthase has been identified in 
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human. Barth syndrome (BTHS) is the only human disease known to be mainly 
caused by a defect in CL metabolism [173, 174]. BTHS patients present mutations in 
the tafazzin gene encoding the CL transacylase involved in the remodelling cycle of 
CL [172]. Tafazzin catalyses the transfer of unsaturated acyl chain from PC to 
MLCL to generate mature CL. Unlike CL-synthase deficient cells that present a 
decrease in the total amount of CL, inactivation of tafazzin in BTHS cells results in a 
decrease in mature CL and an accumulation of saturated MLCL [180, 181]. This 
makes BTHS cells a unique model for studying the role of the acyl chain 
composition of CL in apoptosis. Mature CL strictly contains unsaturated fatty acyl 
chains, which are readily oxidizable targets. The evidence that oxidation of CL by 
cytochrome c is required for the release of apoptogenic factors underpinned the 
importance of the acyl chain composition of CL in apoptosis [214]. New strategies 
designed to manipulate the degree of saturation of CL acyl chains could represent a 
new mean of controlling the cell’s fate and open new therapeutic window in anti-
cancer treatment. In this context, CL remodelling, and tafazzin in particular, may 
constitute suitable targets to regulate apoptosis.  
This chapter investigates the role of CL and its acyl-chain composition in apoptosis 
using two cellular models of tafazzin-deficient cells: BTHS-derived lymphoblastoid 
cells and HeLa-derived tafazzin-knockdown cell lines.  
3.2 Results 
3.2.1 Characterisation of BTHS lymphoblastoid cells 
Lymphocytes were isolated from the blood of two unrelated BTHS patients 
(DB105.2 and DB105.3) and two unrelated disease-control individuals (DB037 and 
DB015.2). These cells were immortalised ex-vivo by Epstein-Barr virus infection to 
give rise to lymphoblastoid cell lines. BTHS cell lines have been provided and 
characterised previously by Richard I. Kelley [244]. BTHS patients carry mutations 
in the tafazzin gene that lead to the expression of inactive mutant forms of the 
protein. All patients were male and characterized by the triad, cardiomyopathy, 
neutropenia and 3-methylglutaconic aciduria. Lymphoblastoid cell samples from 
BTHS and control patients were prepared and sent to the Laboratory of Genetic and 
Metabolic diseases at the University of Amsterdam. The extraction of lipids and CL 
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analysis were carried out by Riekelt Houtkooper. Lipids were extracted and CL and 
MLCL were separated from non polar lipids and other phospholipids by High 
Performance Liquid Chromatography (HPLC) and analysed by mass spectrometer. 
Figure 3-1A represents the mass spectra of CL and MLCL molecular species 
isolated from cultured lymphoblastoid cells of a control (DB037) and a BTHS 
(DB105.2) patient. In each spectrum the levels of CL and MLCL molecular species 
are normalized to an exogenous CL internal standard (m/z 619.5) set at 100 %. In 
control cells, five different clusters of CL molecular species are present. Each cluster 
contains CL with different acyl chain compositions. The difference of mass between 
clusters relates to the difference in acyl chains. Within the same cluster, peaks 
represent different degree of saturation of the fatty acyl chains; the higher m/z values 
the more saturated the acyl chains. In Figure 3-1A, CL clusters are numbered from 1 
to 5. These clusters have been characterized previously [181]. In control cells, the 
most abundant CL molecular species were present in cluster 2 and 3 containing C16:1, 
C18:1 and C18:2 acyl chains. Cluster 4 contained C18:1 and C18:2 acyl chains only 
whereas cluster 5 corresponded to CL with C20:4, C18:2 and C18:1 acyl chains. In 
comparison to control cells, BTHS lymphoblastoid cells presented an overall 
reduction of CL molecular species with a dramatic decrease of cluster 3 (Figure 3-
1A). In control and BTHS cells three clusters of MLCL fatty acyl chain species were 
observed. These MLCL clusters were strongly increased in BTHS cells, in particular 
cluster 2 containing MLCL with C18:1 and C16:0 acyl chains. Moreover, in BTHS cells 
each CL clusters moved to higher m/z values indicating an increasing in the degree 
of saturation of the acyl chains. In the mass spectra, the area of each CL (m/z 655-
745) and MLCL (m/z 565-610) peaks were measured and normalized to the area of 
internal CL standard peaks and the quantity of protein. Summation of all these peak 
areas was used to quantify the total amount of CL and MLCL. Semi-quantitative 
analysis of total CL and MLCL levels in the DB037 control and two BTHS cells 
(DB105.2 and DB105.3) are represented in figure 3-1.B. 
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Figure 3-1: Alteration of CL composition in Barth syndrome (BTHS) lymphoblastoid 
cells.
(A) Representative mass spectra of MLCL and CL  molecular species in control (DB037) and 
BTHS (DB105.2) cells. Cells were lysed and normalized for protein levels (1 mg) and lipids 
were extracted and analysed by mass spectrometry. CL i.s and PG i.s correspond to the CL 
and PG internal standards, respectively. (B) Semiquantitative representation of the levels of 
CL and MLCL in control (DB037) and two BTHS cells (DB105.2 and DB105.3). These values 
are averages ± SD of duplicate samples for each cell lines.
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Both BTHS cells, DB105.2 and DB105.3, exhibited a decrease in CL levels to 40 % 
and 50 % of the control. Additionally, in BTHS cells the level of MLCL was 14 
times higher than in control cells. All together, these results show that BTHS 
lymphoblastoid cells display low level of mature CL and an accumulation of MLCL. 
This was also associated with a decrease in the degree of unsaturation of the acyl 
chains in CL. This is not surprising as tafazzin was shown to encode the CL 
transacylase catalysing the transfer of unsaturated acyl chains from PC to MLCL 
[172]. Therefore, BTHS lymphoblastoid cells represent a good model to investigate 
the role of CL and its acyl chain composition in apoptosis.  
In CL synthase knockdown HeLa cells, mitochondria presented disorganised cristae 
indicated that CL is directly required for maintenance of mitochondrial inner 
membrane structure [165]. To address the role of CL remodelling in mitochondrial 
structure, two control and two BTHS lymphoblastoid cells were fixed and analysed 
by transmission electron microscopy. As shown in figure 3-2, in control cells (A-B, 
DB037 or DB015.2) mitochondria adopted an orthodox configuration characterized 
by relatively large matrix volume and by parallel and individualized tubular cristae, 
which often elongate through the entire body of the organelles (red arrow) [245]. In 
stark contrast, BTHS cells displayed abnormal mitochondrial morphology (Figure 3-
2C and D). Mitochondria appeared swollen and presented complete disorganized 
cristae (red arrow). Cristae have lost their tubular shape and are interconnected to 
form honeycomb-like structures (Figure 3-2C, red arrow). Thus, these results 
suggest that CL remodelling is required for maintaining the structure of the 
mitochondrial inner membrane.  
The different complexes of the electron transport chain reside in the mitochondrial 
inner membrane. Therefore, the effect of CL deprivation on OXPHOS was 
investigated in BTHS mitochondria. Mitochondria from control and BTHS cells were 
isolated and the ability of these mitochondria to oxidize succinate was monitored 
indirectly using an oxygen electrode. Figure 3-3 represents the consumption of 
oxygen of control (A) and BTHS (B and C) mitochondria in the presence of 
succinate. Once added to the respiratory medium (containing KH2PO4 and MgCl2), 
control mitochondria began to oxidize the endogenous succinate present in the 
DB037 DB015.2
DB105.2 DB105.3
Figure 3-2: Mitochondria from BTHS patients present an abnormal morphology.
(A and B) Electron micrographs of a cluster of normal mitochondria. (C and D) Electron 
micrographs of BTHS lymphoblastoid cells. These are representative of triplicate 
experiments for each cell lines. Red arrows point to the organization of the cristae in the 
different samples. Bars=1 μm.
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matrix. Endogenous succinate was rapidly consumed by complex II and its oxidation 
resulted in a slight increase in oxygen consumption. This step was defined by Briton 
Chance as the respiratory state-1 [246] (Figure 3-3A). Upon addition of unlimited 
amount of exogenous succinate (10 mM), mitochondria generated and stabilized an 
electrochemical gradient of protons through the proton-pumping activity of the 
respiratory complexes III and IV. This resulted in a further increase in oxygen 
consumption (respiratory state-4). To challenge the coupling between the electron 
transport chain and ATP synthase, 200 μM of ADP was added to the reaction. Under 
these conditions (respiratory state-3), the ATP synthase uses the gradient of protons 
generated as a driving force to phosphorylate ADP to ATP. In response to this influx 
of protons, the electron transport rate increases and thus more oxygen is consumed. 
As shown in Figure 3.3A the oxygen consumption stayed constant at state-3 after the 
first ADP addition indicating that ADP was added in excess. Finally, in order to test 
the activity of the electron transport chain independently of the ADP 
phosphorylation, carbonyl cyanide m-chloro phenyl hydrazone (CCCP) was added to 
the reaction. CCCP is a mitochondrial uncoupling agent that dissipates the 
electrochemical gradient of protons across the mitochondrial inner membrane and 
thus short-circuits the electron transport chain from the ATP synthase. This 
uncontroled influx of protons activates the electron transport at its maximum rate and 
results in maximal respiration rate until anoxia is reached (32 min). The coupling of 
the electron transport chain to the ATP synthase characterized the quality of the 
mitochondria and can be evaluated by the the repiratory control ratio value (RCR). 
RCR corresponds to the ratio of the respiration rate in state-3 to the respiration rate in 
state-4. In control lymphoblastoid cells the RCR was 2.25. The same experiment was 
performed on mitochondria isolated from BTHS cells (Figure 3.3B and C). BTHS 
mitochondria (DB105.2 and DB105.3) were able to oxidize succinate at state-4 with 
the same efficiency as control mitochondria. However, both had lost the ability to 
respond to ADP and to establish the respiratory state-3. As a result, BTHS 
mitochondria exhibited lower RCR: 1.08 and 1.3 for DB105.2 and DB105.3, 
respectively. This may be due to either a loss of coupling between the electron 
transport chain and the ATP synthase or to an inhibition of the phosphorylation 
machinery. The fact that CCCP was able to activate the oxygen consumption of 
BTHS mitochondria to a similar extent as in control mitochondria strongly suggests 
that the inhibition of the respiratory state-3 is due to an inhibition of the 
phosphorylation machinery. Altogether these data indicate that CL remodelling is 
Figure 3-3: Defective OXPHOS in BTHS mitochondria. 
(A) Oxygraph of control mitochondria oxidizing succinate. (B and C) Oxygraphs of BTHS 
mitochondria oxidizing succinate. Mitochondria (M) were incubated at 0.5 mg of 
protein/ml in reaction buffer and 10 mM of succinate (Suc) was added as oxidizable
substrate. ADP was added to 0.2 mM and CCCP was added to 1 μM. The value of the 
respiratory control ratio (RCR) is indicated for each cell lines. Each figure is a 
representative of 3 experiments.
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required to sustain OXPHOS and to maintain mitochondrial structure. 
In order to investigate the involvement of CL and its fatty acyl chain composition in 
apoptosis, the sensitivity of BTHS lymphoblastoid cells to extrinsic and intrinsic 
apoptotic stimuli was analyzed. The extrinsic pathway was challenged using anti-Fas 
antibody that mimics the Fas ligand and engages the Fas receptor at the plasma 
membrane to activate the cascade of caspases (see section 1.5.2). The intrinsic 
pathway was activated using the chemotherapeutic drug, etoposide (VP-16). 
Etoposide is a semi-synthetic compound derived from a toxin present in the 
mandrake root Podophyllum. It has been clinically used for more than 20 years to 
treat a wide spectrum of human cancers and remains one of the most prescribed anti-
cancer drugs in the world. Etoposide targets and inhibits topoisomerase II, an 
enzyme that maintains the DNA topology. Topoisomerase II removes knots and 
tangles from the genome by generating transient double-stranded breaks in DNA. 
Etoposide stabilizes the topoisomerase II-cleaved DNA complex and thus kills cells 
through accumulation of DNA breaks. In fact, DNA damage activate p53 that 
triggers the intrinsic mitochondrial apoptotic pathway.  
Lymphoblastoid cells from control and BTHS patients were treated with either anti-
Fas antibody or etoposide and cell death was assessed by Annexin V/ Propidium 
iodide (PI) staining. The AnnexinV/PI assay allows the detection of phosphatidyl-
serine (PS) externalization, characteristic of apoptosis, and the detection of the loss 
of plasma membrane integrity, a general feature of cell death. Phospholipids are 
asymmetrically distributed between the two leaflets of the plasma membrane. In 
healthy cells, phosphatidyl-choline (PC) and sphyngomyelin (SM) predominantly 
reside in the outer leaflet whereas PS and phosphatidyl-ethanolamine (PE) are mainly 
located in the inner leaflet. Translocation of PS to the outer leaflet of the plasma 
membrane is an early event in apoptosis that occurs after caspase activation but 
before the loss of plasma membrane integrity in vitro. In vivo, exposure of PS to the 
extra-cellular surface serves a recognition signal for neighbouring cells to 
phagocytose the apoptotic cells in order to avoid the disruption of the plasma 
membrane and consequently an inflammatory reaction. Externalization of PS on the 
cell surface can be detected with Annexin V. Annexin V binds to the negatively 
charged phospholipids like PS in presence of Ca2+. Therefore, after treatment, cells 
were resuspended in Ca2+containing buffer. By conjugating FITC to Annexin V it is 
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possible to identify and quantify apoptotic cells by flow cytometry. PI binds to DNA 
by intercalating between the bases. PI is membrane impermeant and excluded from 
healthy cells. PI incorporates into DNA of cells that have loss their plasma 
membrane integrity. These have either undergone late apoptosis, a stage often 
referred to as secondary necrosis. Therefore, AnnexinV/PI double staining technique 
was used to distinguish between healthy cells (Annexin V negative / PI negative), 
early apoptotic cells (Annexin V positive / PI negative), late apoptotic or secondary 
necrotic cells (Annexin V positive / PI positive) and necrotic cells (Annexin V 
positive / PI positive).  
Lymphoblastoid cells from control or BTHS patients were treated with 0.5 μg.ml-1 of 
anti-Fas antibody for 24 and 48 hours. Figure 3.4A shows two representative 
experiments of Annexin V/ PI assays on control (DB015.2) and BTHS (DB105.2) 
cells. At the beginning of the experiment (time 0), both control and BTHS cells were 
mostly detected at the lower left quadrant of the plot (double negative) indicative of 
viable cells (90 % and 92 % for control and BTHS cells, respectively). In both cell 
lines, there was a small population of cells in the upper right quadrant, corresponding 
to the basal level of cell death. This indicated that these cells lines were both in a 
good state before treatment. It is important to mention that basal cell death of 
untreated cells was always checked at each time point in order to rule out false 
interpretation of the effect of apoptotic stimulus (Data not shown). After 24 hours 
incubation with 0.5 μg.ml-1 of anti-Fas antibody, 5.26 % of control cells were 
detected at the early apoptotic quadrant (lower right) and 29.44 % at the late 
apoptotic quadrant (upper right). In contrast, at the same time, only 3.17 % of the 
BTHS cells became early apoptotic and only 11.54 % were at the late apoptotic 
stage. This difference was further amplified after 48 hours of treatment. In fact, only 
57 % of the control cells were viable after 48 hours whereas almost 90 % of BTHS 
were still healthy. The percentages of Annexin V positives cells (early and late 
apoptosis) of three independent experiments are represented in figure 3.4B for the 
two control and two BTHS cell lines. Both control lymphoblastoid cell lines had 
similar behaviour upon anti-Fas antibody treatment with around 40 % of cells 
undergoing apoptosis after 48 hours (blue lines). On the other hand, BTHS were 
strongly resistant to anti-Fas antibody and only 8 % apoptosis was observed after two 
days of treatment (red lines).  
A
0 24h
Figure 3-4: BTHS cells are resistant to extrinsic apoptotic stimuli. 
(A) Dot plot of annexin V (green fluorescence @ 585 ± 42 nm) vs PI (red fluorescence 
@ 530 ± 30 nm) staining cells. Upper panels correspond to control DB015.2 cells and 
lower panels to the DB105.2 BTHS cells. These plots are representative of 6 
experiments (B) Kinetics of apoptosis induced by anti-Fas antibody in control and 
BTHS cells. Control cells are represented in blue, BTHS in red. Error bars are standard 
errors of the mean of 6 independent experiments (C)  Percentage of cell death induced 
by anti-Fas antibody after 48 hours incubation. (A-C) Cells were treated with a single 
dose of 0.5 μg.ml-1 of anti-Fas antibody. (D) Percentage of cell death induced by 
recombinant TNFα (20 ng.ml-1) together with cycloheximide (CHX- 20 μg.ml-1) after 24 
hours incubation. (E) Control (DB037) and BTHS-derived (DB105.2 and DB105.3) cells 
were analysed by FACS, using anti-Fas antibody, for the levels of surface-exposed Fas
receptor. Error bars are standard errors of the mean of 3 independent experiments.  
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The effect of anti-Fas antibody on the viability of control and BTHS lymphoblastoid 
cells was determined in an independent experiment by single PI staining (PI 
exclusion). Figure 3.4C represents the percentage of cell death (PI positive cells) 
after 48 hours in the presence of anti-Fas antibody. These results are consistent with 
data in figure 3.4A and B and provide more evidence that BTHS cells were 
protected from anti-Fas antibody induced apoptosis. Importantly, this resistance was 
not due to a decrease in levels of surface-exposed Fas on BTHS cells (Figure 3.4E). 
The same results were obtained when control and BTHS cells were treated with 
TNFα in the presence of cycloheximide, an inhibitor of protein translation. In the 
absence of protein synthesis, the anti-apoptotic pathway of TNFR1 mediated by 
NFκB is inhibited and TNFα activate extrinsic apoptosis. Like with anti-Fas 
antibody, BTHS lymphoblastoid cells were strongly resistant to TNFα−induced 
apoptosis (Figure 3.4D). Altogether these data suggest that the inactivation of 
tafazzin and consequently of CL remodelling confers resistance to the extrinsic 
pathway of apoptosis. 
The same experiments were carried out using DNA-damage inducing agents that 
activate apoptosis through the intrinsic pathway.  Lymphoblastoid cells from control 
and BTHS patients were treated with 5 μM etoposide for 24 and 48 hours and cell 
death was assessed by Annexin V/ PI double staining. As shown in figure 3.5A even 
though the DB037 control cells exhibited a slightly lower sensitivity to etoposide, 
DB015.2 control and the two BTHS lymphoblastoid cells underwent apoptosis to the 
same extent and kinetics after treatment with etoposide. In fact, around 50 % of 
apoptosis was observed in these three cell lines after 48 hours. The measure of cell 
viability by PI exclusion further supported the data of figure 3.5A. Figure 3.5B 
shows the percentage of cell death (PI positive cells) of control and BTHS cells after 
treatment with 5 μM etoposide for 48 hours. No differences of sensitivity were 
observed between the control and BTHS cells in response to etoposide; around 50 % 
of cell death was obtained after 48 hours treatment in the four cell lines. The same 
results were obtained using the DNA damage-inducing drug cisplatin (Figure 3.5C). 
To conclude, these results suggest that while inactivation of tafazzin does not affect 
the ability to undergo intrinsic apoptosis, it strongly protects cells from the extrinsic 
apoptotic pathway.  
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Figure 3-5: BTHS cells are sensitive to intrinsic apoptotic stimuli. 
(A) Kinetics of apoptosis induced by etoposide in control and BTHS lymphoblastoid cells. 
Control cells (DB037 and DB015.2) are represented in blue, BTHS (DB105.2 and 
DB105.3) in red. Error bars are standard errors of the mean of 3 independent experiments 
(B) Percentage of cell death induced by etoposide after 48 hours incubation. (A and B) 
Cells were treated with a single dose of 5 μM etoposide. (C) Percentage of cell death 
induced by cisplatin (25 μM) after 48 hours incubation. Error bars are standard errors of 
the mean of 3 independent experiments. 
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3.2.2 Knocking-down tafazzin decreases CL level and 
protects cells from extrinsic apoptosis. 
Since CL is a phospholipid specific of the mitochondrial membrane, it was 
reasonable to speculate that tafazzin inactivation and thus CL remodelling alteration 
inhibit the mitochondria-dependent step of the extrinsic apoptotic pathway (type II).  
However, lymphoblastoid cells were not an easy model to work with. These cells 
were difficult to grow and none of the methods of transfection tested (lipocarrier, 
Calcium Phosphate, electroporation) was successful. Therefore, in order to directly 
investigate the correlation between inactivation of tafazzin, alteration of CL 
metabolism and the resistance to extrinsic pathway it was important to generate a 
Barth syndrome-like model in a type II cell line. The cervical carcinoma HeLa cells 
are easy to grow, easily transfectable using common protocol and they also posess a 
individualized mitochondrial network making it a good cellular system for 
mitochondrial immunofluorescence analysis. First it was confirmed that HeLa cells 
behave as type II cells in response to Fas-receptor mediated apoptosis. In type II 
cells, the apoptotic signal initiated at the DR is relay to the mitochondria via the 
cleavage and activation of the BH3-only protein Bid. HeLa cells were transfected 
with incremental doses of short interfering RNA (siRNA) targeting the pro-apoptotic 
protein Bid and the efficiency of this oligonucleotide to reduce Bid expression was 
analysed by western-blot after 48 hours. As shown in figure 3.6A, 50 nM of siBid 
efficiently decreased the level of Bid in HeLa cells. This was due to a specific 
silencing of Bid expression since the non-targeting siRNA pool (scRNA) did not 
affect the level of Bid. 48 hours after transfection with 50 nM of each siRNA, HeLa 
cells were treated with 0.3 μg.ml-1 of anti-Fas antibody for 24 hours and cell viability 
was analysed by PI staining (Figure 3.6B). Depleting Bid in HeLa cells strongly 
inhibited Fas receptor-mediated cell death. In fact, 40 % of cells died in presence of 
scRNA whereas only 20 % of cell death was observed in HeLa siBid transfected 
cells. The Annexin V assay was originally developed to measure apoptosis in cells in 
suspension such as lymphocytes. This technique is not suitable for adherent cells 
such as HeLa cells. Detachment of adherent cells by trypsinization generally 
interferes with the binding of Annexin V to membrane PS, making apoptosis 
measurement a technical problem. Therefore, apoptosis was analysed by monitoring 
the activity of the effector caspases using the cell permeable substrate Red-DEVD-
fmk. Caspase-3 is the major effector caspase that is activated in response to most of 
the apoptotic stimulations and cleaves a plethora of substrates after the DEVD motif. 
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Figure 3-6: HeLa cells display a type II response to Fas-induced apoptosis.
(A) Western-blot analysis of endogenous Bid in HeLa cells transfected with incremental 
doses of either non targeting (scRNA) or Bid-targeting siRNAs (siBid). (B-C) Involvement of 
Bid in Fas mediated-apoptosis. HeLa cells were transfected with 50 nM of scRNA or siBid
for 48 hours and treated with 0.5 μg.ml-1 of anti-Fas antibody for 24 hours. (B) Cell death 
was analysed by PI exclusion. (C) Caspase-3 activation was monitored using Red-DEVD-
fmk (D) Western-blot analysis of Bcl-XL expression in HeLa Bcl-XL-overexpressing stable 
clones (Bcl-XL1 and 2) as compared to the parental cell lines transfected with the empty 
vector (Mock). (E) Role of Bcl-XL in Fas-mediated apoptosis. Mock or Bcl-XL
overexpressing HeLa cells were treated with 0.3 μg.ml-1 of anti-Fas antibody for 12, 24 and 
48 hours. Cell death was analysed by PI exclusion. (A and D) Cell lysates were 
immunoblotted with the indicated antibody. Actin was used as loading control. (B, C and E) 
Error bars are standard errors of the mean of 3 independent experiments.
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Once caspase-3 is activated Red-DEVD-fmk binds irreversibly to its active site and 
the cell become fluorescent. However, DEVD is not specific for caspase-3 and can 
be cleaved by high concentrations of other several caspases. According to the 
previous data, silencing Bid protected HeLa cells from Fas-induced apoptosis 
(Figure 3.6C). In fact, transfection of HeLa cells with siBid reduced apoptosis from 
70 % to 30 %. These results indicate that Bid is required for Fas-induced apoptosis in 
HeLa cells and strongly suggest that HeLa are type II cells. It is worth noting that 
there was still a significant induction of apoptosis (30 %) in siBid-transfected HeLa 
cells. This may be a consequence of the inefficient Bid silencing with siBid. Indeed, 
as can be seen in figure 3.6A, siBid did not completely knockdown Bid in HeLa 
cells. In type II cells, but not type I cells, Fas receptor-mediated apoptosis requires a 
mitochondria-dependent step and is inhibited by Bcl-2 or Bcl-XL [56]. Therefore, to 
confirm that they are indeed type II cells HeLa cells were transfected with Bcl-XL, 
stable clones were selected and Bcl-XL expression was analysed by western-blot. 
Figure 3-6D shows Bcl-XL overexpression in two of these clones as compared to the 
endogenous level of Bcl-XL in the parental cells lines transfected with the empty 
vector (Mock). These cells were treated with 0.3 μg.ml-1 of anti-Fas antibody for 14, 
24 and 48 hours and cell death was assessed by PI exclusion. Figure 3-6E represents 
the kinetics of cell death in these two Bcl-XL overexpressing clones as compared to 
the mock transfected HeLa. Fas-induced apoptosis was completely inhibited by Bcl-
XL overexpression in HeLa cells. These results together with the results presented in 
figure 3-6B and C demonstrate that HeLa cells are type II cells and require a 
mitochondrial amplification step to activate apoptosis in response to DR engagement. 
For these reasons, HeLa cells were chosen as cellular system to generate a model, 
similar to BTHS. 
To knock down tafazzin in HeLa cells, siRNA targeting tafazzin were designed 
(siTaz). HeLa cells were transiently co-transfected with 100 ng of plasmid encoding 
tafazzin-GFP fusion protein and 50 nM of either a non-specific or tafazzin-targeting 
siRNAs. Twenty four hours after transfection, cells were incubated with 50 nM of 
TMRE to stain the mitochondrial network. TMRE is a fluorescent dye that 
accumulates in mitochondria in a mitochondrial membrane potential dependant 
manner. The efficient siRNAs were identified by their ability to decrease the 
expression of tafazzin-GFP. The level and localization of tafazzin-GFP were 
analysed by confocal microscopy (Figure 3-7A).  
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Figure 3-7: Tafazzin localizes to the mitochondria and is efficiently ablated by a specific 
tafazzin siRNA. 
HeLa cells were transiently co-transfected with a plasmid encoding tafazzin-GFP fusion protein 
and either a non-specific (scRNA) or tafazzin-targeting siRNAs (siTaz). (A) Cells were analysed by 
confocal microscopy for the levels and localization of tafazzin-GFP 48 hours after transfection. 
TMRE was used to visualize the mitochondria. The specificity of siTaz was controlled by co-
transfecting the oligonucleotides with pEGFPN1. These pictures are representative of triplicate 
experiments. (B) Western-blot analysis of tafazzin-GFP in HeLa cells co-transfected with 
pTazGFPN1 plasmid and incremental doses of siTAZ for 72 hours. Cell lysates were subjected to 
12 % SDS-PAGE and immunoblotted with anti-GFP monoclonal antibody. Actin was used as 
loading control. Duplicates of each samples were ran.
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B
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When HeLa cells were transfected with 100 ng of parental plasmid pEGFPN1 in the 
presence of 50 nM of scRNA, cells displayed an overall green fluorescence. In 
contrast, tafazzin-GFP expressed as a punctuated pattern in the presence of scRNA. 
The green fluorescence perfectly overlaid with the TMRE fluorescence indicating 
that tafazzin localizes to the mitochondria. Interestingly, this result strongly suggests 
that the remodelling of CL takes place within the mitochondria. No tafazzin-GFP 
expression was observed when cells were co-transfected with 50 nM of siTaz. This 
knockdown was due to a specific silencing of tafazzin mRNA since siTaz did not 
modify the expression of GFP in pEGFPN1-transfected cells. The efficiency of siTaz 
was also verified by western-blot analysis 72 hours after transfection (Figure 3-7B). 
Altogether these results indicate that 50 nM of siTaz was able to efficiently reduce 
the expression of tafazzin and this silencing was maintained for at least 72 hours.  
Next, HeLa cells were transfected with 50 nM of scRNA or siTaz and their 
sensitivity to Fas-mediated apoptosis was investigated. Two days after transfection 
cells were treated with anti-Fas antibody and the cell viability was analyzed by PI 
staining after 24 hours. Importantly, transient depletion of tafazzin in HeLa cells did 
not modify the sensitivity of these cells to Fas-induced apoptosis (Figure 3-8B). 
Even though tafazzin was efficiently knocked down by siTaz during the course of the 
treatment (Figure 3-7B), it is likely that due to their slow turnover, CL have not been 
changed 72 hours after transfection. In fact, lipid radio-labelling experiment has 
revealed that CL has the highest half life of all the mitochondrial phospholipids in rat 
liver and brain [247]. Thus, phospholipids were extracted from HeLa cells transiently 
transfected with scRNA or siTaz and the CL composition was analysed by HPLC-
MS as described in section 3.2.1. The semiquantitative analysis of total CL level is 
shown in figure 3-8A. As expected, transient depletion of tafazzin using siTaz did 
not modify the level of CL. With this in mind, the generation of a stable tafazzin 
knockdown seemed the obvious approach to overcome this problem.  
The 21mers targeting sequence of siTaz was used to generate a short hairpin RNA 
(shRNA) encoding plasmid (shTaz). Two complementary DNA oligonucleotides of 
64 nucleotides containing the siRNA targeting sequence in both sense and antisense 
orientation were designed and cloned into the pSuperRetroGFPNeo vector to 
produce shTaz. A non-targeting shRNA plasmid, pSuperRetroGFPScramble 
(shControl), was used as control. HeLa cells were stably transfected with shTaz or  
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Figure 3-8: Transient depletion of tafazzin using siTaz does not affect the level of CL 
and the sensitivity to Fas-mediated apoptosis. 
HeLa cells were transiently transfected for 48 hours with a non-specific (scRNA) or tafazzin-
targeting siRNAs (siTaz) and analysed for their cardiolipin composition (A) or treated for 24 
hours with 0.5 μg.ml-1 of anti-Fas antibody (B). (A). Semiquantitative representation of the 
levels of CL. (B). Cell death was analysed by PI exclusion. These values are averages ± SD 
of triplicate samples for each condition.
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shControl and 8 clones were isolated for each construct. Total RNA was extracted 
from these clones and cDNA was prepared by reverse transcriptase reaction. Tafazzin 
and actin cDNAs were specifically amplified by 30 cycles of PCR and the expression 
level of these cDNAs were analyzed on agarose gel and visualized by ethidium 
bromide staining. Figure 3-9A shows the expression of tafazzin in shTaz and 
shControl HeLa clones. As compared to the shControl clones, the level of tafazzin 
expression was reduced in 5 of the shTaz selected clones. Two clones for each 
construct were selected based on their relative tafazzin expression. These included 
clones 6 and 7 of shControl-transfected HeLa (called shControl1 and shControl2, 
respectively) and clones 7 and 8 for the shTaz transfected cells (called shTaz1 and 
shTaz2, respectively) (red tick). The detection of cDNAs products of a reverse-
transcriptase PCR (RT-PCR) reaction on agarose gel does not allow accurate 
quantification since the ethidium bromide detection is rather insensitive and the PCR 
reaction may pass the exponential phase of amplification. In contrast, real time PCR 
(or Q-PCR) quantifies the level of cDNAs at each amplification cycle by monitoring 
the fluorescence of incorporation of SYBR green into the DNA. Q-PCR gives the 
expression level of target genes normalized to the level of reference genes under the 
same condition. In order to quantify the level of tafazzin expression in the selected 
HeLa clones, Q-PCR analysis were performed. Figure 3-9B shows the expression of 
tafazzin in shControl and shTaz HeLa clones relative to the level in parental 
untransfected HeLa cells. This expression was normalized using two housekeeping 
genes, β actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
reference. As compared to the parental cell line, no significant changes in tafazzin 
expression were observed in shControl HeLa clones. However, this expression was 
profoundly reduced when HeLa cells were stably transfected with shTaz. In fact, 
comparing to the parental cell lines tafazzin was down-regulated by 12 and 15 fold in 
the shTaz1 and shTaz2, respectively. Cell lysates were prepared from these different 
clones and the efficiency of shTaz to knockdown tafazzin protein was analysed by 
western-blot (Figure 3-9C). Both shTaz clones exhibited a significant reduction in 
endogenous tafazzin as compared to control cells.  
Having shown that tafazzin was efficiently silenced in HeLa cells raised the question 
whether this would affect the CL composition in a similar pattern as in BTHS 
lymphoblastoid cells. Phospholipids were extracted from HeLa shControl and shTaz 
and the CL composition was analysed by HPLC-MS as described for the 
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Figure 3-9: Stably knockdown of tafazzin in HeLa cells using short hairpin RNA 
plasmid (shTaz).
HeLa cells were stably transfected with a non-specific (shControl) or tafazzin-targeting 
shRNAs (shTaz) and clones were selected. (A) RT-PCR cDNA products of tafazzin and 
actin for shControl and shTaz clones (B) Real-time PCR analysis of tafazzin expression in 
shControl and shTaz HeLa clones relative to its expression in the parental untransfected
HeLa cells. The reaction was normalized to the expression of actin and GAPDH. Error bars 
are standard errors of the mean of 3 independent experiments. The sequences of tafazzin, 
actin and GAPDH primers used for the PCR reactions are indicated in Table1 (section 
2.1.2). (C) Western-blot analysis of endogenous tafazzin in shControl and shTaz HeLa
clones. Actin was used as a loading control. Cell lysate from shTaz1R revertant clone was 
also analysed (last lane). 
François Gonzalvez, 2007                                                          102
François Gonzalvez, 2007                                                                                                    103 
 lymphoblastoid cells in section 3.2.1. Figure 3-10A represents the mass spectra of 
CL and MLCL molecular species in shControl1 (shControl) and shTaz1 (shTaz) 
clones. shControl HeLa presented four different clusters of CL molecular species 
with similar m/z values as in the lymphoblastoid cells. Like the BTHS cells, shTaz 
HeLa cells showed an overall reduction of CL molecular species as compared to 
shControl cells (Figure 3-10A). In shControl and shTaz cells three clusters of MLCL 
fatty acyl chain species were also present. The semiquantitative analysis of total CL 
and MLCL levels in shControl cells (shControl1 and shControl2) and shTaz cells 
(shTaz1 and shTaz2) is presented in figure 3-10B. In comparison with shControl 
cells, the level of CL was decreased by 24 % and 39 % in shTaz1 and shTaz2, 
respectively. As seen in lymphoblastoid cells, the level of MLCL was also increased 
in shTaz HeLa cells although to a lesser extent. These results show that HeLa shTaz 
cells display a similar CL pattern as BTHS cells characterized by a low level of 
mature CL and an accumulation of MLCL. These results indicate that tafazzin plays 
a crucial role in remodelling CL in HeLa cells. For these reasons, shTaz HeLa cells 
were used as a model to study the involvement of CL and its acyl chain composition 
in apoptosis.  
In order to investigate the role of tafazzin and CL in apoptosis, the sensitivity of 
shTaz HeLa cells to extrinsic and intrinsic apoptotic stimulations was analyzed. 
shTaz HeLa cells were first treated with 0.3 μg.ml-1 anti-Fas antibody and the cell 
viability was monitored by PI exclusion after 14, 24 and 48 hours. Figure 3-11A 
shows the kinetics of cell death in shControl and shTaz HeLa cells. Like in BTHS 
lymphoblastoid cells, cell death was strongly inhibited in both shTaz HeLa clones as 
compared to shControl cells. In fact, only 25 % of shTaz cells died after 48 hours of 
treatment whereas more than 60 % of cell death was seen in both shControl cells. 
The extrinsic pathway was also challenged by the activation of TNFα-mediated 
apoptosis pathway in the HeLa clones and the cell viability was analyzed by PI 
staining (Figure 3-11B). When HeLa cells were treated with 1 ng.ml-1 of 
recombinant TNFα protein in combination with 1 μg.mL−1 of cycloheximide for 24 
hours, 80 % and 42 % of cell death was induced in shControl1 and shControl2, 
respectively. In stark contrast, shTaz Hela clones were strongly protected from 
TNFα-mediated apoptosis and only 12 % and 8 % of cell death was detected in the 
shTaz1 and shTaz2, respectively. Altogether, these data suggest that inactivation of  
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Figure 3-10: Barth-syndrome like model in HeLa cells. 
HeLa cells were stably transfected with a non-specific (shControl) or Tafazzin-targeting 
shRNAs (shTAZ) and analysed for their cardiolipin composition. (A) Representative mass 
spectra of MLCL and CL molecular species in shControl (shControl1) and shTaz (shTaz1) 
cells. The same amount of protein (1 mg) was extracted for each sample. CL i.s and PG i.s
correspond respectively to the CL and PG internal standards. (B) Semiquantitative
representation of the levels of CL and MLCL in two shControl cells (shControl1 and 
shControl2) and two shTaz cells (shTaz1 and shTaz2). These values are averages ± SD of 
triplicate samples for each cell lines.
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tafazzin and consequently of CL remodelling, confers resistance to the extrinsic 
pathway of apoptosis. 
Finally, the sensitivity of shControl and shTaz HeLa cells to intrinsic stimulation was 
tested using etoposide (Figure 3-11C). HeLa cells were more resistant to etoposide 
than lymphoblastoid cells. No cells death was induced when HeLa were treated using 
5, 10 or 20 μM of etoposide for 48 hours (Data not shown) and only 35 % of 
shControl died after 24 hours in presence of 60 μM etoposide. Surprisingly, only 10 
% of cells death was observed in shTaz HeLa cells under the same conditions 
indicating that these cells were also protected from etoposide-induced apoptosis.  
Taken together, these results show that tafazzin inactivation in BTHS or HeLa cells 
lead to an inhibition of CL maturation and confer resistance to the extrinsic apoptotic 
pathway. Although these data established a correlation between CL remodelling and 
apoptosis, the role play by CL and its acyl chain pattern in apoptosis needed to be 
further investigated.  
3.2.3 Full-length tafazzin is required for CL remodelling and 
Fas-induced apoptosis. 
Having shown that inactivating tafazzin altered CL maturation and extrinsic 
apoptosis in BTHS and HeLa shTaz cells raised the question whether introducing 
active tafazzin back to these cells could reverse their CL composition and restore 
their sensitivity to extrinsic apoptosis stimulations. As mentioned in section 1.6.2, 
four splice variants of tafazzin are expressed in human [176, 177]. The functionality 
of these different variants has been investigated by complementation analysis in 
tafazzin-deficient yeast Δtaz [178]. This yeast mutant strain presents a similar CL 
profile to BTHS cells with a decrease in CL and accumulation of MLCL levels. Only 
the human variant lacking exon 5 ( tafazzinΔ5) was able to completely restore the CL 
composition of Δtaz yeast suggesting that tafazzinΔ5 was the only functional splice 
variant in human [178]. Based on these results, this variant was re-introduced by 
retroviral-infection in BTHS lymphoblastoid cells. Retroviruses are an efficient way 
of stably delivering genes into mammalian cells. Unlike adenovirus-mediated 
delivery, retroviruses integrate into the host genome and thus allow a long term 
expression of target genes. To optimize the conditions of infection, a retroviral 
construct encoding GFP (pLpC-GFP) was transfected into packaging cells  
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Figure 3-11: Tafazzin-deficient HeLa cells are resistant to apoptosis. 
(A) Kinetics of cell death induced by anti-Fas antibody in shControl (blue) and shTaz (red) 
clones. Cells were treated with a single dose of 0.3 μg.ml-1 of anti-Fas antibody and cell 
death was analysed by PI exclusion. (B) Percentage of cell death induced by recombinant 
TNFα in shControl and shTaz HeLa cells. Cells were treated for 48 hours with 1 ng.ml-1 of 
recombinant TNFα in the presence of 1 μg.ml-1 of cycloheximide. (C) Etoposide-induced cell 
death in shControl and shTaz HeLa cells. Cells were treated for 24 hours with 60 μM of 
etoposide. Error bars are standard errors of the mean of 3 independent experiments. 
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(see section 1.2.4.2). The produced retroviruses were collected and used to infect the 
lymphoblastoid control cells DB037. After two days, the cells were transferred into 
selective medium. The efficiency of selection was monitored under fluorescent 
microscope (Figure 3-12A, left panel). Three weeks after selection, a high GFP 
expression was observed in DB037 control. Once the infection method has been 
optimized, the DB105.2 BTHS cells were infected with retroviruses encoding 
tafazzinΔ5. To control the efficiency of infection, the same cells were infected in 
parallel with GFP-expressing retroviruses. Like the control cells, most of the 
DB105.2 cells were green after three weeks of selection (Figure 3-12A, right panel). 
It is worth noting that while the control lymphoblastoid cells DB037 clumped in 
culture, BTHS DB105.2 cells grew as individualized cells. The expression of 
tafazzin was quantified by Q-PCR in DB105.2 cells infected with either GFP or 
tafazzinΔ5 expressing retroviruses (Figure 3-12B).  
Phospholipids were extracted from these cells lines and their CL composition was 
analyzed by HPLC-MS. The semi-quantitative analysis of total CL and MLCL levels 
in DB105.2GFP and DB105.2tafazzinΔ5 are shown in figure 3-13A, in comparison 
to those levels in DB037 control and in DB105.2 parental cells. No significance 
difference in CL or MLCL levels was observed between the DB105.2GFP and the 
parental cell lines DB105.2. Surprisingly, introducing tafazzinΔ5 into DB105.2 did 
not significantly affect the CL level, while the MLCL level was completely reduced 
to its normal level. Since CL level was still low in DB105.2tafazzinΔ5 cells (45 % of 
the control) it was investigated whether reversion of the MLCL to its normal level 
would be sufficient to restore the sensitivity of these cells to the extrinsic apoptotic 
pathway. To address this issue, DB105.2GFP and DB105.2tafazzinΔ5 were treated 
with anti-Fas antibody for 24 hours and cell death was analysed by PI staining. The 
experiment was also carried out in control DB037 and the parental cell line DB105.2. 
As shown in figure 3-13B, the over-expression of tafazzinΔ5 in DB105.2 did not 
restore sensitivity to Fas-mediated apoptosis. In fact, only 10 % of 
DB105.2tafazzinΔ5 cells died in response to anti-Fas antibody whereas more than 45 
% of cell death was induced under the same conditions in DB037 control cells.  
In parallel, the full-length tafazzin variant was introduced into HeLa tafazzin-
deficient cells (shTaz1). To overcome the effect of shTaz on tafazzin expression, a 
siRNA resistant vector expressing human full lengh tafazzin was generated. 
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Figure 3-12: Retroviral infection of lymphoblastoid cells.
(A) Expression of GFP in lymphoblastoid cells. Control (DB037) and BTHS (DB105.2) cells 
were infected using a retroviral vector expressing GFP (pLpC GFP). Three weeks after 
selection the cells were observed under a fluorescent microscope (B) Real-time PCR analysis 
of tafazzin expression in DB105.2GFP and DB105.2tafazzinΔ5 relative to its expression in the 
parental DB105.2 cell line. This was normalized to the expression of actin and GAPDH. Error 
bars are standard errors of the mean of 3 independent experiments. The sequences of 
tafazzin, actin and GAPDH primers used for the PCR reactions are indicated in Table1 
(section 2.1.2).
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Figure 3-13: Tafazzin Δ5 does not restore the CL composition and the sensitivity of 
BTHS cells to Fas-mediated apoptosis. 
(A). Semiquantitative analysis of the levels of CL and MLCL in control (DB037), BTHS 
(DB105.2), DB105.2GFP and DB105.2tafazzinΔ5 (DB105.2TazΔ5). (B). Fas-induced cell 
death in DB105.2tafazzinΔ5. Control (DB037), BTHS (DB105.2). DB105.2GFP and 
DB105.2tafazzinΔ5 were treated for 24 hours with 0.5 μg.ml-1 of anti-Fas antibody and cell 
death was analysed by PI staining. Error bars are standard errors of the mean of 3 
independent experiments.
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Three silent mutations were introduced within the siTaz targeted sequence of tafazzin 
to avoid the recognition of tafazzin mRNA by the siRNA and therefore protect it 
from degradation. shTaz1 HeLa cells were stably transfected with this siRNA-
resistant vector and tafazzin expression was analyzed by western blot. As shown in 
figure 3-9C, expressing the siRNA resistant vector into shTaz1 restored the 
expression of tafazzin to a similar level than shControl cells. To investigate whether 
re-expressing tafazzin into shTaz1HeLa cells restored a normal cardiolipin profile, 
CL and MLCL levels were quantified in the revertant shTaz1R cell line (Figure 3-14 
A). In shTaz1R, CL rose to a similar level as control cells and the MLCL level was 
profoundly reduced as compared to the parental cell line (shTaz1). Contrary to 
tafazzinΔ5, which only restored the level of MLCL in BTHS cells, expression of the 
full-length variant reversed both CL and MLCL levels to the normal level in HeLa 
tafazzin-deficient cells. This data strongly suggest that full length tafazzin is the only 
functional variant of tafazzin in human. The transduction of full-length tafazzin into 
BTHS lymphoblastoid cells was also attempted but unfortunately it was unsucessful. 
To check whether the restoration of CL profile also restored sensitivity to Fas-
mediated apoptosis, shControl1, the revertant shTaz1R and its parental cell lines 
shTaz1 were treated with anti-Fas antibody for 24 hours and analysed by PI staining 
(Figure 3-14B). Consistent with the previous results (Figure 3-11A), tafazzin-
deficient shTaz1 cells were strongly resistant to Fas-mediated apoptosis as compared 
to shControl1. Importantly, the revertant shTaz1R cells showed a 4 fold increase in 
their sensitivity to Fas-mediated apoptosis as compared to the parental cell lines 
(shTaz1). In fact, more than 40 % of shTaz1R cells died after Fas-treatment whereas 
only 10 % of cell death was induced in shTaz1.  
In response to a wide variety of apoptotic stimulations, executioner caspases such as 
caspase-3 cleaves the Poly-ADP Ribose Polymerase (PARP) at the DEVD motif into 
a 85 kDa and a 25 kDa fragment [248, 249]. Therefore, PARP cleavage was used as 
a marker to detect apoptosis in the different HeLa clones (shControls, shTaz and 
shTaz1R) after treatment with anti-Fas antibody (Figure 3-14C). Fas-activation 
induced PARP cleavage in both shControl cells. This cleavage was strongly inhibited 
in both shTaz. Consistent with the previous data, more PARP cleavage was observed 
in the revertant shTaz1R cells as compared to the parental cell lines. In fact, the level 
of cleaved form in the revertant was comparable to those levels in control cells. 
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Figure 3-14: Full length tafazzin restores the CL composition and sensitises HeLa
tafazzin-deficient cells to Fas-mediated apoptosis.
(A). Semiquantitative representation of the levels of CL and MLCL in two shControl cells 
(shControl1 and shControl2), two shTaz cells (shTaz1 and shTaz2) and in shTaz1 revertant
(shTaz1R). These values are averages ± SD of triplicate samples for each cell lines. (B). Fas-
induced cell death in shTaz1 revertant. shControl1, shTaz1 and shTaz1 revertant cell lines were 
treated for 24 hours with 0.3 μg.ml-1 of anti-Fas antibody. Error bars are standard errors of the 
mean of 3 independent experiments. (C). Western-blot analysis of PARP cleavage in shControl, 
shTaz and shTaz1R. HeLa cells were treated for 14 hours with 0.3 μg.ml-1 of anti-Fas antibody. 
Actin was used as loading control.
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Hence, expressing the full length variant of tafazzin in tafazzin-deficient cells 
sensitized the cells to Fas-mediated apoptosis. This indicates that the resistance to 
apoptosis observed in tafazzin knockdowned HeLa cells was not due to an 
unspecific-targeting of the shTaz construct.  
All together, these data provide the first evidence that tafazzin and thus mature CL 
can influence the extrinsic-apoptotic pathway. 
3.3 Discussion 
To shed more light on the role of CL in apoptosis, two experimental approaches have 
been used. The first was the use of BTHS lymphoblastoid cells that are defective in 
CL maturation due to an inactive mutant form of tafazzin. The second strategy was 
the generation of a Barth-syndrome-like model by knocking-down tafazzin in HeLa 
cell lines.  
In the first experimental approach, immortalized lymphoblastoid cells generated 
from BTHS and control patients were analysed for their CL composition. These 
analyses were performed at Ronald Wanders’ Laboratory (AMC, Amsterdam), which 
developed an accurate method to quantify CL and MLCL using HPLC-ESI-tandem-
MS [181, 250]. As expected, BTHS cells exhibited a reduced level of CL and a 
profound accumulation of its degradation intermediate MLCL. These two features 
were associated with a reduction of the unsaturation degree of CL acyl chains. CL 
deficiency has been reported in a wide variety of BTHS tissues including fibroblasts, 
lymphoblasts, myocardium, skeletal muscle and platelets [179, 180, 250-252]. This 
defect was not due to a decrease in CL biosynthesis but due to an inhibition in CL 
remodelling [179]. Decrease of the degree of unsaturation of the CL acyl chains was 
also reported in several BTHS tissues [181]. In BTHS heart for example, 
tetralinoleyl-CL (C18:2)4 was completely absent whereas the levels of saturated CL 
molecular species were increased. Only few studies have shown an accumulation of 
MLCL in BTHS tissues. This may account for a lack of detection due to technical 
and experimental limitations. Elevated levels of MLCL were found in muscle, heart, 
lymphocytes, and in fibroblasts generated from BTHS patients [181, 253].  
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To date, diagnosis of BTHS is based on molecular screening of platelets or 
fibroblasts for tafazzin mutations. However, more than 90 different pathogenic 
mutations have been described making it a time consuming approach. Detection of 3-
methylglutaconic aciduria has also been used as biochemical marker to diagnose 
BTHS, but elevations of 3-methyl glutaconic acid has been observed in other 
mitochondrial disorders [253]. Elevated level of MLCL was recently shown to be a 
specific hallmark of BTHS. Measurement of the MLCL/CL ratio in fibroblasts has 
been proposed as a simpler and more sensitive diagnostic test for BTHS [253].  
In his seminal report in 1983, Barth observed the presence of abnormal mitochondria 
in tissue biopsies from BTHS patients [173]. In cardiac biopsy, mitochondria 
appeared enlarged with disorganized cristae [254]. The same mitochondrial 
alterations were observed in BTHS lymphoblastoid cells. In these cells, 
mitochondrial cristae have lost their tubular and individualized shape and appeared 
interconnected. These observations are supported by a recent electron microscopy 
tomography study on mitochondria from BTHS lymphoblasts [255]. 3-D 
reconstruction of these mitochondria showed that their cristae contact to each other 
forming an enclose and continuous cavities with multiple branches. These 
mitochondrial inner membrane connections would account for the honeycomb 
appearance of the mitochondria observed in BTHS cells (Figure 3-2C).  
Since CL is mostly located in the mitochondrial inner membrane (see section 1.6.3), 
these results suggest that inhibition of CL remodelling due to tafazzin inactivation is 
responsible for the alteration of cristae organization. This hypothesis is supported by 
the phenotype of tafazzin-deficient Drosophila [256]. In these flies, mutations of 
tafazzin generated a BTHS phenotype, with the characteristic features: CL 
deficiency, alterations of mitochondrial configuration namely cristae disorganization, 
and motor weakness. The role of CL in mitochondrial structure has also emerged 
from studies of other cellular models. Mitochondria of CHO-PGS-S cells lacking PG 
and CL appeared swollen and have disorganized cristae [198, 206]. More recently, 
mitochondrial cristae reorganization has also been observed in the CL-synthase 
knockdown HeLa cells [165]. Inhibiting CL synthesis in these cells decreased the 
total level of CL without affecting its molecular species composition. Therefore, it is 
likely that mature CL are required to maintains the mitochondrial inner membrane 
configuration. In CL-synthase and tafazzin-deficient yeast models, CL have been 
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shown to be required for the stabilization and the organization of the respiratory 
complexes III and IV into supercomplexes [257-259]. Deficiency of CL may 
predispose the mitochondrial inner membrane to protein aggregation and thus may 
lead to cristae membrane adhesions observed in BTHS mitochondria. Clearly, further 
studies are required to define the exact mechanism by which CL maintains the 
structure of the mitochondrial inner membrane. 
The discussed above alterations in mitochondrial morphology due to CL deficiency 
are also associated with an impaired OXPHOS capacity. Mitochondria isolated from 
BTHS cells were able to oxidize succinate at the same rate than the control but have 
lost their ability to respond to ADP and to establish the respiratory state-3. No 
change in the respiration rate of uncoupled BTHS-derived mitochondria was 
observed suggesting that the respiratory state-3 inhibition was due to an alteration of 
the phosphorylation machinery. This machinery includes the ANT, the mitochondrial 
phosphate carrier and the ATP synthase, three mitochondrial enzymes that require 
CL for their optimal activities [191, 193, 195]. Thus, it is conceivable that in BTHS 
mitochondria the CL deficiency is not sufficient to inhibit the activity of the 
respiratory complexes but it results in the inhibition of the phosphorylation 
machinery. To summarize, these findings strongly suggest that tafazzin and thus CL 
remodelling are required to sustain OXPHOS and to maintain mitochondrial 
structure.  
Analysis of the sensitivity of BTHS cells to apoptotic stimulations revealed that these 
cells were protected from the DR-inducing extrinsic apoptotic pathways (Fas and 
TNF) but were still able to undergo apoptosis in response to intrinsic stimulations 
such as DNA damage-inducing drugs (etoposide and cisplatin). This raised the 
question whether tafazzin inactivation rendered the BTHS cells resistant to extrinsic 
apoptosis. Silencing tafazzin using siRNA oligonucleotides seemed the obvious 
approach to address this issue. Since tafazzin is a mitochondrial enzyme involved in 
the acylation of CL, it was assumed that tafazzin inactivation would inhibit extrinsic 
apoptosis at the mitochondrial level and thus would only protect type II cells from 
Fas-mediated apoptosis. Therefore, the type II HeLa cells were chosen as a cell 
model for the siRNA approach. Transient knockdown of tafazzin in HeLa cells did 
not affect the CL composition and the sensitivity of these cells to anti-Fas antibody 
mediated apoptosis. To surmount this problem, tafazzin has been stably silenced 
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using a short-hairpin RNA expressing plasmid. To date, this is the first tafazzin-
deficient model generated in human cells. These cells displayed a reduced level of 
CL and an accumulation of MLCL making them a good BTHS-like model. 
Moreover, ectopic expression of full length tafazzin to level equivalent to the 
endogenous levels (Figure 3-9C) in tafazzin-deficient HeLa cells, using a siRNA 
resistant vector, reversed the CL and MLCL pattern. These data provide the first 
evidence that full length tafazzin is required for the remodelling of CL in human 
cells.  
Like the BTHS cells, tafazzin-deficient-HeLa cells were protected from the extrinsic 
apoptotic pathway. Importantly, the sensitivity of these cells to anti-Fas antibody was 
restored by expressing full length tafazzin. Taken together, these data strongly 
indicate that tafazzin and thus mature CL are required for efficient Fas-mediated 
apoptosis in type II cells. These findings contrast with those obtained in CL-synthase 
deficient HeLa cells where CL deficiency was associated with an increase in Fas and 
TNF mediated cell death [165]. However, it is difficult to compare CL-synthase 
deficient and tafazzin-deficient HeLa cells. First, different biochemical reactions are 
affected in both models: CL synthesis and CL remodelling. Whereas inhibition of CL 
synthesis reduce CL and MLCL without discriminating between their molecular 
species, inhibition of CL remodelling alters its fatty acyl composition and leads to a 
deficiency in unsaturated mature CL. Second, CL synthase deficiency was associated 
with an increasing in PG which may substitute, to some extent, for CL [165]. 
However, under stress conditions, such as apoptotic stimulations, the lack of total CL 
would result in bioenergetic alterations that would predispose the cells to necrosis. In 
fact, CL-synthase knockdown cells appeared necrotic when stimulated with anti-Fas 
antibody [165]. 
In contrast to BTHS cells, tafazzin-deficient HeLa cells were also resistant to 
etoposide-induced apoptosis. This may account for the fact that HeLa cells present an 
innate resistance to DNA damage-induced apoptosis. While 40 % of lymphoblastoid 
cells died after 24 hours of treatment with 5 μM of etoposide, 60 μM of drug was 
required to kill a similar proportion of HeLa cells. HeLa cells contain integrated 
human papilloma virus (HPV) 18 DNA sequence in their genome encoding the HPV 
proteins E6 and E7 [260, 261]. The viral protein E6 promotes the degradation of p53 
[262]. Because p53 is degraded by E6 in HeLa cells, these cells are likely to be 
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resistant to p53-mediated apoptosis and thus to DNA damage-inducing agents. 
Therefore, it is conceivable that when treated with high concentration of etoposide, 
HeLa cells undergo apoptosis through a p53-independent pathway that require 
tafazzin. It will be interesting to study whether this cell death is now dependant on 
extrinsic signals via an autocrinic loop. 
Interestingly, while full length tafazzin restored the CL and MLCL composition in 
tafazzin-deficient HeLa cells, the variant lacking exon-5 only restored low MLCL 
levels in BTHS cells. In stark contrast, only the Δexon5 and not the full length 
variant of human tafazzin was able to restore the CL profile in tafazzin-deficient 
yeast model [178]. This may be due to the absence of exon 5 in yeast tafazzin. In 
fact, exon 5 was only found in primate species [177, 178]. These results, together 
with the recent discovery of BTHS patients with mutations in exon 5, strongly 
support the idea that full length tafazzin represents the only functional variant in 
human. More studies are needed to further understand the role of these two tafazzin 
variants in human. This has never been investigated in human before mainly due to 
the lack of a suitable experimental model. Tafazzin-deficient HeLa cells may 
represent a novel model to address this issue.  
Moreover, only full length tafazzin was able to restore the sensitivity of tafazzin-
deficient cells to Fas-mediated apoptosis. No reversion in sensitivity was observed 
when just MLCL was restored to normal level by tafazzinΔ5, suggesting that 
decrease of CL level and not accumulation of MLCL confer resistance to Fas-
mediated apoptosis. It would be interesting to investigate whether the full length 
tafazzin is able to restore the CL level and the sensitivity to Fas-mediated apoptosis 
in BTHS cells. Unfortunately, BTHS cells were only infected with retroviruses 
expressing the exon 5-deficient variant.  
To conclude, this chapter showed for the first time that tafazzin and thus mature CL 
are required for extrinsic apoptotic pathways in type II cells. It also underpins the 
importance of the acyl chain composition of CL in apoptosis. This raised the 
question how alterations of CL remodelling make cells resistant to the extrinsic 
apoptotic pathways without affecting their sensitivity to intrinsic apoptosis. The 
mechanism by which tafazzin inactivation confer resistance to Fas-mediated 
apoptosis will be discussed in the next chapter.  
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4 Mechanism of apoptosis resistance in 
tafazzin-deficient cells 
4.1 Introduction 
The previous chapter demonstrated that tafazzin deficiency confers resistance to the 
extrinsic apoptotic pathway in type II cells. It does not however address any of the 
molecular mechanisms involved in this resistance. Since tafazzin catalyses the 
remodelling of CL in mitochondria, it was logical to speculate that inhibition of CL 
maturation would block the transduction of the apoptotic signal at the mitochondria. 
As mentioned previously, CL has been previously implicated in several 
mitochondrial steps leading to the release of apoptogenic factors from the 
mitochondria. These steps include the transmission of the apoptotic signal to the 
mitochondria by the Bcl-2 family of proteins and the execution of the mitochondrial 
outer membrane permeabilization [101, 127, 128]. The results described in the 
previous chapter, together with recent observation showing that CL peroxidation is 
required for the release of apoptogenic factors from the mitochondria suggest that the 
acyl chain composition of CL is playing an important role in apoptosis [214]. 
However, the mechanism by which these acyl chains participate in apoptosis has not 
been shown. In order to understand the role of unsaturated mature CL in apoptosis, 
this chapter explores the molecular mechanisms by which tafazzin inactivation 
protects cells from the extrinsic apoptotic pathway.  
4.2 Results 
4.2.1 Inhibition of mitochondrial apoptosis in tafazzin-
deficient cells 
As mentioned in section 1.5.5.4, caspase-3 is one of the key effector caspases in 
apoptosis, responsible for the cleavage of many essential cellular proteins such as 
PARP. In response to apoptotic stimuli, initiator caspases are activated and drive 
forward the caspase cascade by directly activating the effector caspases. Upon 
cleavage, caspase-3 zymogens adopt an active dimeric conformation composed of 
two subunits, a large subunit of 17 kDa and a small subunit of 12 kDa [249].  
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Figure 4-1: Inhibition of caspase-3 activation in tafazzin-deficient HeLa cells.
(A). Analysis of caspase-3 and PARP cleavage by western-blot. HeLa shControl1 and 
shTaz2 were incubated for 14 hours with 0.3 μg.ml-1 of anti-Fas antibody and cells 
lysates were immunoblotted with the indicated antibody. Actin was used as loading 
control. Each blot is representative of 3 independent experiments (B). Analysis of 
caspase-3 activity by flow cytometry. HeLa shControl and shTaz cells were incubated for 
8 hours with 0.3 μg.ml-1 of anti-Fas antibody and then labelled using the cell permeable 
caspase-3 substrate Red-DEVD-fmk.  Red-labelled cells were quantified by FACS 
analysis. Error bars are standard errors of the mean of 3 independent experiments.
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Caspase-3 activation was analysed by western-blot in control and tafazzin-deficient 
HeLa cells after treatment with anti-Fas antibody for 14 hours (Figure 4-1A). The 
antibody used was raised against the p17 subunit and detects the pro-caspase-3 (32 
kDa). As expected, anti-Fas antibody activated caspase-3 in shControl cells as judged 
by the formation of three cleaved products of caspase-3 at around 20 kDa in size. 
These products result from the cleavage of three different sites in the pro-domain of 
caspase-3. No cleavage was observed when cells were pre-incubated with 20 μM of 
DEVD-fmk prior to treatment, indicating that DEVD-fmk efficiently inhibited 
caspase-3 activation. As compared to the control, caspase-3 activation was strongly 
inhibited in shTaz2 HeLa cells. Similar results were obtained when caspase-3 
activity was analysed by the cleavage of its substrate, PARP. As shown in Figure 3-
14C, PARP cleavage was strongly reduced in tafazzin-deficient cells. In order to 
confirm and quantify the inhibition of caspase activation in shTaz cells, caspase 
activity was directly monitored using the cell permeable substrate Red-DEVD-fmk. 
Red-DEVD-fmk irreversibly binds to activated caspases and labelled the cells with a 
red fluorescence that can be detected by FACS. shControl and shTaz cells were 
treated with anti-Fas antibody for 8 hours and caspase-3 activity was assessed 
(Figure 4-1B). Consistent with the western-blot analysis, caspase-3 activity was 
strongly reduced in both tafazzin-deficient clones as compared to the two control 
clones. Altogether, these results show that inactivation of tafazzin in HeLa cells 
inhibits Fas-mediated caspase-3 activation. As mentioned in section 1.5.3.3, cells 
undergoing apoptosis are characterized by an early dissipation of their mitochondrial 
membrane potential (Δψm). Δψm can be measured by flow cytometry using TMRE, a 
mitochondria-specific cationic lipophilic fluorescent dye. TMRE is cell permeable 
and accumulates in the mitochondria matrix in a Δψm dependant manner. Therefore, 
a loss of Δψm is detected by a decrease of the fluorescence intensity. HeLa cells were 
treated with anti-Fas antibody for 24 hours and mitochondrial membrane potential 
was assessed by TMRE staining. Figure 4-2A represents the percentage of cells with 
high TMRE fluorescence (High Δψm) before and after Fas-receptor activation. After 
anti-Fas antibody treatment, more than 50 % of the shControl1 cells have lost their 
Δψm whereas only 10 % of the tafazzin-deficient cells exhibited a low Δψm under the 
same condition. Interestingly, expressing full-length tafazzin in these cells restored 
their ability to undergo mitochondrial membrane depolarization to a level 
comparable to shControl cells. These data indicate that tafazzin and thus mature CL 
are required for Fas-induced mitochondrial depolarization.  
Figure 4-2: Inhibition of mitochondrial membrane depolarization in tafazzin-deficient 
HeLa cells. 
(A) HeLa shControl, shTaz and shTaz1R were treated with 0.3 μg.ml-1 of anti-Fas antibody for 
24 hours. Cells were then stained with 50 nM of TMRE and the fluorescence was quantified 
by flow cytometry. (B) Effect of DEVD on mitochondrial membrane depolarization. ShControl1 
and shTaz2 cells were incubated in the presence or absence of 20 μM of DEVD and treated 
as in (A). Error bars are standard errors of the mean of 3 independent experiments. 
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This raised the question whether the loss of Δψm induced by Fas receptor activation 
occurred upstream or downstream of the mitochondrial outer membrane 
permeabilization. In order to address this issue, caspases were inhibited using 20 μM 
of DEVD (Figure 4-1A). Incubation with DEVD completely protected shControl1 
cells from mitochondrial depolarization (Figure 4-2B). This indicates that the loss of 
Δψm observed after anti-Fas antibody treatment is dependent on caspase activation. 
In type II cells, such as HeLa cells, caspase-3 activation requires the release of 
apoptogenic factors from the mitochondria [56]. In this context, caspase-3 is 
activated by caspase-9 following cytochrome c release and apoptosome formation 
(section 1.5.3.7.1). This suggests that loss of Δψm occurs downstream of the 
mitochondrial outer membrane permeabilization.  
Since caspase-3 was inactivated in tafazzin-deficient cells, the ability of these cells to 
induce mitochondrial outer membrane permeabilization (MOMP) was investigated. 
Following MOMP, release of apoptogenic factors occurs in a hierarchical manner. 
First, cytochrome c, Smac/DIABLO and EndoG are released to the cytosol and 
activate the caspases cascade. Once activated, effector caspases (such as caspase-3) 
target the mitochondria and then further amplify the release of apoptogenic factors 
[80]. In response to intrinsic stimulations, cytochrome c and Smac/DIABLO are 
released in a caspase independent-manner [80, 81]. However, in type II cells 
transduction of the extrinsic apoptotic signal from Fas receptor to the mitochondria 
required the activation of caspase-8 at the DISC (section 1.5.4). To avoid the 
amplifying effect of caspase-3 on mitochondrial permeabilization, caspase-3 was 
inhibited with 20 μM DEVD (Figure 4-1A). Under these conditions, tafazzin-
deficient HeLa cells were treated with anti-Fas antibody for 14 hours and 
cytochrome c and Smac/DIABLO releases were analysed by immunostaining. As can 
be seen in figure 4-3A and B, under untreated conditions cytochrome c was 
distributed in a punctated pattern within the cytosol of shControl and shTaz cells. 
This pattern is characteristic of a mitochondrial staining (Figure 1-7). When 
shControl cells were treated with anti-Fas antibody, several cells in each microscopic 
field lost their mitochondrial punctated pattern and displayed a diffused cytoplasmic 
distribution of cytochrome c, indicative of cytochrome c release from mitochondria 
(Figure 4-3A, white arrows). No diffused pattern was observed when tafazzin-
deficient HeLa cells were treated with anti-Fas antibody (figure 4-3B).  
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Figure 4-3: Inhibition of cytochrome c release in Tafazzin-deficient HeLa cells. 
(A). Confocal microscopy analysis of cytochrome c immunostaining in shControl cells. (B) 
Confocal microscopy analysis of cytochrome c immunostaining in shTaz HeLa cells. HeLa
shControl and shTaz were incubated with 20 μM of DEVD and then treated with 0.3 μg.ml-1
anti-Fas antibody for 14 hours. Cells were fixed, permeabilized and stained using anti-
cytochrome c antibody (red). DAPI (blue) was used to stain the nuclei. Each picture is a 
representative of all the microscopic field observed under each condition. 
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Figure 4-4: Inhibition of Smac/DIABLO release in tafazzin-deficient HeLa cells. 
Confocal microscopy analysis of Smac/DIABLO immunostaining in shControl and shTaz
HeLa cells. HeLa shControl and shTaz were incubated with 20 μM of DEVD and then 
treated with 0.3 μg.ml-1 anti-Fas antibody for 14 hours. Cell were fixed, permeabilized and 
stained using anti-Smac/DIABLO antibody (red). DAPI (blue) was used to stain the nuclei. 
Each picture is a representative of all the microscopic field observed under each condition.
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Similar results were observed when cells were stained for Smac/DIABLO (Figure 4-
4). Fas-induced Smac/DIABLO release was observed in shControl cells whereas no 
diffused pattern was observed in shTaz cells under the same conditions. These 
findings indicate that Fas mediated cytochrome c and Smac/DIABLO releases are 
inhibited in tafazzin-deficient cells. Therefore, it appeared that the block in the 
apoptotic cascade in tafazzin-deficient cells is due to either defects in the process of 
the release of apoptogenic factors from the mitochondria or due to alterations in 
upstream steps.  
4.2.2 Tafazzin-deficient mitochondria are able to release 
cytochrome c in vitro 
It was previously suggested that CL is required for Bax-mediated permeabilization of 
the mitochondrial outer membrane [101]. The observation that cytochrome c and 
Smac/DIABLO release were inhibited in tafazzin-deficient cells raised the question 
whether the inhibition of apoptosis in these cells was due to alterations in the 
mechanism of MOMP. To address this issue, mitochondria were isolated from 
tafazzin-deficient cells and their ability to release cytochrome c was tested in vitro 
using a synthetic peptide derived from the BH3 domain of Bid (Bid BH3). BidBH3 
was shown to induce cytochrome c release through the activation of Bax and Bak 
oligomerization [95, 96]. To maintain the electron transport chain functional during 
the experiment, isolated mitochondria from control and BTHS cells were incubated 
in the presence of succinate and rotenone (section 1.2.1). These mitochondria were 
then treated for 15 minutes with incremental doses of BidBH3 peptide (from 1 to 100 
μM) and the presence of cytochrome c in the buffer was analysed by western-blot 
(Figure 4-5). The amount of cytochrome c present in the buffer of untreated 
mitochondria (first lane) is an indication of the quality of the mitochondrial 
preparation. In fact, mitochondria in good shape retain cytochrome c in their 
intermembrane space. To determine the maximal amount of cytochrome c available 
for release, mitochondria were lysed using a detergent (Triton, last lane). In the 
absence of treatment, only small amounts of total cytochrome c were detected in the 
buffer of control and BTHS mitochondria, indicating that mitochondria preparations 
were of good quality. As expected, BidBH3 peptide induced cytochrome c release in 
a dose-dependant manner. No cytochrome c was released when mitochondria from 
control cells (DB037) were treated with 1 μM of BidBH3 (second lane). Cytochrome 
c releasing activity was initiated when 5 μM of BidBH3 (third lane) was used and the 
Figure 4-5: BTHS mitochondria are capable of releasing cytochrome c in response to 
BidBH3 peptide. 
Mitochondria were isolated from control (DB037) and BTHS lymphoblastoid cells (DB105.2 
and DB105.3) and incubated in the presence of 10 mM of succinate and 1 μM rotenone. 
Mitochondria were treated with incremental doses of BidBH3 peptide for 15 minutes at 37°C 
and then centrifuged at 10,000 x g for 5 minutes. The supernatants were collected and 
immunoblotted with anti-cytochrome c antibody. 
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release was further increased with increasing amount of the peptide. In fact, 50 μM 
of peptide was sufficient to completely release cytochrome c from control 
mitochondria. Interestingly, BidBH3 peptide was as efficient in releasing cytochrome 
c in BTHS mitochondria as it was in control mitochondria. Initial and maximal 
cytochrome c release from BTHS mitochondria was observed at BidBH3 peptide 
concentration of 5 μM and 50  μM, respectively. These results indicate that even 
though BTHS cells are protected from the extrinsic apoptotic pathway, their 
mitochondria are capable of undergoing MOMP, suggesting that the block in 
apoptosis in BTHS cells occurs upstream of this event. 
4.2.3 tBid interacts with and releases cytochrome c from 
tafazzin-deficient mitochondria 
As mentioned in section 1.6.6.3, the first demonstration that CL plays a role in 
apoptosis was when it was shown to provide a “docking” site for tBid at the contact 
sites between the inner and the outer mitochondrial membranes [127, 128]. In type II 
cells, Bid is essential for the transduction of the apoptotic signal from the DR to the 
mitochondria (section 1.5.4). Following Fas receptor activation, Bid is cleaved into 
its active form tBid by caspase-8. Then, tBid translocates to the mitochondria and 
release cytochrome c through Bax/Bak activation [99, 100, 125, 126]. Several studies 
have shown that interaction of tBid with CL does not involve its BH3 domain but a 
CL binding domain that become exposed after caspase-8 cleavage [127, 131, 132, 
263]. Therefore, the ability of tBid to translocate to and to induce cytochrome c 
release from tafazzin-deficient mitochondria was tested. Under similar conditions to 
the previous experiment, mitochondria were isolated from control and BTHS cells 
and incubated for 15 minutes in the presence of increasing amounts of recombinant 
tBid. The release of cytochrome c to the buffer was then analysed by western-blot 
(Figure 4-6.A). Surprisingly, tBid released cytochrome c with the same efficiency in 
BTHS mitochondria and in control mitochondria. In both mitochondria, no 
cytochrome c release was detected with 0.2 nM tBid and the maximum release was 
observed using 0.5 nM tBid. Previously, tBid was shown to require either Bax or Bak 
to induce cytochrome c release [62]. In fact, via its BH3 domain tBid induces the 
oligomerization of the proteins Bax and Bak on the mitochondrial membrane and 
leads to the permeabilization of the outer membrane [99, 100]. Since Bax is mainly 
in the cytosol and Bak normaly resides in the mitochondrial outer membrane, the  
Figure 4-6: tBid induces Bak oligomerization and cytochrome c release in BTHS 
mitochondria. 
Mitochondria were isolated from control or BTHS cells and incubated in the presence of 10 mM
succinate and 1 μM rotenone. Mitochondria were treated with incremental doses of tBid for 15 
minutes at 37ºC and then centrifuged at 10,000 x g for 5 minutes. The supernatant and 
mitochondrial pellets were collected. Supernatant were immunoblotted with anti-cytochrome c 
antibody (A). Mitochondrial pellets were resuspended in 10 mM of DMSO or 10 mM of BMH and 
immunoblotted with anti-Bak antibody. Only DB037 and DB105.2 are shown in (B) but similar 
results were obtained in mitochondria isolated from DB105.3 cells. * and ** indicate the inter and 
intra cross-linked forms of Bak, respectively.
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ability of tBid to induce Bak oligomerization in BTHS mitochondria was 
investigated. After tBid treatment, mitochondrial membranes were collected and 
incubated with the cross-linker, Bis-MaleimidoHexane (BMH) [100]. BMH is a 
homobifunctional maleimide that is able to covalently cross-link sulfhydryl groups (-
SH) and therefore to stabilize the Bak oligomers in the mitochondrial membrane. The 
oligomerization of Bak was then visualized by western-blot analysis (Figure 4-6B). 
In the absence of cross-linker (first lane) Bak monomer was detected as a single band 
that migrated at around 27-kDa (Control or BTHS). BMH cross-linking was 
characterized by the appearance of a faster mobility band of around 21 kDa (**), 
which corresponds to an intramolecular cross-linked Bak monomer. As for 
cytochrome c release, Bak oligomerization was initiated with 0.5 nM tBid. In the 
presence of BMH, addition of tBid to control mitochondria (DB037) shifted Bak into 
two higher molecular weight complexes at around 38 kDa and 55 KDa (*). At the 
same time, the faster mobility species of Bak (21 kDa) decreased. These changes 
were further evident when increasing amounts of tBid were used. In accordance with 
the cytochrome c releasing experiments, tBid induced Bak oligomerization with the 
same efficiency in mitochondria from control or BTHS cells.  
In order to confirm these controversial results, the same in vitro experiments were 
carried out in mitochondria isolated from tafazzin-deficient HeLa cells. Mitochondria 
isolated from shControl1 and shTaz2 HeLa cells were incubated for 15 minutes with 
increasing amount of recombinant tBid and the release of cytochrome c and 
Smac/DIABLO was analysed by western-blot (Figure 4-7A). Consistent with the 
previous data, tBid released cytochrome c and Smac/DIABLO in a dose dependant 
manner with the same efficiency in shControl1 and shTaz2 mitochondria. In fact, 0.1 
nΜ of tBid was sufficient to initiate the release of cytochrome c and Smac/DIABLO 
and complete release of these proteins were obtained using 0.25 nM tBid. In this 
experiment the mitochondrial fractions were also collected and analysed by western-
blot for the presence of cytochrome c. The mitochondrial complex I was used as a 
loading control. In agreement with the analysis of the supernatants, the amount of 
cytochrome c in the mitochondrial pellets was reduced with the same kinetics in 
shControl1 and shTaz2 cells. To determine whether mature CL were required for the 
binding of tBid to the mitochondria, mitochondrial pellets were also analysed for the 
presence of tBid. Due to limitation in detectability of tBid antibody used, no bands  
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Figure 4-7: tBid interacts with mitochondria and induces Bak-oligomerization and 
subsequent cytochrome c release in tafazzin-deficient mitochondria. 
(A) tBid interacts with mitochondria and release cytochrome c and Smac/DIABLO from tafazzin-
deficient mitochondria (shTaz2). Mitochondria were isolated from control (shControl1) or shTaz2 
cells and incubated in the presence of 10 mM succinate and 1 μM rotenone. Mitochondria were 
treated with incremental doses of tBid for 15 minutes at 37ºC and then centrifuged at 10,000 x g 
for 5 minutes. The supernatant and mitochondrial pellets were collected and immunoblotted with 
the indicated antibody. (B) tBid induces Bak-oligomerization in tafazzin-deficient mitochondria 
(shTaz2). Mitochondrial pellets were resuspended in DMSO or 10 mM BMH and immunoblotted
with anti-Bak antibody. Complex I was used as a loading control of mitochondrial fractions. 
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were detected at tBid concentration lower than 0.25 nM. Importantly, at tBid 
concentration higher than 0.25 nM, tBid was detected at the same extent in 
mitochondria from tafazzin-deficient and control HeLa cells. The ability of tBid to 
induce Bak-oligomerization in mitochondria from tafazzin-deficient HeLa cells was 
also investigated by cross-linking the mitochondrial pellet (Figure 4-7B). In the 
presence of BMH, tBid shifted Bak into three higher order multimers around 50 kDa, 
75 kDa and 96 kDa (*). The sizes of these complexes are consistent with that of 
dimeric, trimeric and tetrameric form of Bak. Like in mitochondria from 
lymphoblastoid cells, Bak oligomerization after tBid treatment was as efficient in 
mitochondria from tafazzin-deficient HeLa cells (shTaz2) as it was in mitochondria 
from shControl cells. Altogether, these results show that the inactivation of tafazzin 
and consequently the decrease of mature CL do not affect the ability of tBid to 
interact with mitochondria, to induce Bak-oligomerization and subsequently to 
release apoptogenic factors from the mitochondria. These results also indicate that 
the apoptotic block in tafazzin-deficient cells lies upstream to tBid activity. 
4.2.4 Inhibition of caspase-8 activity in tafazzin-deficient cells 
Next, the cleavage of Bid by caspase-8 was assessed in tafazzin-deficient cells. To 
achieve this goal, lymphoblastoid cells from BTHS and control patients were 
incubated with anti-Fas antibody for 24 hours and cell lysates were analysed by 
western-blot for the presence of Bid (Figure 4-8A). As seen under untreated 
conditions, Bid full length was expressed at the same level in control and BTHS 
cells. After Fas-activation this level was decreased in both control cells (DB037 and 
DB015.2). Unfortunately, the cleaved product, tBid was below detection level in this 
experiment. Surprisingly, when BTHS cells were treated with anti-Fas antibody, no 
change in full-length Bid level was observed. Bid cleavage was also analysed in 
tafazzin-deficient HeLa cells (Figure 4-8B). Expression of full-length Bid was 
similar in shControl1 and shTaz2 cells. As expected, the level of full-length Bid was 
reduced in shControl1 after Fas-treatment. However, like in BTHS cells, no 
reduction in the full-length Bid was detected in shTaz1. Therefore, these results 
indicate that the processing of Bid is inhibited in tafazzin-deficient cells. Since Bid is 
cleaved by caspase-8 following Fas activation in type II cells, it was assumed that the 
inhibition of apoptosis in tafazzin-deficient cells occurred at the level of caspase-8 
activity.  
Figure 4-8: Inhibition of Bid cleavage in tafazzin-deficient cells.
(A) Bid cleavage in  control and BTHS lymphoblastoid cells. Control (DB037-lanes 1 , 3; 
DB015.2-lanes 2, 4) and BTHS (DB105.2-lanes 5, 7; DB105.3-lanes 6, 8) cells were 
incubated for 24 hours with 0.5 μg.ml-1 of anti-Fas antibody and cells lysates were 
immunoblotted with anti-Bid antibody. (B) Bid cleavage in  shControl1 and shTaz1 HeLa
cells. HeLa shControl1 and shTaz2 were incubated for 14 hours with 0.3 μg.ml-1 of anti-
Fas antibody and cells lysates were immunoblotted with anti-Bid antibody. (A-B) Actin was 
used as loading control. Each blot is representative of 3 independent experiments. 
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To directly test this assumption, caspase-8 activation was monitored in tafazzin-
deficient cells using a caspase-8 activity detection kit (Calbiochem).This assay 
utilizes the specific cleavage sequence of caspase-8, IETD, conjugated to 
sulforhodamine (Red-IETD-fmk) as a fluorescent marker. Red-IETD-fmk is a cell 
permeable and non-toxic compound that irreversibly binds to active caspase-8 in 
cells. The fluorescence label allows the detection of caspase-8 activation directly by 
flow cytometry. Lymphoblastoid cells from control and BTHS patients were 
incubated for 24 hours with anti-Fas antibody and caspase-8 activity was assessed 
(Figure 4-9A). In response to Fas treatment, caspase-8 was activated in around 40 % 
of the control cells (DB037 and DB015.2). However, this activation was strongly 
reduced in both BTHS cell lines. Next, shControl1 and shTaz HeLa cells were 
treated with anti-Fas antibody for 8 hours and caspase-8 activation was analysed 
(Figure 4-9B). After Fas-activation, more than 70 % of shControl1 cells activated 
caspase-8. Like in BTHS cells, this activation was significantly diminished in both 
shTaz cells. In fact, less that 30 % of shTaz cells displayed caspase-8 activity. As 
described in section 1.5.5.5, dimerization of caspase-8 zymogen at the DISC is a 
prerequisite event for the autoprocessing of caspase-8 into its fully active form [143, 
144, 146]. Upon dimerization, pro-caspase-8 is first cleaved between its two active 
subunits to generate the p43 and p10 products. Then, cleavage of the p43 between 
the DED prodomain and the p18 subunit produce the dimeric active form p18/p10. 
Therefore, caspase-8 autocleavage was analysed by western-blot in tafazzin-deficient 
cells (Figure 4-10). Two anti-caspase-8 antibodies were used to detect the different 
cleavage products of caspase-8: an antibody raised against the large active subunit 
p18 to recognize the p43 and the p18 subunits and the anti-DED antibody to detect 
the procaspase-8 (p55), the p43 and the cleaved DED domain (p26). As expected, 
Fas activation induced the cleavage of procaspase-8 (p55) into p43, p26 and p18 in 
both lymphoblastoid control cells (Figure 4-10A). The amounts of these cleaved 
products were all reduced in BTHS cells in particular the p43 and the active cleaved 
form p18. Auto-processing of caspase-8 was also assessed in tafazzin-deficient HeLa 
cells. When shControl1 were treated with anti-Fas antibody, procaspase-8 was 
cleaved into p43, p26 and p18 (Figure 4-10B). Like in BTHS cells, these cleaved 
forms were strongly diminished in shTaz2 cells. These data together with the results 
of figures 4-8 and 4-9 strongly indicate that tafazzin and thus mature CL are required 
for the activation of caspase-8 after Fas-engagement in type II cells.  
Figure 4-9: Inhibition of caspase-8 activity in tafazzin-deficient cells.
(A) Control (DB037 and DB015.2) and BTHS (DB105.2 and DB105.3) lymphoblastoid cells 
were incubated for 24 hours with 0.5 μg.ml-1 of anti-Fas antibody and then labelled using the 
cell permeable caspase-8 substrate Red-IETD-fmk.  Red-labelled cells were quantified by 
flow cytometry. (B) shControl1, shTaz1 and shTaz2 HeLa clones were incubated for 8 hours 
with 0.3 μg.ml-1 anti-Fas antibody and then labelled using the cell permeable caspase-8 
substrate Red-IETD-fmk.  Red-labelled cells were quantified by by flow cytometry. Error 
bars are standard errors of the mean of 3 independent experiments. 
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Figure 4-10: Inhibition of caspase-8 cleavage in tafazzin-deficient cells.
(A) Caspase-8 cleavage in BTHS lymphoblastoid cells. Control (DB037-lanes 1 , 3; DB015.2-
lanes 2, 4) and BTHS (DB105.2-lanes 5, 7; DB105.3-lanes 6, 8) cells were incubated for 24 
hours with 0.5 μg.ml-1 anti-Fas antibody and cells lysates were immunoblotted with anti-
caspase-8 antibodies (anti-DED, upper pannel and anti-p18, middle pannel). (B) Caspase-8 
cleavage in tafazzin-deficient HeLa cells. shControl1 and shTaz2 HeLa cells were incubated for 
14 hours with 0.3 μg.ml-1 of anti-Fas antibody and cells lysates were immunoblotted with anti-
caspase-8 antibodies (anti-DED, upper pannel and anti-p18, middle pannel). (A-B) Actin was 
used as loading control. Each blot is representative of 3 independent experiments.  
B
A
actin
Untreated
Control
1        2        3         4         5       6        7   8
Fas Untreated
BTHS
Fas
(p55)
(p43)
(p26)
(p18)
p18DED
shCont1
Unt Fas Unt Fas
shTaz2
(p55)
(p26)
(p18)
caspase-8
Anti-DED
actin
caspase-8
Anti-p18
(p43)
caspase-8
Anti-p18
p10
François Gonzalvez, 2007                                                          137
François Gonzalvez, 2007                                                                                                    138 
These results further suggest that the inhibition of the apoptotic cascade in tafazzin-
deficient cells occurs at the level of caspase-8 activation. 
4.2.5 Mitochondrial caspase-8 translocation is inhibited in 
tafazzin-deficient cells 
Procaspase-8 was previously shown to interact with the mitochondria under 
physiological conditions and active caspase-8 was also found to associate with the 
mitochondrial outer membrane during apoptosis [158, 159, 264, 265]. Since caspase-
8 activity was affected by the inactivation of tafazzin it was tempting to speculate 
that mature CL were required for the activation of caspase-8 on the mitochondria. To 
address this, the processing of caspase-8 was analyzed on the mitochondria of control 
and tafazzin-deficient cells. shControl1 and shTaz2 HeLa cells were treated with 
anti-Fas antibody for 14 hours and cytosolic- or mitochondria-enriched fractions 
were isolated by differential centrifugations. These fractions were then analysed by 
western-blot for caspase-8 using the anti-p18 antibody. Because of experimental 
limitations, it was impossible to normalize these two fractions based on their cellular 
volume ratio. In figure 4-11, the mitochondria-enriched fraction is ten times higher 
than cytosolic fraction. The quality of the cell fractionation was controlled using an 
antibody against the subunit 4 of the respiratory complex IV (COXIV) localized in 
the mitochondrial inner membrane and an antibody recognizing the cytosolic protein 
actin. As shown in figure 4-11, COXIV was detected only in the mitochondria-
enriched fractions whereas actin was mainly present in the cytosol. The small traces 
of actin detected in the mitochondrial fraction may account for the interactions of 
mitochondria with actin cytoskeleton [266]. Under physiological conditions 
(untreated), procaspase-8 (p55) was detected in the cytosol and the mitochondria of 
shControl1 and shTaz2 cells. No difference in procaspase-8 expression was detected 
between these two cell lines. Activation of Fas in shControl1 cells induced the 
cleavage of cytosolic and mitochondria-associated procaspase-8 into the p43 and p18 
products. As compared to control cells, no difference in caspase-8 cleavage was 
observed in the cytosolic fraction of Fas-treated shTaz2 cells. However, 
mitochondria from these cells showed a significant reduction in the levels of p43 and 
p18 cleaved products. These results show that the processing of caspase-8 in the 
mitochondria requires tafazzin and indicate that mature CL might be involved in the 
activation of caspase-8 on the mitochondrial membrane. This suggests that either 
cytosolic pro-caspase-8 undergoes an initial step of autocleavage at the DISC (the  
Figure 4-11: Tafazzin is required for the autoprocessing of caspase-8 on the 
mitochondria. 
shControl1 and shTaz2 cells were incubated for 14 hours with 0.3 μg.ml-1 anti-Fas antibody 
and fractionated to cytosolic- and mitochondria-enriched fractions. For each fraction, 100 μg 
of proteins  were resolved on acrylamide gel and immunoblotted with anti-caspase-8 
antibody (anti-p18 subunit). Subunit 4 of complex IV (COXIV)  and actin were used as 
loading controls for mitochondria and cytosolic fractions, respectively. This blot is 
representative of 3 independent experiments .
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removal of it C-terminus p10 domain) before translocating to the mitochondria or 
mitochondrial pro-caspase-8 autoprocesses at the mitochondria following an 
apoptotic signal and acquires enhanced activity. 
To determine whether procaspase-8 and its cleavage products were integrated into or 
loosely attached to the mitochondrial membranes, mitochondrial-enriched fractions 
from untreated or Fas treated shControl1 cells were washed with an alkali carbonate 
buffer. This technique removes soluble and peripheral membrane proteins and 
separates them from membrane integral proteins. After 30 minutes, mitochondrial 
membrane proteins were collected by centrifugation at 100,000 g (Alkali-resistant 
fraction) and the loosely attached proteins were released in the supernatant (Alkali-
sensitive fraction). These two fractions were then analysed by western-blot for the 
presence of caspase-8. Bak and the respiratory complex I were used as markers of the 
mitochondrial outer and inner membranes, respectively. The efficiency of the alkali 
extraction was controlled by the dissociation of the subunit B of the respiratory 
complex II (SDHB), which is loosely associated to the matrix side of the 
mitochondrial inner membrane. In untreated or Fas-treated mitochondria, SDHB was 
released by alkali wash whereas Bak and complex I were only detected in the alkali-
resistant fraction (Figure 4-12). In untreated mitochondria, procaspase-8 was 
extracted by alkali treatment indicating that under normal conditions procaspase-8 is 
loosely attached to the mitochondrial outer membrane. The sensitivity of procaspase-
8 to alkali treatment was not affected by Fas activation, indicating that procaspase-8 
is only loosely attached to the mitochondrial outer membrane. In contrast to 
procaspase-8, the cleaved products of caspase-8, especially p43 and p18, were 
resistant to the extraction. However, significant amounts of the p26 product, which is 
the non active DED domain of the enzyme, was also released into the supernatant 
after alkali extraction, suggesting that unlike the active domains of processed 
caspase-8, the DED is not fully inserted into the mitochondrial membranes. These 
results suggest that once the first cleavage of pro-caspase-8 occurs at the DISC, p43 
product translocates and integrates into the mitochondrial membranes through its 
exposed p18 subunit. 
 
Figure 4-12: The p18 and p43 subunits of caspase-8 integrate into the mitochondrial 
membranes after Fas activation.
shControl1 cells were either untreated or treated for 14 hours with 0.3 μg.ml-1 anti-Fas
antibody. Mitochondria-enriched fractions were isolated and resuspended for 30 minutes 
at 4°C in respiration buffer (unwash) or in alkali medium (Alkali wash) containing 0.1 M 
Na2CO3, pH11.5. Mitochondrial membranes were then pelleted by ultracentrifugation and 
the supernatants (S100 fraction) and pellets were collected. For each fraction, 100 μg of 
proteins  were resolved on acrylamide gel and immunoblotted with anti-caspase-8 
antibodies (antiDED and anti-p18 subunits). The efficiency of the alkali-extraction was 
controlled using three mitochondrial proteins: Bak (mitochondrial outer-membrane protein) 
complex I (mitochondrial inner-membrane protein) and subunit-B of the succinate
deshydrogenase (SDHB, loosely associated to the matrix side of the mitochondrial inner-
membrane). This blot is representative of 3 independent experiments.  
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4.2.6  Mitochondrial caspase-8 translocation is an early 
apoptotic event independent of Bid 
Following Fas-activation, caspase-8 cleaves the BH3-only protein Bid into tBid, 
which rapidly translocates from the cytosol to the mitochondria [125, 126]. Since the 
cleavage of Bid was inhibited in tafazzin-deficient cells it was assumed that tBid may 
be involved in the targeting of caspase-8 to the mitochondria. To directly address this 
issue, Bid was knocked down in shControl1 cells using siBid as previously described 
(section 3.2.2). Two days after transfection, cells were treated with anti-Fas antibody 
for 14 hours and mitochondria-enriched fractions were isolated. These fractions were 
then analysed by western-blot for the presence of caspase-8. As shown in figure 4-
13, siBid efficiency reduced the level of full-length Bid in the cytosolic and 
mitochondrial fractions. In the presence of untargeting control siRNA and anti-Fas 
antibody, cleavage of Bid was detected in the cytosol and mitochondria. 
Interestingly, depleting Bid did not affect the ability of caspase-8 cleaved products 
(p43 and p18) to translocate to the mitochondria.  
4.3 Discussion 
The results presented in the previous chapter showed that tafazzin is required for 
efficient Fas-mediated apoptosis in type II cells and highlighted the importance of 
the acyl chain composition of CL in this pathway. This chapter focused on 
understanding the mechanism by which mature CL participates in extrinsic apoptosis 
by using two models of tafazzin-deficient cells, BTHS-derived lymphoblastoid cells 
and tafazzin-knockdown HeLa cell lines.  
To understand the role of mature CL in extrinsic apoptosis, the known steps in this 
process were investigated in tafazzin-knockdown cells after activating Fas signalling. 
First, analysis of caspase-3 activity, which in type II cells requires cytochrome c 
release from mitochondria and the formation of apoptosome, showed a marked 
decrease in caspase-3 activity in tafazzin-deficient cells. This indicates that the block 
in the apoptotic pathway in tafazzin-deficient cells was either due to an inhibition of 
apoptosome formation or to defects in upstream steps.  
Even though CL have been previously reported to participate in many of the 
mitochondrial-dependent steps that lead to the release of apoptogenic factors, the 
Figure 4-13: Mitochondrial caspase-8 translocation is independent of Bid.
shControl1 cells were transfected with 50 nM of scRNA or siBid for 48 hours and incubated 
with 0.3 μg.ml-1 anti-Fas antibody for 14 hours. Mitochondrial and cytosolic fractions were 
isolated by differential centrifugations and immunoblotted with the indicated antibody. 
Complex I was used as a loading control for mitochondrial fraction. This blot is 
representative of 3 independent experiments. 
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exact mechanism played by CL and its fatty acyl composition in this process still 
awaits further investigation [161]. Therefore, the role of mature CL in the release of 
apoptogenic factors was investigated. Fas-activation failed to release cytochrome c 
and Smac/DIABLO from mitochondria in tafazzin-deficient HeLa cells. This was not 
due to alterations in MOMP mechanisms since isolated mitochondria from these cells 
were still able to release cytochrome c in response to BidBH3 peptide. Moreover, the 
ability of tBid to induce Bak-oligomerization and cytochrome c release was not 
affected in tafazzin-deficient mitochondria. Interestingly, tBid was 100 times more 
efficient in releasing cytochrome c than BidBH3 peptide thus supporting the model 
that the cytochrome c releasing activity of tBid required BH3 independent events 
[85, 130]. Taken together, these results indicate that mature CL is not required for the 
permeabilization of the mitochondrial outer membrane by the multi-BH domain 
protein Bax and Bak. This is consistent with previous results obtained using CL-
synthase deficient mitochondria from yeast and HeLa cells, which showed that Bax 
does not require CL to release cytochrome c [129, 165, 232].  
Next, the model of CL as a mitochondrial “docking” site for tBid was investigated in 
mitochondria from BTHS and tafazzin-knockdown HeLa cells. tBid interacted with 
the same efficiency with control and tafazzin-deficient mitochondria. This may 
account for the ability of MLCL, which accumulates in tafazzin-deficient cells to 
compensate the function of CL. Indeed, tBid was previously found to bind to MLCL 
in artificial membranes [226, 227]. Therefore, it is likely that in tafazzin-deficient 
mitochondria, MLCL support the association of tBid with the mitochondrial outer 
membrane.  
Given that neither MOMP nor interaction and apoptotic function of tBid on 
mitochondria were affected in tafazzin-deficient cells, further investigation of the 
impaired apoptotic process focused on the pathway connecting Fas response to the 
mitochondria. Upon Fas activation in lymphoblastoid cells or HeLa control cells, 
caspase-8 was activated and induced the cleavage of Bid into its active form tBid. 
Surprisingly, these two events were strongly inhibited in BTHS and tafazzin-
deficient HeLa cells. This was also associated with the inhibition of the 
autoprocessing of caspase-8 into p43 and p18 cleaved products. These results 
demonstrate for the first time that tafazzin plays a crucial role in the activation of 
caspase-8 in response to Fas activation in type II cells, and underscore the 
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importance of mature CL in this process. This unexpected observation raised the 
question how a mitochondrial specific lipid affects the activity of caspase-8. Because 
pro- and active caspase-8 were previously shown to associate with the mitochondria 
[158, 159, 264, 265], it was investigated whether mature CL were involved in the 
activation of caspase-8 on the mitochondria. Under normal conditions, procaspase-8 
was found associated with the cytosolic and mitochondria-enriched fractions in 
control HeLa cells. After Fas-activation, autoprocessing of procaspase-8 into p43, 
p26 and p18 cleaved products was detected in both fractions. Procaspase-8 and p26 
were loosely attached to the mitochondria (alkali-sensitive fraction) whereas p43 and 
p18 cleaved forms were inserted into the mitochondrial membranes (alkali-resistant 
fraction). Therefore, upon Fas activation, p43 cleaved product translocates and 
integrates into the mitochondrial membranes through its p18-exposed subunit. The 
translocation of p43 caspase-8 to the mitochondria was significantly reduced in 
tafazzin-deficient cells. The fact, that procaspase-8 was cleaved in the cytosolic 
fraction of tafazzin-deficient cells after Fas engagement, together with the lack of 
caspase-8 activation in BTHS and tafazzin-knockdown cells strongly indicate that 
activation of caspase-8 in type II cells mainly occurs at the mitochondria and requires 
mature CL. This is consistent with the seminal description of the type I and type II 
Fas-signalling pathways. In type II cells, DISC formation is strongly reduced and 
activation of caspase-8 is delayed and requires a mitochondrial step [56]. The 
observation that caspase-8 activation was inhibited by overexpressing Bcl-2 and Bcl- 
XL raised the questions whether caspase-8 was activated downstream to the 
mitochondria or at the mitochondrial membrane [56]. It was previously shown that 
Bcl-XL, with the help of the protein BAR (bifunctional apoptosis regulator), 
sequesters active caspase-8 at the mitochondrial outer membrane [159]. Altogether 
these data provide strong evidence that in type II cells, caspase-8 is activated in a two 
step process. First, after Fas activation a small amount of procaspase-8 is activated at 
the DISC to produce the p43 cleaved products. Then, p43 translocates to the 
mitochondria in a CL dependant manner and enhances the full activation of 
procaspase-8 at the mitochondrial membrane. The delay in caspase-8 activation in 
type II cells may account for the time required for p43 caspase-8 to relay the signal 
from the cell surface to the mitochondria. However, these results did not exclude the 
possibility that other partners may be involved in the activation of caspase-8 at the 
mitochondrial membranes. Recently, the FLICE-associated huge protein (FLASH) 
was shown to translocate from the nucleus to the mitochondria in response to Fas 
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activation, where it interacts with mitochondrial-associated caspase-8 [267]. Whether 
FLASH participates or not in the regulation of caspase-8 activation on the 
mitochondria awaits further investigation. Furthermore, the BH3 only protein Bid 
was not required for the translocation of p43 to the mitochondria in HeLa cells 
indicating that activation of caspase-8 on mitochondria is an early event that 
precedes the processing of Bid.  
In summary, this chapter demonstrated that the inhibition of the extrinsic apoptotic 
pathway in tafazzin-deficient cells takes place at the level of caspase-8 activation. 
Cells deficient in caspase-8 are resistant to Fas and TNFα−mediated apoptosis but 
are still sensitive to death induced by intrinsic stimulations such as etoposide [53]. 
Inactivation of caspase-8 is consistent with the results obtained in the previous 
chapter where it was shown that BTHS cells were protected from extrinsic apoptosis 
but were still able to undergo apoptosis in response to DNA damage. In contrast, 
tafazzin-deficient HeLa cells were protected from apoptosis induced by high dose of 
etoposide. However, as mentioned previously, etoposide activates the p53 apoptotic 
pathway, which is impaired in HeLa cells. It is possible that in this context, HeLa 
cells undergo apoptosis through a p53-independent pathway which involves a 
tafazzin-dependent step. Moreover, etoposide-induced apoptosis was found to 
require caspase-8 in several p53-deficient cells such as Jurkat and breast cancer cells 
[264, 268]. Taken together, these results suggest that etoposide induce apoptosis via 
two signalling pathways, a p53 dependant pathway and a caspase-8 dependant 
pathway. It is likely that inhibition of both pathways in tafazzin-deficient HeLa cells 
confered resistance to etoposide-induced apoptosis.  
It was shown here for the first time that mature CL are required for the interaction 
and in turn the activation of caspase-8 on the mitochondrial membrane in type II 
cells. It is still to be determined whether other proteins, such as FLASH, participate 
with mature CL in the activation of caspase-8 on the mitochondrial membranes. 
However, the exact mechanism by which mature CL specifically recruits caspase-8 
p43 to the mitochondria remains unclear. Nevertheless, caspase-8 is likely to interact 
with mitochondria at the contact site between the mitochondrial inner and outer 
membranes, where CL is exposed to the cytosolic face of the mitochondria (Figure 
1-7). As mentioned in section 1.6.6.1, the unsaturated acyl chains of CL are 
peroxidized by ROS following a wide variety of apoptotic stimulations [212-214].  
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A decrease of the unsaturation degree of CL may protect CL from peroxidation. 
Therefore, it is likely that in BTHS and tafazzin-deficient HeLa cells the reduction of 
unsaturated mature CL may decrease its sensitivity to peroxidation. One can 
speculate that peroxidized CL may be the recognition signal of caspase-8 on the 
surface of mitochondria. Clearly, further study is required to identify the mechanism 
of interaction between CL and caspase-8 and to elucidate whether peroxidation plays 
a role in this process. 
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5 Activation of caspase-8 at the 
mitochondrial membrane: the activating 
platform model 
5.1 Introduction 
The previous chapter showed that mature CL are required for the activation of 
caspase-8 on the mitochondrial membranes in type II cells. Even though the 
activation of caspase-8 on the mitochondria has already been proposed, the exact 
mechanism by which this initiator caspase become activated at the mitochondrial 
membranes remains elusive [158, 159, 264, 265, 267]. As discussed in section 
1.5.5.3, activation of initiator caspases requires the recruitment of the zymogens to 
activating platform (PIDDosome for caspase-2, DISC for caspase-8, apoptosome for 
caspase-9) that promotes the dimerization of the pro-caspases and in turn, leads to 
their autoprocessing into active forms [143-145]. The results from chapter 4 
demonstrated that targeting the p43 caspase-8 cleaved product to mature CL is 
required for the full activation of caspase-8 in type II cells and suggested that mature 
CL provides an activating platform for procaspase-8 at the mitochondria. One 
question remained is what are the consequences of activating caspase-8 on the 
mitochondria. Stegh et al proposed a model in which active caspase-8 translocates 
from the mitochondria to the cytosol to target the cleavage of plectin, a cross-linking 
protein of cytoskeletal filaments [158]. However, whether mitochondrial active 
caspase-8 can directly induce MOMP has not been investigated yet. 
The aim of the results discussed in this chapter was to understand the mechanisms 
governing the activation of caspase-8 on the mitochondrial membranes, and to 
analyse the effects of this activation on the mitochondria-dependant steps of 
apoptosis.   
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5.2 Results 
5.2.1 Caspase-8 oligomerizes on mitochondrial-membranes 
following Fas activation  
Previous studies have demonstrated that initiator caspases are activated upon 
dimerization on activating platforms. Therefore, it was of interest to examine 
whether caspase-8 could oligomerize on mitochondrial membranes following Fas 
activation. shControl1 HeLa cells were treated with anti-Fas antibody for 14 hours, 
and mitochondria were incubated in the presence of BMH to stabilize caspase-8 
oligomers in the mitochondrial membrane. The oligomerization of caspase-8 was 
then visualized by western-blot analysis (Figure 5-1). In the presence of DMSO, 
procaspase-8 was detected as a single band that migrated at around 55-kDa. As 
expected, only the p43 and p26 cleaved products were detected using the anti-DED 
antibody after Fas-activation. Following BMH cross-linking, a slightly faster 
mobility band for procaspase-8 was observed (asterisks). This probably corresponds 
to an intramolecular cross-linked form of procaspase-8. It is noteworthy that after Fas 
activation, BMH shifted the first cleaved form of caspase-8 (p43) (which 
disappeared) into higher molecular weight complexes at around 50 kDa, 80 kDa 
(major species*), 120 kDa, 160 kDa and 200 kDa (minor species*). The 50 kDa is 
likely to be the heteromer of p43 and the active subunit p10. However, the estimated 
sizes of the other caspase-8 cross-linked complexes are consistent with homo-
oligomerization of p43 into dimer, trimer, tetramer and pentamer, respectively. These 
oligomers were not detected using the anti-p18 antibody. It is possible that 
oligomerization of caspase-8 hides the epitope recognized by the anti-p18 antibody. 
Therefore, these results provide the first evidence that p43 caspase-8 oligomerizes in 
the mitochondrial membranes in response to Fas activation and further suggest that 
mitochondria provide an activating platform for caspase-8.  
5.2.2 Active caspase-8 induces cytochrome c release in a CL 
dependant manner 
Next it was investigated whether mitochondrial active caspase-8 could initiate the 
mitochondrial step of apoptosis. To address this, mitochondria were isolated from 
HeLa cells and incubated with increasing amounts of recombinant active caspase-8 
(p18/p10 heteromer). Then, the ability of the active heteromer to translocate to the  
Figure 5-1: Caspase-8 oligomerizes in the mitochondrial membranes in response to 
Fas-activation. shControl1 cells were treated with 0.3 μg.ml-1 anti-Fas antibody for 14 hours 
and  mitochondrial fractions were isolated by differential centrifugations. Mitochondrial 
fractions were resuspended in  buffer containing either DMSO or 10 mM of BMH for 30 
minutes. Mitochondrial  pellets were then collected and immunoblotted with anti-DED 
caspase-8 antibody (left). The blot was then stripped and reprobed with the anti-p18 
caspase-8 antibody (right). Complex I was used as a loading control for mitochondrial 
fraction. This blot is representative of 3 independent experiments.
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mitochondria and to release cytochrome c was assessed by western-blot (Figure 5-
2A). Active caspase-8 interacted with shControl1 mitochondria and induced 
cytochrome c release in a dose dependant manner. In fact, 100 ng of recombinant 
caspase-8 initiated the releasing of cytochrome c from these mitochondria and almost 
all the cytochrome c was released with 500 ng. Importantly, active caspase-8 had the 
same affinity to tafazzin-deficient mitochondria. However, active caspase-8 was less 
efficient in releasing cytochrome c from shTaz2 mitochondria. In these 
mitochondria, cytochrome c release was initiated when 200 ng of active caspase-8 
was used and 500 ng had comparable activity to 200 ng in shControl1 mitochondria. 
These results indicate that active caspase-8 requires tafazzin, thus mature CL, to 
release cytochrome c from isolated mitochondria. Although the early processed form 
of caspase-8 (p43) requires CL to interact with and to be processed on the 
mitochondrial membrane (Figure 4-11), the fully active caspase-8 (p18/p10) had the 
same affinity for control and tafazzin-deficient mitochondria (Figure 5-2A). These 
results suggest that mature CL is essential either for the activity of fully processed 
caspase-8 on mitochondrial membranes or for the availability of its substrates on the 
mitochondrial membranes.  
To investigate whether the lack of mature CL affect the activity of recombinant 
caspase-8 on mitochondrial membranes, the oligomerization of active caspase-8 was 
analysed in tafazzin-deficient mitochondria. Isolated mitochondria from shControl1 
and shTaz2 were treated with increasing amount of recombinant active caspase-8 and 
incubated in the presence of BMH to stabilize the caspase-8 oligomers in the 
mitochondrial membrane. The oligomerization of caspase-8 was then visualized by 
western-blot analysis using the anti-p18 antibody (Figure 5-2B). In the presence of 
BMH, active caspase-8 oligomerized into higher molecular weight complexes in 
shControl1 mitochondria. The major specie (**) at around 28 kDa likely corresponds 
to the active heteromer p18/p10. The size of the other crosslinked complexes (~36 
kDa, 38 kDa, 45 kDa and 55 kDa) is consistent with that of multimers of p18 either 
alone, or together with p10. Interestingly, active recombinant caspase-8 efficiently 
oligomerized on tafazzin-deficient mitochondria suggesting that mature CL were not 
require to sustain the activity of active caspase-8 on mitochondrial membrane.  
Figure 5-2: Mitochondrial active caspase-8 induces cytochrome c release in a CL-
dependant manner.
(A) Mitochondria were isolated from shControl1 or shTaz2 cells and incubated in the 
presence of 10 mM of succinate and 1 μM rotenone. Mitochondria were treated with 
incremental doses of recombinant active caspase-8 p18/p10 for 15 minutes at 37°C. The 
supernatant and mitochondrial pellets were collected and immunoblotted with the 
indicated antibody. (B) Mitochondrial pellets were resuspended in DMSO or 10 mM BMH 
and immunoblotted with anti-caspase-8 (anti-p18) antibody. Complex I was used as a 
loading control for mitochondrial fraction. This blot is representative of 3 independent 
experiments.
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5.2.3 Caspase-8 induced cytochrome c release is regulated 
by the Bcl-2 family proteins 
In order to investigate whether active caspase-8 induced cytochrome c through 
Bax/Bak activation, the ability of recombinant active caspase-8 to induce 
mitochondrial Bak oligomerization was analysed. Under the same conditions as in 
the previous experiment (Figure 5-2), mitochondria from shControl1 and shTaz2 
were treated with increasing doses of active recombinant caspase-8 and the 
membranes were crosslinked using BMH (Figure 5-3A). In both mitochondria, 
BMH induced the appearance of the faster mobility form of Bak at around 21 kDa 
(**). In shControl1, active caspase-8 induced Bak oligomerization in a dose 
dependant manner. Active-caspase-8 shifted the faster mobility form of Bak into a 
higher molecular weight complexe at around 38 kDa (*) correlating to a dimeric 
form of Bak (Figure 4-6B). Interestingly, the formation of these higher order 
complexes was considerably reduced in shTaz2 mitochondria and the level of the 
faster mobility species of Bak was not decreased (Figure 5-3A).  
Next, the ability of the anti-apoptotic protein Bcl-XL to regulate caspase-8-induced 
cytochrome c release was tested. Mitochondria were isolated from shControl1 and 
Bcl-XL1 cells and incubated with 200 ng of active recombinant p18/p10. Consistent 
with previous results, active caspase-8 interacted and released cytochrome c from 
shControl1 mitochondria (Figure 5-3B). However, even though active caspase-8 
interacted with mitochondria overexpressing Bcl-XL, it failed to release cytochrome 
c from these mitochondria. Taken together, these results indicate that caspase-8 
induced-cytochrome c release is tightly regulated by the Bcl-2 family proteins.
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Figure 5-3: Caspase-8 induced-cytochrome c release is regulated by the Bcl-2 family 
proteins.
(A) Active caspase-8 induces Bak-oligomerization in a CL-dependant manner. Mitochondria 
were isolated from shControl1 or shTaz2 cells and incubated in the presence of 10 mM
succinate and 1 μM rotenone. Mitochondria were treated with increasing amount of 
recombinant active caspase-8 p18/p10 for 15 minutes at 37°C. Mitochondrial pellets were 
resuspended in DMSO or 10 mM BMH and immunoblotted with  anti-Bak antibody. A low (30 
seconds) and a high (10 minutes) exposure of the same blot are shown. (B) Bcl-XL inhibits 
caspase-8-induced cytochrome c release. Isolated mitochondria from shControl1 or Bcl-XL1 
cells were incubated in the presence of 200 ng recombinant caspase-8. The supernatant and 
mitochondrial pellets were collected and immunoblotted with the indicated antibody. These 
blots are representative of 3 independent experiments. 
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5.2.4 Active caspase-8 induced cytochrome c release through 
the cleavage of mitochondrial-associated Bid 
Since caspase-8 cytochrome c releasing activity was dependant on Bak and 
completely blocked by Bcl-XL, it was tested whether the BH3 only protein Bid, 
specific substrate of caspase-8, may be involved in this process. To directly address 
this issue, Bid was depleted from shControl1 cells using siBid. Two days after 
transfection, mitochondria were isolated and treated with recombinant active 
caspase-8 to induce cytochrome c release (Figure 5-4). When mitochondria isolated 
from scRNA transfected cells were incubated with active caspase-8, cytochrome c 
was efficiently released. At the same time, mitochondrial-associated Bid was cleaved 
into tBid. Importantly, depleting mitochondrial Bid did not affect the interaction of 
active caspase-8 with the mitochondria but significantly reduced its ability to release 
cytochrome c (Figure 5-4). These results indicate that caspase-8-induced 
cytochrome c release activity requires the presence of full-length Bid on the 
mitochondria and the cleavage of mitochondrial associated Bid into tBid.  
5.2.5 CL is required for the physiological association of full-
length Bid with the mitochondria 
Having shown that active caspase-8 cleaves mitochondrial-associated Bid to induce 
cytochrome c release, it was investigated whether the full-length Bid protein was 
present on tafazzin deficient mitochondria and available to caspase-8. As can be seen 
in figure 5-5A, the levels of the full-length Bid were dramatically reduced in 
mitochondria isolated from tafazzin-deficient cells as compared to control 
mitochondria. It is therefore likely that the lack of Bid on shTaz2 mitochondria 
decreases the mitochondrial formation of tBid and subsequently inhibits cytochrome 
c release after treatment with active caspase-8. 
To compare the appearance of tBid on mitochondria from control and tafazzin-
deficient cells, isolated mitochondria were incubated with incremental doses of 
active caspase-8 and then subjected to an alkali wash to extract the loosely associated 
proteins (Figure 5-5B). Consistent with the previous results, recombinant active 
caspase-8 inserted with the same efficiency into shControl1 and shTaz2 
mitochondria. However, following incubation of mitochondria with increasing 
amounts of recombinant caspase-8, a corresponding rise in membrane-inserted tBid  
Figure 5-4: Caspase-8 cleaves mitochondrial-associated Bid and induces cytochrome 
c release.
shControl1 cells were transfected with 50 nM of scRNA or siBid for 48 hours. Mitochondria 
isolated from scRNA or siBid transfected cells were incubated in the presence of 10 mM
succinate and 1 μM rotenone and treated with 200 ng of recombinant active caspase-8 
p18/p10 for 15 minutes at 37ºC. The supernatant and mitochondrial pellets were collected 
and immunoblotted with the indicated antibody. These blots are representative of 3 
independent experiments. 
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Figure 5-5: CL is required for the physiological association of full-length Bid with the 
mitochondria and for presenting Bid to active caspase-8. 
(A) Tafazzin deficient mitochondria lack full-length Bid. The levels of endogenous full-length 
Bid protein on untreated mitochondria, isolated from shControl1 or tafazzin-knockdown 
(shTaz2) HeLa cells were analysed by western blot. (B) Active caspase-8 inserts into 
mitochondrial membranes and cleaves mitochondrial-associated Bid into tBid. Mitochondria 
were isolated from shControl1 and shTaz2 cells and incubated in the presence of 10 mM
succinate and 1 μM rotenone and treated with increasing amount of recombinant active 
caspase-8 p18/p10 for 15 minutes at 37°C. The mitochondrial pellets were then washed in 
alkali buffer and analysed by western-blot for caspase-8 insertion into mitochondrial 
membranes and for tBid formation. (A-B) Subunit 6 of complex I was used as mitochondrial 
loading control. These blots are representative of 3 independent experiments. 
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was seen in control but not in tafazzin-deficient mitochondria. Altogether, these 
results demonstrate that caspase-8 cleaves Bid on the mitochondrial membrane and 
that the lack of Bid on tafazzin-deficient mitochondria prevents caspase-8-mediated 
cytochrome c release. These results further indicate that mature CL is essential for 
the physiological association of full-length Bid with the mitochondria and it plays a 
crucial role in presenting Bid to active caspase-8. 
5.3 Discussion 
The previous chapter provides the first evidence that CL are essential for the 
activation of caspase-8 on the mitochondrial membranes in type II cells. It did not 
however address any of the mechanisms by which this initiator caspase acquires full 
activity on the mitochondrial membranes. This chapter focused on understanding the 
mechanism by which caspase-8 is activated on the mitochondrial membranes and the 
effect of this activation on the mitochondrial step of apoptosis. 
In stark contrast to effector caspases that are directly activated upon cleavage by the 
initiator caspases, activation of the initiator caspases requires the recruitment and 
subsequent dimerization of the zymogens on activating platform. Such triggering 
complexes include the DISC for caspase-8 and 10 [41], the apoptosome for caspase-9 
[107], the PIDDosome for caspase-2 [269] and the inflammasome for caspase 1 and 
5 [270]. Activation of caspase-8 on the mitochondria has been reported before [158, 
159, 264, 265, 267]. However, none of these studies have unravelled the mechanism 
by which this activation takes place. Here, it is shown for the first time that in 
response to Fas activation, the p43 caspase-8 cleaved product oligomerizes in the 
mitochondrial membranes. It is likely that by analogy to the DISC, oligomerization 
of caspase-8 at the mitochondria involves homophilic interaction through their 
DEDs. This is supported by the observation that active caspase-8 was unable to 
process its own precursor in vitro [146]. Whether or not the oligomerization of 
caspase-8 on the mitochondrial membranes involves protein adaptor, such as FADD 
in the DISC, awaits more investigations. 
These findings, together with the results of the previous chapter, suggest that in 
response to Fas activation, the p43 caspase-8 product generated at the DISC moves 
and inserts to the mitochondrial membranes where it oligomerizes and subsequently 
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further processes into its fully active form p18/p10. It remains unclear whether only 
DISC-generated p43 translocates and oligomerizes on mitochondria, or whether p43 
oligomerizes with mitochondria-associated procaspase-8. Since DISC formation is 
reduced in type II cells [56], it is likely that the small amount of p43 caspase-8 
produced at the DISC moves to the mitochondria and oligomerizes with 
mitochondrial-associated pro-caspase-8 to enhance its activation.  
The significance of the cleavage events for the activation of initiator caspases is still 
a matter of debate. Dimerization of procaspase-8 was reported to be sufficient for the 
acquisition of the catalytic activity [144]. In contrast, another model states that auto-
processing is a prerequisite event for the activation of procaspase-8 [143, 146]. In 
this scenario, the cleavage of the dimerized procaspase-8 leads to a change in its 
substrate specificity and enable the enzyme to recognize and activate the effector 
caspases [143, 146]. The results of this chapter further support the importance of 
procaspase-8 cleavages for the full activation of the enzyme. Therefore, it is 
conceivable that oligomerization of p43 caspase-8 on the mitochondria represents a 
prerequisite event that brings two identical catalytic units together and provides 
enzymatically competent conformation for the autoprocessing of the active dimer on 
the mitochondrial membranes.  
Once it was demonstrated that caspase-8 translocated to and activated in the 
mitochondrial membranes in response to Fas activation in type II cells, further 
emphasis was given to explore the role of active caspase-8 in the mitochondrial 
phase of apoptosis. In vitro, active recombinant caspase-8, p18/p10, inserted into 
mitochondrial membranes and released cytochrome c from mitochondria. Caspase-8-
induced cytochrome c releasing activity was dependent on Bak oligomerization and 
was completely blocked by Bcl-XL. Therefore, it was tested whether caspase-8-
induced cytochrome c release was dependent on the BH3 only protein Bid. Depletion 
of Bid on the mitochondria by RNA interference showed that caspase-8-induced 
cytochrome c releasing activity requires the cleavage of mitochondrial associated Bid 
into tBid. In the seminal study that identified Bid as a substrate of caspase-8, active 
caspase-8 was shown to require cytosolic Bid in order to release cytochrome c in 
vitro [126]. Here, it was shown that caspase-8-induced cytochrome c release activity 
does not require a cytosolic factor. Indeed, active caspase-8 inserts into the 
mitochondria and cleaves mitochondrial associated Bid into tBid that integrates into 
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the mitochondrial membrane and subsequently releases cytochrome c. The reason for 
this discrepancy is likely to be the amount of caspase-8 used in both studies. In fact, 
Luo et al. did not detect any cytochrome c release by incubating mitochondria with 
20 ng of recombinant active caspase-8, which is 5 times lower than the amount 
required for initiating the release of cytochrome c in this study (Figure 5-2).  
Importantly, although active caspase-8 was able to interact with and efficiently insert 
into tafazzin-deficient mitochondria, it was less efficient in releasing cytochrome c 
from these mitochondria. However, the basal level of full-length Bid was 
dramatically reduced in tafazzin-deficient mitochondria and hence less available for 
caspase-8 cleavage. Indeed, following incubation of mitochondria with increasing 
amounts of recombinant caspase-8, a corresponding rise in membrane-inserted tBid 
was seen in control, but not in tafazzin-deficient mitochondria. Taken together, these 
results provide the first evidence that tafazzin is required for the physiological 
association of full-length Bid with the mitochondria. Even though Bid was first 
described as a cytosolic protein [124-126], a growing body of evidences suggest that 
Bid binds to the surface of mitochondria [230, 271, 272]. Additionally, these results 
indicate that mature CL promotes the association of Bid to the surface of the 
mitochondria and that MLCL, which accumulate in tafazzin-deficient mitochondria 
are not able to compensate for CL in this function. This was surprising since tBid 
was shown to efficiently translocate to tafazzin-deficient mitochondria (Chapter 4). 
This may be due to different type of interactions between Bid or its truncated form 
with the mitochondria. In fact, while Bid is loosely associated with the surface of the 
mitochondria, tBid inserts into the mitochondrial membranes. The three-dimensional 
structure of Bid presents an overall similarity to that of Bax and Bcl-XL [263, 273]. 
However, Bid lacks the hydrophobic C terminal domain responsible for the insertion 
of Bax and Bcl-XL into the mitochondria (Figure 1-4). Bid is composed of eight α-
helices, of which α3 contains the BH3 domain, and two hydrophobic helices (H6 and 
H7) are buried at the centre of the molecule. Upon caspase-8 cleavage, these 
hydrophobic helices become exposed to the surface and the net charge of the 
molecule increased [263]. This may provide the targeting of tBid to the 
mitochondrial CL [224, 274]. However, whether this specific binding involved 
hydrophobic and/ or electrostatic interactions remains to be defined. Clearly, more 
investigations are required to characterize the mechanism by which Bid and tBid 
interact with CL.  
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To summarize, this chapter shows that CL enables the association of full length Bid 
with the mitochondrial membranes under normal physiological conditions. Thus, Bid 
is directly available for active caspase-8 on the mitochondrial surface and is cleaved 
into tBid, which in turn inserts into the mitochondrial membranes and induces 
cytochrome c release. Therefore, by tethering full-length Bid on mitochondria and by 
providing an activation site for caspase-8 following Fas signalling, CL brings 
together both the enzyme and its substrate and provides a platform from which to 
launch the mitochondrial phase of apoptosis. Thus, in type II cells CL is required 
both for grasping and activating the less or pre-active forms of caspase-8 on the 
mitochondria and for holding and presenting its substrate Bid. 
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CHAPTER 6 GENERAL DISCUSSION AND 
SUMMARY 
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6 General discussion and summary 
One of the hallmarks of cancer cells is their acquired resistance to apoptosis [236]. 
Most of the signals that elicit apoptosis converge on the mitochondria to induce 
MOMP and commit cells to death [31, 32]. The fact that MOMP represents a point of 
no return in the apoptotic pathway has prompted efforts to develop agents capable of 
triggering it in cancer cells. MOMP is a complex event involving the coordinated 
effort between numerous Bcl-2 family proteins.  
In addition to this complex protein machinery, CL has emerged as a participant in 
many of the mitochondrial-dependent steps that lead to MOMP [161]. However, until 
recently, investigation of the role of CL and its fatty acyl chain composition in 
apoptosis has been limited by the lack of cellular model. Following the cloning of 
human CL synthase, the role of CL in apoptosis was further studied in a mammalian 
cell model in which CL synthase was knocked down [165]. Inhibition of CL 
synthesis decreased the total level of CL without affecting its acyl chain composition 
and resulted in the accumulation of its precursor PG. These CL-deficient cells, 
however, displayed accelerated necrosis-like cell death likely due to severe 
bioenergetic alterations [165].  
In this work, the role of CL and its acyl chain composition in apoptosis was 
investigated using novel cell models of BTHS patient-derived cells and tafazzin-
knocked down HeLa cells containing reduced amounts of unsaturated mature CL and 
an accumulation of MLCL. In both cellular models, inactivation of tafazzin conferred 
resistance to the extrinsic pathway of apoptosis. This resistance was directly due to 
the inhibition of CL remodelling. Indeed, when tafazzin was transiently knocked 
down in HeLa cells, neither the CL pattern nor the sensitivity of these cells to Fas-
mediated apoptosis was altered. These results, together with the fact that rescuing the 
level of mature CL in tafazzin-deficient cells sensitized the cells to extrinsic 
apoptosis demonstrate that mature CL are required for efficient Fas-mediated 
apoptosis in type II cells.  
Further investigation of the impaired apoptotic pathway in tafazzin-deficient cells 
revealed that the major block was in caspase-8 activation. In this study, mature CL 
was identified as a crucial component of a mitochondrial platform required for 
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caspase-8 translocation, oligomerization and activation following Fas signalling in 
type II cells. Additionally, it is shown here that mature CL provides the physiological 
association of full-length Bid with the mitochondria. Therefore, by normally 
presenting Bid on the mitochondria and by providing an activation site for caspase-8 
after Fas activation, CL brings both the enzyme and its substrate together and 
provides a platform from which to initiate the mitochondrial phase of apoptosis. This 
newly identified activating platform, we termed “mitosome”, is likely to be localized 
at the contact site between the mitochondrial inner and outer membranes, where CL 
is exposed to the surface of the mitochondria.  
Altogether, these data suggest a model in which the p43/p10 caspase-8 cleaved 
product relays the apoptotic signal from the plasma membrane to the mitochondria in 
type II cells (Figure 6-1). In response to Fas receptor engagement, a small amount of 
procaspase-8 is activated at the DISC and produces the p43 products. Then, the 
p43/p10 caspase-8 translocates and inserts into CL-enriched mitochondrial 
membrane domains, where it further oligomerizes and subsequently autoprocesses 
into its fully active form p18/p10. Next, active caspase-8 directly cleaves Bid 
associated with these CL-enriched mitochondrial domains into tBid, which in turn 
inserts into the mitochondrial membrane and induces cytochrome c release. This 
work provides strong evidence that in type II cells, caspase-8 is activated in a two 
steps process, first at the DISC where it generates the p43/p10 form and second on 
the mitochondria where it acquires its full activity. The reason of such a complex 
regulation of caspase-8 activation was likely evolved to minimize the chances of 
accidental activation in healthy cells. However, while caspase-8 has been shown to 
require mature CL to be activated on the mitochondrial membranes, it is unclear 
whether this activation is direct, or whether other partners such as FLASH [267] 
participates in the activation of caspase-8 on mitochondria. It is also possible that 
Bcl-xL and BAR which have been shown to sequester active caspase-8 on the 
mitochondrial membranes take part in the “mitosome” [159]. Therefore, it will be 
interesting and important to perform mass spectrometry analysis of 
immunoprecipitated mitochondrial caspase-8 complexes to identify other 
components of this mitochondrial platform. 
Figure 6-1: The “mitosome” model in type II cells.
1. In response to Fas receptor activation, a small amount of procaspase-8 is activated at 
the DISC and generates the p43/p10 product. 2. The p43/p10 caspase-8 translocates 
and inserts via its exposed p18 subunit into CL-enriched mitochondrial membrane 
domains. 3. This results in the clustering and subsequent oligomerization of p43/p10 in 
the mitochondrial membranes. 4. Mitochondrial caspase-8 oligomerization provides 
enzymatically competent conformation for the autoprocessing of p43/p10 into the active 
heterodimer p18/p10. 5. CL also provides the association of Bid with the mitochondria. 
Thus, Bid is directly available for active caspase-8 on the mitochondrial surface and is 
cleaved into tBid, which in turn, inserts to the mitochondria and induces Bak
oligomerization (6.) and subsequent cytochrome c release (7.).  
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Decrease of tafazzin expression has been previously reported in B-cell lymphoma 
and breast carcinoma [275, 276]. These findings suggest that tafazzin may represent 
a new tumour suppressor. To date, BTHS has not been correlated with cancers. 
However, since BTHS has a high rate of mortality during infancy and early 
childhood it is possible that improving the life expectancy of BTHS patients would 
increase their predisposition to cancers. The characteristic symptoms of BTHS 
include cardiomyopathy, skeletal myopathy, neutropenia and growth retardation 
[173, 174]. BTHS children usually die early from cardiac failure or septicaemia. No 
sign of apoptosis resistance has been associated with the BTHS phenotype. Most of 
the neutropenic disorders have been attributed to an increased of neutrophil 
apoptosis. However, in the case of BTHS, this deficiency has been ascribed to an 
alteration in the development of neutrophils [173]. In addition to these four cardinal 
features, BTHS is often characterized by noncompaction of the left ventricular 
myocardium due to prominent trabeculations [277]. Interestingly, the same defects in 
heart development were observed in mice-deficient in caspase-8 [53]. Therefore, it is 
possible that the developmental abnormalities associated with BTHS have evolved at 
least partially from the inactivation of caspase-8.  
Recently, caspase-8 has been defined as a metastasis suppressor gene in 
neuroblastoma cells [278]. Stupack et al reported that caspase-8 does not impact on 
primary tumours growth but prevents the spread of invasive neuroblastoma cells by 
promoting cell death at tumour margins. In this context, caspase-8 mediated-
apoptosis is independent on DR and controls by other cell surface receptors known as 
integrins, which bind to components of the extracellular matrix. This process, called 
integrin-mediated death (IMD), occurs when cells are present in an inappropriate 
extracellular matrix and results in the recruitment and thus activation of caspase-8 by 
clusters of unligated integrins at the plasma membrane [279]. Thus, loss of caspase-8 
in neuroblastoma overcomes IMD and facilitates the survival and invasion of the 
cells into surrounding tissues. However, the molecular mechanisms that link cell 
surface adhesion and the intracellular apoptotic machinery are unknown. It will be 
therefore of considerable interest to investigate whether mitochondria in general and 
mature CL in particular are required for activating caspase-8 in response to IMD, and 
whether CL levels are altered during advanced tumour development. 
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To conclude, the work presented in this thesis provides some new insight into the 
mechanism by which CL regulates apoptosis with the discovery that mature CL 
participates in a new mitochondrial-associated platform, called the “mitosome”, 
required for the activation of caspase-8 in type II cells. 
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Abstract Cardiolipin (CL) is a mitochondria-specific phos-
pholipid which is known to be intimately linked with the mi-
tochondrial bioenergetic machinery. Accumulating evidence
now suggests that this unique lipid also has active roles in
several of the mitochondria-dependant steps of apoptosis.
CL is closely associated with cytochrome c at the outer
leaflet of the mitochondrial inner membrane. This interaction
makes the process of cytochrome c release from mitochon-
dria more complex than previously assumed, requiring more
than pore formation in the mitochondrial outer membrane.
While CL peroxidation could be crucial for enabling cy-
tochrome c dissociation from the mitochondrial inner mem-
brane, cytochrome c itself catalyzes CL peroxidation. More-
over, peroxy-CL directly activates the release of cytochrome
c and other apoptogenic factors from the mitochondria. CL
is also directly involved in mitochondrial outer membrane
permeabilization by enabling docking and activation of pro-
apoptotic Bcl-2 proteins. It appears therefore that CL has
multiple roles in apoptosis and that CL metabolism con-
tributes to the complexity of the apoptotic process.
Keywords Mitochondria . Apoptosis . Cardiolipin
Background
It has long been known that mitochondria are the ATP gen-
erating powerhouse of the cell and the site of other key
metabolic pathways involving fatty acid, amino acid and
steroid metabolism. However, in the early 1990s it became
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clear that in addition to these critical life-supporting roles,
mitochondria play a central part in the execution of apoptotic
cell death.
The involvement of mitochondria in apoptosis first came
into focus with the discoveries that most pro-apoptotic stim-
uli induce an early release of mitochondrial proteins, which
activates the cellular apoptotic program and disrupts mi-
tochondrial bioenergetics [1, 2]. These mitochondrial pro-
teins, known as apoptogenic factors, include cytochrome
c, smac/diablo, HtrA2/Omi, AIF and endonuclease G, of
which cytochrome c has been the most intensively studied.
Cytochrome c is normally involved in the ATP generation
pathway in mitochondria, transferring electrons from the cy-
tochrome bc1 complex (complex III) to cytochrome oxidase
(complex IV). But once released into the cytosol, cytochrome
c induces a cytochrome c/dATP/Apaf-1/pro-caspase-9 com-
plex termed the apoptosome [3]. The apoptosome activates
caspase-3, resulting in the degradation of many cellular com-
ponents. Cells deficient in cytochrome c, Apaf-1, caspase-9
or caspase-3 have impaired apoptosis in response to intrin-
sic mitochondria-dependent signals, underpinning the im-
portance of these components [4–7].
In response to apoptotic signals coming from the cy-
tosol, mitochondria-dependent apoptosis requires permeabi-
lization of the mitochondrial outer membrane. Mitochondrial
membrane permeabilization is tightly regulated by proteins
of the Bcl-2 family and is often considered the point of no
return in the apoptotic signalling cascade, leading to several
events such as DNA degradation in the nucleus and exposure
of phosphatidylserine (PS) on the outer leaflet of the plasma
membrane [8, 9].
PS was the first lipid identified to have a role in apop-
tosis regulation, when it was shown that exposure of PS
on the surface of apoptotic lymphocytes forms a recognition
site for phagocytosis by macrophages [10]. The sphingolipid
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Fig. 1 Molecular (left) and schematic (inset) structure of cardiolipin.
Cardiolipin is a dimer of phosphatidylglycerol (PG) and phosphatidic
acid (PA). It comprises four acyl chains, two phosphate groups and three
glycerols (schematically represented by blue circles). Under physiolog-
ical pH one of the phosphate groups is de-protonated, making cardi-
olipin a negatively-charged phospholipid
ceramide has attracted much attention in recent years. Cel-
lular ceramide levels increase in response to a wide variety
of apoptotic stimuli (e.g. TNFα, Fas ligand, IFNγ , stau-
rosporine and etoposide) preceding the mitochondrial steps
of apoptosis [11]. Although the mechanism of ceramide-
mediated apoptosis is still a matter of debate, a growing
body of evidence supports a direct effect of ceramide on
mitochondria resulting in alterations in bioenergetics, gener-
ation of reactive oxygen species and permeabilization of the
mitochondrial outer membrane [11].
Another class of lipids termed cardiolipin (CL) has at-
tracted new interest in the field of cell death. CL is a glycerol-
based phospholipid (Fig. 1) most of which is found in the
mitochondrial inner membrane. Several independent studies
suggest that CL has either survival- or death-supporting roles
in cells. This review summarizes recent data and discusses
the complex and controversial role of CL in apoptosis.
Cardiolipin physiology
Cardiolipin synthesis
The name “cardiolipin” alludes to the fact that it was first
isolated from bovine heart. CL or diphosphatidylglycerol,
whose dimeric structure distinguishes it from other glyc-
erophospholipids, has the glycerol-phosphate and two acyl
groups of each monomer bound together through a single
glycerol head. This results in four acyl chains, three glyc-
erols and two phosphate groups per molecule (Fig. 1). CL
is detected exclusively in bioenergetic membranes such as
those of bacteria and mitochondria, thus providing more ev-
idence for the endosymbiotic origin of mitochondria. The
biosynthetic pathway of CL in mammals has been well de-
scribed [12, 13]. Briefly, CL is synthesized de novo in a
four step pathway catalyzed by four mitochondrial enzymes,
yielding a CL archetype. The first three steps correspond to
the phosphatidylglycerol (PG) pathway and pass trough the
generation of the common intermediates, phosphatidic acid
(PA), cytidine-5′-diphosphate-diacylglycerol (CDP-DG) and
phosphatidylcytidine-monophosphate (CMP). The final step
is unique to CL synthesis and is catalyzed by CL synthase.
In this reaction, a molecule of PG condenses with a molecule
of the intermediate CDP-DG to yield diphosphatidylglycerol
or CL. The human CL synthase gene has recently been iden-
tified by its ability to restore a CL profile to the CL synthase
deficient yeast mutant crd1 [14]. Considering the variety
of fatty acids, the number of potential combinations of the
acyl chains is high, and indeed, the pattern of CL molecular
species varies between organisms and even between tissues.
Eukaryotic CL has a characteristic acyl chain pattern which
is restricted to 18 carbons [15]. In human heart the predomi-
nant C18 fatty acid is linoleic acid (C18:2) so heart CL contains
mostly C18:2 acyl chains. However human lymphoblast CL
contains predominantly oleyl chains (C18:1) [16]. The signif-
icance of this specificity is still not understood. Interestingly,
the enzymes involved in the pathway of CL synthesis exhibit
no selectivity for a specific acyl chain length [17]. Therefore,
once synthesized in mitochondria, a maturation step replac-
ing the original acyl chains with specific C18 unsaturated
ones is required.
The generation of mature CL requires a cycle of two re-
actions: the hydrolysis of one original acyl chain to generate
a monolyso-CL (MLCL), now containing only three acyl
groups, followed by the reacylation of MLCL with a specific
C18 acyl chain. Phospholipase A2 catalyzes the first step of
acyl chain removal [18]. However, the enzyme catalyzing
MLCL-acyltransferase activity has not been identified [18,
19].
Barth syndrome (OMIM # 302060) is the only hu-
man genetic disorder discovered where alterations of CL
metabolism are a primary cause of disease [20, 21]. This
X-linked genetic disorder is due to mutations in the tafazzin
gene (TAZ) located on region Xq28 [22]. Analyses of the CL
profile of different tissues obtained from Barth syndrome
patients revealed a decrease in CL and an increase in MLCL
and sequence alignments of TAZ showed homology with
the glycerolipid acyltransferase family [23–25]. While these
data suggest TAZ encodes the mitochondrial MLCL acyl-
transferase, the biochemical function of Tafazzin has not
been fully characterized.
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Fig. 2 The non-bilayer hexagonal structure of lipids was characterised
in vitro and proposed to contribute to the structure of contact sites
between the inner and outer membranes of mitochondria. Negatively-
charged phospholipids (such as cardiolipin) are more likely to adopt
this structure which may fuse the mitochondrial membranes at the
contact sites and redistribute cardiolipin on the cytosolic face of the
mitochondria
Cardiolipin localization in mitochondria
CL is specific to mitochondrial membranes but its precise
location within the different compartments of the organelle
is still the subject of controversy. For many years CL was
assumed to be associated exclusively with the mitochondrial
inner membrane where, as measured in bovine heart mi-
tochondria, it represents ∼25% of the total phospholipids
[26]. More recently CL has also been identified in the mi-
tochondrial outer membrane (∼4%) and especially at the
contact sites connecting the outer membrane with the in-
ner one [27–29]. Through the contact sites, CL may reach
the mitochondrial outer membrane and the cytosolic face of
the mitochondria. This notion is supported by the fact that
the two major phospholipids present in contact sites, phos-
phatidylethanolamine (PE) and CL (∼25% each) have the
ability to adopt a non-bilayer hexagonal HII phase in vitro
(Fig. 2) [30]. Such structures can contribute to the fusion of
two membranes [31].
The role of cardiolipin in bioenergetics
The exclusive presence of CL in bioenergetic membranes
suggests that it interacts with the electron transport
chain complexes involved in oxidative phosphorylation.
Indeed, CL is required for optimal activity of complex
I (NADH:ubiquinone oxido-reductase), complex III
(ubiquinone:cytochrome c oxido-reductase), complex IV
(cytochrome c oxidase) and complex V (ATP synthase),
four large complexes integrated in the inner mitochondrial
membrane [32, 33]. Further, complexes III, IV and V
were shown to contain CL in their quaternary structure
[32, 34, 35] and CL was observed within the 3D crystal
structure of Eschericia Coli succinate dehydrogenase, an
ortholog of the mitochondrial respiratory complex II (succi-
nate:ubiquinone oxido-reductase) [36]. CL is also required
by mitochondrial substrate carriers, including the adenine
nucleotide translocator (ANT), acylcarnitine translocase
and phosphate carrier [37–40]. It was reasonable to predict
therefore that a deficiency in CL would result in alterations
in cell respiration. A Chinese hamster ovary (CHO) cell
line containing a temperature-sensitive (ts) mutant of PG
synthase (CHO-PGS-S) has provided the first indication of
the potential involvement of CL in cellular bioenergetics
[41]. At the non-permissive temperature (40◦C) these cells
exhibit a decrease in oxygen consumption and ATP produc-
tion, accompanied by a compensatory increase in glycolysis
[42]. However, since these cells have reduced levels of both
PG and CL at 40◦C, it is not possible to attribute these
bioenergetic defects to CL alone. Other studies using the CL
synthase deficient yeast mutant crd1, have provided more
direct evidence for the requirement of CL for mitochondrial
bioenergetics. Somewhat surprisingly, the crd1 mutant
could grow, though not as efficiently as wild type yeast,
on non-fermentable carbon sources, indicating that CL is
not essential for oxidative phosphorylation [43]. However,
several bioenergetic defects, associated with a reduction of
ANT activity, reduced mitochondrial membrane potential
and an overall decrease in oxidative phosphorylation, were
observed in the crd1 mutant when grown under stress
conditions [44–46]. Thus, CL appears to be required for sus-
tained mitochondrial inner membrane integrity and function.
Cytochrome c is an essential hemoprotein which func-
tions as a mobile electron carrier between complex III and
complex IV. Only 15% of cytochrome c is free in the inter-
membrane space [47, 48] while most of it is attached to
the mitochondrial inner membrane via specific interactions
with CL [49, 50]. Two types of interactions, hydrophobic
and electrostatic, have been linked to two distinct CL bind-
ing sites on cytochrome c. Initially, these interactions were
thought to play a role in the electron-shuttling activity of
cytochrome c by keeping the molecule in the proximity of
the respiratory chain [50]. More recently, CL-cytochrome c
interactions were suggested to participate in the regulation
of apoptosis (see below).
Cardiolipin maintains the structure of the mitochondrial
inner membrane
The mitochondria of CHO-PGS-S cells appear swollen and
have disorganized cristae [42, 51]. However, as mentioned
above, these alterations cannot be solely attributed to CL
since these cells lack both CL and PG. A more recent study
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of HeLa cells in which the expression of CL synthase was
decreased by RNA interference (RNAi) indicated that CL is
directly required for maintenance of mitochondrial structure
[52]. This report, however, contrasts with the phenotype of
the crd1 yeast mutants, which lack CL but maintain normal
mitochondrial morphology [53]. The differences between CL
synthase-deficient mammalian cells and yeast may be due the
ability of PG to supplant the membrane-preserving function
of CL in yeast.
Cardiolipin in relation to apoptosis
Cardiolipin levels and oxidative stress
Loss of CL is associated with diverse pathophysiological
conditions such as ageing and ischemia/reperfusion pro-
cesses [54, 55]. For example, the loss of CL during is-
chemia/reperfusion is followed by a decrease in oxidative
phosphorylation which may contribute to myocyte death in
the peri-infarct regions of the ischemic myocardium. The de-
cline in mitochondrial respiratory functions the accumulation
of reactive oxygen species (ROS). Under normal physiolog-
ical conditions mitochondrial CL may protect cells from
oxidative stress in part through the deacylation-reacylation
cycle discussed above. However, CL is also a vulnerable
target of ROS due to its unsaturated acyl chains and its
close proximity to ROS generation sites. ROS cause the
peroxidation of CL and a parallel decrease in the activi-
ties of complexes I and IV [56, 57]. Currently this seems to
be very much a “chicken and egg” issue, and it is unclear
whether ROS trigger the loss of CL or whether loss of CL
triggers ROS generation. It is clear, however, that during
many cell death processes ROS and loss of CL are closely
linked in a cycle of CL peroxidation. Peroxidation of CL
also occurs following a variety of apoptotic stimuli such as
nitric oxide, Fas receptor stimulation, NGF deprivation, stau-
rosporine and actinomycin D [58–60]. Interestingly, apopto-
sis via a pathway involving a decrease in CL synthesis was
seen in neonatal rat cardiac myocytes and in breast cancer
cells treated with saturated fatty acids, particularly palmitate
[61, 62].
Cardiolipin—Cytochrome c interactions regulate
cytochrome c release
As mentioned above, the majority of cytochrome c is bound
to the outer leaflet of the mitochondrial inner membrane.
Cytochrome c has a net charge of +8 at physiological pH al-
lowing it to bind membranes primarily through electrostatic
interactions with the head groups of anionic phospholipids
such CL [49, 50]. Cytochrome c has a hydrophobic cavity
which may account for hydrophobic interactions with the
fatty acyl chains of CL [63]. Two CL binding sites on cy-
tochrome c have been proposed; the A-site which facilitates
electrostatic interactions with the negative charges of CL and
the C-site which is involved in hydrophobic interactions with
the fatty acyl chain of CL [50]. These sites are responsible
for two different conformations of cytochrome c in the inter-
membrane space: a loosely bound conformation involving
site A and a tightly bound conformation at site C that par-
tially embeds the protein in the membrane [64]. Loosely
bound cytochrome c participates in the transfer of electrons
from complex III to complex IV, as well as in ROS scaveng-
ing [65, 66]. Tightly bound cytochrome c was proposed to
possess peroxidase activity that utilizes hydrogen peroxide
generated in the mitochondria to peroxidate CL (see below)
[58].
For both types of CL binding it was proposed that
cytochrome c release from mitochondria would first require
the dissociation of its interactions with CL (Fig. 3) [67,
68]. This is consistent with recent findings showing that in
CL-deficient cells, a greater fraction of cytochrome c is free
or loosely bound [52]. The fact that, in vitro, cytochrome
c has a lower affinity for peroxidized CL than CL, suggests
that CL peroxidation may enable cytochrome c detachment
from the inner membrane (Fig. 3). Complete release of
cytochrome c into the inter-membrane space requires
dissociation of both the hydrophobic and the electrostatic
interactions between cytochrome c and CL [69]. The
final release of cytochrome c from mitochondria requires
additional steps in the process, consisting of the permeabi-
lization of the outer membrane. Cristae remodelling was
also shown to be required for cytochrome c re-distribution
within the mitochondrial inter-membrane space before its
release [70] but whether the dissociation of CL-cytochrome
c interactions is related to this process awaits further studies.
Still, the studies described above strongly indicate that CL
and cytochrome c are physically associated and for some
functions at least they are also interdependent.
Cardiolipin: Docking site for tBid
Bid is a pro-apoptotic protein of the diverse Bcl-2 family,
possessing sequence homology only within the conserved
Bcl-2 Homology 3 (BH3) domain [71]. Bid has attracted
increasing interest since it was identified to be a substrate of
caspase-8 in response to activation of death receptors such
as Fas. During apoptosis, N-terminal cleavage of Bid by
caspase-8 produces p15 tBid, the active form which rapidly
targets mitochondria and triggers cytochrome c release [72,
73]. One important target of tBid on the mitochondrial outer
membrane is Bax, a multi-BH domain pro-apoptotic Bcl-2
protein which interacts with the BH3 domain of tBid [74].
In fact, tBid binding to the first α helix of Bax was shown to
be crucial for the pro-apoptotic activity of tBid [74].
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Fig. 3 Cytochrome c (red) is
attached to cardiolipin on the
outer surface of the
mitochondrial inner membrane
and therefore, permeabilization
of the mitochondrial outer
membrane is not sufficient for
cytochrome c release. The
dissociation of cytochrome c
from cardiolipin is a required
step prior to outer membrane
permeabilization and is
triggered by cardiolipin
peroxidation. Recently it was
shown that cardiolipin
peroxidation is catalyzed by the
bound cytochrome c itself [58]
Fig. 4 Cardiolipin executes
apoptosis-supporting roles at the
mitochondrial outer membrane.
(A) Cardiolipin serves as a
docking platform for the
pro-apoptotic Bcl-2 protein
tBid, particularly at contact sites
of the inner and outer
membranes. (B) Cardiolipin
assists the perforation of the
mitochondrial outer membrane
by tBid and Bax. The
mechanism is still elusive
The first apoptosis-promoting role of CL emerged from
biochemical studies of tBid interactions with mitochondrial
lipids using liposomes and the CHO-PGS-S cell line [75].
Wang and co-workers showed that the pro-apoptotic protein
tBid interacts exclusively with liposomes that contain at
least physiological levels of CL and demonstrated that
tBid co-localization with CHO-PGS-S mitochondria is
CL-dependent. The CL-binding domain of tBid was mapped
to helices 4–6 of the Bid protein [75]. Interestingly, helix
6 was later shown to be a part of a hairpin structure which
is important for the lipid binding properties of tBid [76].
Subsequently, electron tomogram studies showed that tBid
interacts with mitochondria specifically at the inner and outer
membrane contact sites, which are rich in CL (Fig. 4(A))
[77]. As discussed above, CL-rich membranes may adopt a
non-bilayer hexagonal HII configuration at the contact sites
(Fig. 2), enabling access of CL to the cytosolic surface of
mitochondria [27]. The model of CL as a mitochondrial
“docking” site for tBid is supported by several studies.
For example, in vitro assays using artificial membranes
or isolated mitochondria showed that recombinant tBid
can bind CL and MLCL [78–83]. Adding tBid to isolated
mitochondria immediately inhibits ADP-stimulated respi-
ration and oxidative phosphorylation, as a result of ANT
inactivation [84, 85]. The function of tBid may be either
BH3-domain-dependent or independent. The former induces
oligomerization of the multi-BH domain pro-apoptotic Bcl-2
proteins Bax and Bak on the mitochondrial outer membrane,
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while a BH3-independent interaction of tBid with CL [82]
could be responsible for cristae remodelling, [80] and for
inhibition of oxidative phosphorylation [85]. Cristae re-
modelling and perturbations of mitochondrial bioenergetics
take place simultaneously and are both independent of Bak.
It is possible therefore that tBid acts by two sequential
mechanisms: the first is BH3 domain independent, which
involves CL, leading to structural and functional impair-
ment, and the second is BH3 domain dependent, employing
interactions with other pro-apoptotic Bcl-2 proteins, namely
Bak and Bax, leading to mitochondrial outer membrane
permeabilization. Thus, the interaction of tBid with CL may
prime mitochondria for the action of Bax and Bak.
Cardiolipin redistribution
Another feature of CL observed under apoptotic conditions
is its redistribution within and between membranes. The ex-
posure of CL on the outer leaflet of the mitochondrial inner
membrane was observed after death receptor stimulation be-
fore mitochondria depolarization and PS exposure on the
plasma membrane, and at the same time as ROS generation
[86]. Peroxidation of CL may account for their redistribution
by altering their molecular organization and favouring for-
mation of a non-bilayer hexagonal structure [87]. This could
increase exposure of CL on the contact sites of mitochondrial
membranes and provide access for tBid. It is also suggested
that Bid, which exhibits lipid transfer activity in vitro, relo-
cates CL and MLCL to the plasma membrane of cells un-
dergoing apoptosis [88, 89]. The mechanism and the signifi-
cance of this relocation are still unclear. In addition, tBid may
reorganize CL into micro-domains as was demonstrated in
artificial lipid monolayers containing physiological amount
of CL [85]. Considering the possible role of CL in maintain-
ing mitochondrial structure, changes in CL organization may
result in structural changes of the mitochondrial inner mem-
brane which in turn may affect the activity of membrane-
embedded proteins such as ANT. Therefore, it is conceivable
that tBid affects the structure and function of mitochondria
by binding to and redistributing mitochondrial CL within the
mitochondrial inner membrane and/or within other cellular
compartments.
Cardiolipin and permeabilization of the mitochondrial outer
membrane
CL was also proposed to be required for the action of other
pro-apoptotic Bcl-2 proteins [90]. To study individual func-
tions of Bcl-2-family proteins Newmeyer and co-workers
took an in vitro approach using liposomes and outer mito-
chondrial membrane vesicles. Their work has provided evi-
dence that permeabilization of liposomes to dextran required
both the presence of activated Bax and physiological levels
of CL. Therefore, it was suggested that Bax may permeabi-
lize the mitochondrial outer membrane by altering the local
organization of CL without overall damage to the membrane
itself (Fig. 4(B)). In contrast to this report, other studies using
either the CL synthase deficient yeast crd1, or mitochon-
dria from CL synthase knocked-down cells have shown that
Bax does not require CL for the induction of cytochrome c
release [52, 84, 91]. However, as discussed above, it is pos-
sible that in yeast, PG, which accumulates in the absence of
CL synthase, compensates for the loss of CL. It still awaits
clarification whether CL or its PG precursor are needed, for
Bax to release cytochrome c [92]. This is particularly inter-
esting since hydrophobic and electrostatic interactions make
a different contribution to the binding of cytochrome c to CL
or PG [93].
Cardiolipin-cytochrome c peroxidase activity
CL peroxidation appears to be an early event preceding the
release of cytochrome c and caspase activation. The mech-
anism of CL peroxidation and its involvement in apopto-
sis has gained more attention recently [58, 94]. Kagan and
colleagues showed that cytochrome c can interact with CL
that contains two or more unsaturated acyl groups (C18:2
mostly) to form a hydrogen peroxide peroxidase capable
of oxidizing CL to peroxi-CL (Fig. 3). Using cytochrome
c−/− mouse embryonic cells they provided the first evidence
that cytochrome c is required for the peroxidation of CL.
CL-cytochrome c complex acts as a potent CL-specific oxy-
genase required for the release of pro-apoptotic factors such
as cytochrome c and smac/diablo. It is noteworthy that ox-
idized CL does not merely allow cytochrome c to detach
from the mitochondrial inner membrane but rather has an
active role in inducing apoptosis: when added to isolated
mitochondria, oxidized CL alone induces cytochrome c and
smac/diablo release [58]. Importantly, the peroxidase activ-
ity of the CL-cytochrome c complex depends on unsatu-
rated acyl chains on CL. Indeed, incubation of HL60 cells
with the poly-unsaturated fatty acid docosahexaenoic acid
(C22:6), enriches CL with C22:6 acyl chains, sensitizing the
cells to staurosporine-induced apoptosis [58]. This promoted
the notion that enriching CL with saturated acyl chains may
protect from apoptosis. But although in vitro, saturated CL
cannot stimulate CL-cytochrome c peroxidase activity [58],
CL synthase in a cellular context does not incorporate satu-
rated PG to form fully saturated CL [62]. Nevertheless, the
results, together with the suggestion that oxidized CL may
have a promoting effect on the pro-apoptotic activity of Bcl-2
proteins, point to the importance of CL acyl chain compo-
sition and suggest that manipulation of CL oxidation may
present a good target for sensitising cells to apoptosis. This
also raises the question whether Bcl-2 proteins can regulate
CL-cytochrome c peroxidase activity.
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Conclusions and perspectives
Since their characterization in 1942 research has yielded in-
creasing knowledge of the structure, localization and biosyn-
thetic pathway of CL. Due to its specific location in the mi-
tochondrial membranes, CL has long been viewed through
its interactions with mitochondrial proteins: because it is
required for the optimal activity of most of the respiratory
chain complexes and of several mitochondrial substrate car-
riers, CL is crucial for efficient oxidative phosphorylation
and for correct function and structure of the mitochondrial
inner membrane.
In addition to its role in maintaining mitochondrial in-
tegrity, it is now clear that CL participates in the mitochon-
drial apoptotic pathway. CL is turning out to be involved in
many of the mitochondrial-dependent steps that lead to the
release of apoptogenic factors. These steps include interac-
tions with Bcl-2 proteins, cytochrome c association with and
dissociation from the mitochondrial inner membrane, alter-
ation of the structure of the mitochondrial inner membrane
and permeabilization of the outer one. Moreover, this review
emphasized that CL undergoes both reorganisation and mod-
ification within the mitochondrial membranes. Degradation
of CL into MLCL and transition of CL to the mitochondrial
outer membrane (and potentially to the plasma membrane)
appear to be early events in apoptosis. Peroxidation of the
acyl chains of CL also plays a crucial role in its apoptotic
functions. In fact, this event is catalyzed by cytochrome c
and is required for the release of cytochrome c itself, and of
other apoptogenic factors, from mitochondria.
By way of analogy with sphingomyelin in the plasma
membrane, it is conceivable that CL participates in the forma-
tion of signalling platforms in the mitochondrial membranes.
The arrival of an apoptotic stimulus at the mitochondrial
surface may result in the redistribution of CL into micro-
domains and in further amplification of the apoptotic signal.
This reorganization of CL could lead to the remodelling of
the mitochondrial cristae and to the loss of mitochondrial
functions observed during apoptosis. However, the presence
of CL domains in mitochondria, their structure and the effect
of peroxidation on their organization are not well understood.
This review also highlighted the importance of CL acyl
chain composition. CL strictly contains unsaturated fatty
acyl chains, which are readily oxidizable targets. Manipu-
lating the degree of saturation of the CL acyl chains may
represent a new means of controlling the cell’s fate. New
strategies designed to pharmacologically manipulate the ox-
idation sensitivity of CL may help control cell death and open
new prospects for the treatment of pathologies with dimin-
ished or excessive apoptosis. The recent surge of research
into CL will hopefully provide better understanding both of
acyl chain remodelling and of the role of CL in apoptosis in
the near future.
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